



# BAGCILAR MEDICAL BULLETIN

## Bağcılar Tıp Bülteni

Volume 4, Number 1, March 2019

### ORIGINAL RESEARCH / ARAŞTIRMA

Spinal Metastasis as Presenting Feature of Follicular Type Thyroid Carcinoma: A Case Report and Review of the Literature

Spinal Metastazla Belirti Veren Folliküler Tip Tiroid Karsinomu: Olgu Sunumu ve Literatür Taraması

Azmi Tufan, Burak Eren, Abdurrahim Taş, Neslihan Berker, Özgür Yusuf Aktaş, İlker Güleç, Mustafa Safi Vatansever, Murat Karacan, Günay Vahabova, Feyza Karagöz Güzey

Evaluation of Readmitted Patients After Intensive Care Unit Discharge (Retrospective Study)

Yoğun Bakım Ünitesinden Taburcu Sonrası Tekrar Yatışı Yapılan Hastaların Değerlendirilmesi (Retrospektif Çalışma)

Pınar Öngel Çayören, Kerem Erkalp, Mehmet Salih Sevdı, Serdar Demirgan, Hüseyin Çayören, Aysin Selcan

Effect of Nasopharyngeal Irrigation on Early Eustachian Tube Functions in Patients Undergoing Adenoidectomy: A Clinical Prospective Study

Adenoidektomi Sırasındaki Nazofaringeal İrigasyon Yönteminin Erken Dönemde Östaki Tüp Fonksiyonlarına Etkisi: Prospektif Çalışma

Şahin Öğreden, Hasan Deniz Tansuker, Abdurrahman Buğra Cengiz, Alper Tabaru, Cemal Özyılmaz, Mehmet Faruk Oktay

Different Therapeutic Approach to Idiopathic Normal Pressure Hydrocephalus: Lumboperitoneal Shunts Versus Ventriculoperitoneal Shunts

İdiyopatik Normal Basıncılı Hidrosefalide Farklı Tedavi Yaklaşımları: Lumboperitoneal Şantlar ya da Ventriküloperitoneal Şantlar?

Ayçiçek Çeçen, Merih İş, Erhan Çelikoğlu

Retrospective Analysis of Six Primary Cutaneous T-cell Lymphoma Cases in the Light of Recent Advancements

Altı Primer Kütanöz T-Hücreli Lenfoma Olgusunun Yeni Gelişmeler Işığında Retrospektif Analizi

Betül Taş



# BAGCILAR MEDICAL BULLETIN

## Bağcılar Tıp Bülteni

### EDITORIAL BOARD / EDITÖRLER KURULU

#### Editor in Chief / Yayın Yönetmeni

**Feyza Karagöz Güzey, Assoc. Prof. MD,**

(T.C. Health Ministry, Health Sciences University, İstanbul Bağcılar Training and Research Hospital, Neurosurgery Clinic, İstanbul, Turkey)

(Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye)

#### Associate Editors / Yardımcı Yayın Yönetmenleri

**Cemal Kural, Prof. Dr, MD,**

(T.C. Health Ministry, Health Sciences University, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Orthopedics Clinic, İstanbul, Türkiye)

(Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, İstanbul Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi, Ortopedi Kliniği, İstanbul, Türkiye)

**Mail:** cemalkural@hotmail.com

**Yüksel Altuntaş, Prof. Dr., MD,**

(T.C. Health Ministry, Health Sciences University, Hamidiye Şişli Etfal SUAM, Endocrinology and Metabolism Clinic, İstanbul, Türkiye)

(Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, Hamidiye Şişli Etfal Eğitim ve Araştırma Hastanesi, Endokrinoloji ve Metabolizma Kliniği, İstanbul, Türkiye)

**Mail:** yukselaltuntas@yahoo.com

**Atilla Çelik, Assoc. Prof., M.D.,**

(T.C. Health Ministry, Health Sciences University, Bağcılar Training and Research Hospital, General Surgery Clinic, İstanbul, Turkey)

(Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, İstanbul, Türkiye)

**Kerem Erkalp, Assoc. Prof., M.D.,**

(T.C. Health Ministry, Health Sciences University, Bağcılar Training and Research Hospital, Anesthesiology and Reanimation Clinic, İstanbul, Turkey)

(Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Anestezi ve Reanimasyon Kliniği, İstanbul, Türkiye)

**Ahmet Yaser Müslümanoğlu, MD,**

(İstanbul Bağcılar Training and Research Hospital, Clinic of Urology, İstanbul, Turkey)

(İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, İstanbul, Türkiye)

**Mail:** ymuslumanoglu56@hotmail.com

**Levent Yaşar, MD,**

(İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Gynecology and Obstetrics, İstanbul, Turkey)

(İstanbul Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Kliniği, İstanbul, Türkiye)

**Mail:** leventysr@gmail.com



Galenos Publishing House  
Owner and Publisher  
Erkan Mor

Publication Coordinator  
Burak Sever

Web Coordinators  
Soner Yıldırım  
Turgay Akpınar

Graphics Department  
Ayda Alaca  
Çiğdem Birinci  
Gülşah Özgül

Project Coordinators  
Eda Kolukisa  
Hatice Balta  
Lütfiye Ayhan İrtem  
Sedanur Sert  
Zeynep Altındağ

Project Assistants  
Gamze Aksoy  
Nurcan Açarçay

Finance Coordinator  
Sevinç Çakmak

Research&Development  
Kerim Sancar Ölmez  
Mert Köse

Publisher Contact

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1  
34093 İstanbul, Turkey

Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27

E-mail: info@galenos.com.tr/yayin@galenos.com.tr

Web: www.galenos.com.tr

Publisher Certificate Number: 14521

Publication Date: March 2019

E-ISSN: 2547-9431

International scientific journal published quarterly.

### ADVISORY BOARD / DANIŞMA KURULU

**Family Medicine / Aile Hekimliği**  
Didem Kafadar, M.D.

**Anesthesiology and Reanimation / Anesteziyoloji ve Reanimasyon**

Ayşin Selcan, M.D.  
Tuğhan Utku, M.D.  
Gökçen Başaranoğlu, M.D.  
Veysel Erden, M.D.  
Kerem Erkalp, M.D.  
Funda Gümüş, M.D.

**Biochemistry / Biyokimya**

Suat Hayri Küçük, M.D.  
Zeynep Gülnur Andican, M.D.  
Hafize Uzun, M.D.

**Endocrinology / Endokrinoloji**

Evrım Çakır, M.D.

**Infectious Diseases / Enfeksiyon Hastalıkları**

Bilgül Mete, M.D.  
Kamuran Türker, M.D.

**Gastroenterology / Gastroenteroloji**

Şule Poturoğlu, M.D.  
Elif Yorulmaz, M.D.

**Genetics / Genetik**

Bülent Uyanık, M.D.

**Chest Diseases / Göğüs Hastalıkları**

Özcan Oğurlu, M.D.

**Chest Surgery / Göğüs Cerrahisi**

Murat Öncel, M.D.  
Süleyman Aykut Altunkaya, M.D.

**Cardiovascular Surgery / Kalp ve Damar Cerrahisi**

Vedat Erentuğ, M.D.  
Serpil Gezer Taş, M.D.  
Kamil Boyacıoğlu, M.D.

**Gynecology and Obstetrics / Kadın Hastalıkları ve Doğum**

A.Taner Usta, M.D.  
Ahmet Kale, M.D.  
Pınar Behiye Göksedef, M.D.  
Mahmut Öncül, M.D.  
Barış Mülayim, M.D.

**Cardiology / Kardiyoloji**

Ertuğrul Okuyan, M.D.

**Otolaryngology / Kulak Burun Boğaz**

Mehmet Faruk Oktay, M.D.  
Salih Aydın, M.D.  
Şahin Öğreden, M.D.  
Hasan Deniz, M.D.  
Mehmet Güven, M.D.

**Microbiology / Mikrobiyoloji**

Ayşe Banu Esen, M.D.  
Nazım Nasuhbeyoğlu, M.D.

**Nephrology / Nefroloji**

Numan Görgülü, M.D.

**Neurology / Nöroloji**

Demet Kınay, M.D.  
Sebatiye Erdoğan, M.D.  
Nilüfer Kale İçen, M.D.

**Neurosurgery / Nöroşirürji**

Abdurrahman Aycan, M.D.  
Feyza Karagöz Güzey, M.D.  
Bekir Tuğcu, M.D.  
Burak Eren, M.D.  
İlker Güleç, M.D.

**Nuclear Medicine / Nükleer Tıp**

Eylem Baştuğ, M.D.

**Oncology / Onkoloji**

Serkan Menekşe, M.D.

**Orthopedics and Traumatology / Ortopedi ve Travmatoloji**

M. Akif Güleç, M.D.  
Oktay Adanır, M.D.  
Ender Alagöz, M.D.  
Sever Çağlar, M.D.  
Ozan Beytemur, M.D.  
Utku Gürün, M.D.  
Serdar Yüksel, M.D.

**Pathology / Patoloji**

Ümit Seza Tetikkurt, M.D.  
Damlanur Sakız, M.D.

**Pediatrics / Pediatri**

Özgül Yiğit, M.D.

**Plastic and Reconstructive Surgery / Plastik ve Rekonstrüktif Cerrahi**

Salih Onur Başat, M.D.  
Funda Aköz Saydam, M.D.  
İ. Karaca Başaran, M.D.  
Mehmet Sürmeli, M.D.  
Yunus Doğan, M.D.

**Psychiatry / Psikiyatri**

Mustafa Solmaz, M.D.

**Radiological / Radyoloji**

Aslıhan Semiz Oysu, M.D.  
Zehra Berna Ünan Arık, M.D.  
Mehmet Öncü, M.D.



## ABOUT US

### About the Journal

Bagcilar Medical Bulletin (Bağcılar Tıp Bülteni) (BMB) is periodical scientific publishing of Health Sciences University, İstanbul Bağcılar Training and Research Hospital. This editorially independent, unbiased, international journal periodically publishes peer-reviewed work in the all medical fields on an international scientific basis. Publication language is English for full text and Turkish and English for abstracts. The journal is published in English since December issue of 2016 as an e-journal.

The journal is published quarterly in March, June, September and December.

Original clinical and experimental articles, interesting case studies, and literature reviews made from relevant authors in their branches will be accepted for evaluation in BMB.

The editorial policies are based on the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2017, archived at <http://www.icmje.org/>) rules.

### Owner of the Journal

In the name of T.C. Health Ministry, Health Sciences University, İstanbul Bağcılar Training and Research Hospital, Hospital Administrator Ahmet Yaser Müslümanoğlu, Prof. M.D (T.C. Health Ministry, Health Sciences University, İstanbul Bağcılar Training and Research Hospital, Urology Clinic, İstanbul, Turkey).

### Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI) <http://www.budapestopenaccessinitiative.org/>. By "open access" to peer-reviewed research literature, we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

This journal is licensed under a Creative Commons 4.0 International License.

Creative Commons BY-NC-ND International License.



### Advertisement / Publisher Corresponding Address

Applications for advertisement should be addressed to the publisher; Galenos Yayınevi.

**Publisher:** Galenos Yayınevi Tic. Ltd. Şti.

**Address:** Molla Gürani Mah. Kaçamak Sok. No: 21 34093 İstanbul/Turkey

**Phone:** +90 212 621 99 25

**Fax:** +90 212 621 99 27

**E-mail:** [info@galenos.com.tr](mailto:info@galenos.com.tr)

**Web Page:** [www.galenos.com.tr](http://www.galenos.com.tr)

### HAKKIMIZDA

#### Dergi Hakkında

Bağcılar Tıp Bülteni/Bağcılar Medical Bulletin, (BTB) Sağlık Bilimleri Üniversitesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesinin süreli bilimsel yayımıdır. Uluslararası, hakem değerlendirmeli, İngilizce ve açık erişim olarak yılda 4 sayı (Mart, Haziran, Eylül, Aralık) olarak yayınlanan bilimsel bir dergi olup, tıbbın tüm alanlarındaki bilgi birikiminin uluslararası bilimsel platformda yayılabilmesini amaçlamaktadır. Bu amaçla tıbbın her alanında yapılmış orijinal klinik ve deneysel çalışmalar ve ilginç olgu sunumları ile konusunda uzman yazarların yaptığı literatür derlemeleri yayın için değerlendirmeye alınır.

Bağcılar Tıp Bülteni/Bağcılar Medical Bulletin, yazıların İngilizce dilinde, yazıların özetlerinin Türkçe ve İngilizce dillerinde online olarak yayınlandığı bir dergidir.

Yayın politikaları "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" (2016, <http://www.icmje.org/>) temel alınarak hazırlanmıştır.

#### Derginin Sahibi

T.C.Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi adına Hastane Yöneticisi Ahmet Yaser Müslümanoğlu, Prof. M.D (Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi, İstanbul Bağcılar Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, İstanbul, Türkiye).

#### Açık Erişim Politikası

Dergide açık erişim politikası uygulanmaktadır. Açık erişim politikası Budapest Open Access Initiative (BOAI) <http://www.budapestopenaccessinitiative.org/> kuralları esas alınarak uygulanmaktadır.

Açık Erişim, "(hakem değerlendirmesinden geçmiş bilimsel literatürün), internet aracılığıyla; finansal, yasal ve teknik engeller olmaksızın, serbestçe erişilebilir, okunabilir, indirilebilir, kopyalanabilir, dağıtılabilir, basılabilir, taranabilir, tam metinlere bağlantı verilebilir, dizinlenebilir, yazılıma veri olarak aktarılabilir ve her türlü yasal amaç için kullanılabilir olmasıdır". Çoğaltma ve dağıtım üzerindeki tek kısıtlama yetkisi ve bu alandaki tek telif hakkı rolü; kendi çalışmalarının bütünlüğü üzerinde kontrol sahibi olabilmeleri, gerektiği gibi tanınmalarının ve alıntılanmalarının sağlanması için, yazarlara verilmelidir.

Bu dergi Creative Commons 4.0 Uluslararası Lisansı ile lisanslanmıştır.

Creative Commons BY-NC-ND International License.



#### Yayınevi Yazışma Adresi

Galenos Yayınevi Tic. Ltd. Şti.

Adres: Molla Gürani Mah. Kaçamak Sk. No: 21/1, 34093 İstanbul, Türkiye

**Tel.:** +90 212 621 99 25

**Faks:** +90 212 621 99 27

**E-posta:** [info@galenos.com.tr](mailto:info@galenos.com.tr)

**Web Sayfası:** [www.galenos.com.tr](http://www.galenos.com.tr)



## INSTRUCTIONS TO AUTHORS

### Description

Bagcilar Medical Bulletin is a peer reviewed English journal aiming to publish original research, current review articles, case reports and letters related to all medical fields. The journal is currently published quarterly as online publication. The articles will become freely available to all readers in pdf format as soon as they have been accepted after peer review. Accepted articles will immediately appear as a part of the issue belonging to that publication period. The journal is currently published by Galenos Publishing House. The journal is using online manuscript submission, review and tracking systems.

### Editorial Policies and Review Process

#### Publication Policy

Bagcilar Medical Bulletin considers for publication papers in the following categories:

- Original researches,
- Brief researches,
- Case reports,
- Reviews,
- Letters to the editor

The journal gives high priority to original studies in publication because of aiming to add the findings of searches in Turkey to international scientific knowledge, to share them within the international science milieu and to constitute the introduction of Turkish scientists. The review articles to be published in the journal are authorized by the editor to the relevant authors working on the subject.

#### General Principles

Papers that have not been published before or under evaluation by other publications are accepted for evaluation by the journal, if approved by each of the author. Publication board may amend manuscripts upon informed consent of authors. Editors and redactors are fully empowered to correct mistakes related to orthography, citation as given in National Library of Medicine MEDLINE/PubMed Resources.

For quoted texts, tabulated data and graphics from published papers, author has to obtain permission from the author(s) or the owner of the publishing rights of the source article and indicate the allowance in the paper. Author(s) is responsible to obtain such permissions.

Short presentations that took place in scientific meetings can be referred if announced in the article. The editor hands over the formally acceptable papers to at least two national/international referees for evaluation and gives green light for publication upon modification by the authors in accordance to the referees' claims. Changing the name of an author

(omission, addition or order) in papers submitted to the journal requires permission of all declared authors. Refused papers and graphics are not returned to the author.

#### Author Responsibilities

It is authors' responsibility to ensure that the article is in accordance with scientific and ethical standards and rules. And authors should ensure that submitted work is original. They must certify that the manuscript has not previously been published elsewhere or is not currently being considered for publication elsewhere, in any language. Applicable copyright laws and conventions should be followed. Copyright material (e.g. tables, figures or extensive quotations) should be reproduced only with appropriate permission and acknowledgement. Any work or words of other authors, contributors, or sources should be appropriately credited and referenced. The author(s) must have contributed to the submitted manuscript and must declare that they were involved in substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Those who do not meet all the above criteria should be named in the acknowledgements. Fund raising, data collection or supervision of the research group are not sufficient roles to be accepted as an author. The order of names in the author list of an article should be a co-decision and it should be indicated in the Copyright Transfer Form. The individuals who do not meet the authorship criteria but contributed to the study should take place in the acknowledgement section. Individuals providing technical support, assisting writing, providing a general support, providing material or financial support are examples to be indicated in acknowledgement section. Written informed consent should be taken from the persons whose participations are indicated in the acknowledgement section.

All authors must disclose all issues concerning financial relationship, conflict of interest, and competing interest that may potentially influence the results of the research or scientific judgment. All financial contributions, supports or sponsorship of projects must be clearly explained.

When an author discovers a significant error or inaccuracy in his/her own published paper, it is the author's obligation to promptly cooperate with the Editor-in-Chief to provide retractions or corrections of mistakes. The Author Contribution Form, indicating the authors' contribution to the manuscript and the ICJME Form for Potential Conflicts of Interest should

### INSTRUCTIONS TO AUTHORS

be sent together with the manuscript. Please browse BMB recommendations on roles and responsibilities of authors on <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/>

#### Responsibility for the Editors, Reviewers and Review Process

Editors evaluate manuscripts for their scientific content without regard to ethnic origin, gender, sexual orientation, citizenship, religious belief or political philosophy of the authors. They provide a fair double-blind peer review of the submitted articles for publication. They ensure that all the information related to submitted manuscripts is kept as confidential before publishing.

Editors are responsible for the contents and overall quality of the publication. They should publish errata pages or make corrections when needed. Editor-in-Chief does not allow any conflicts of interest between the authors, editors and reviewers. Only he has the full authority to assign a reviewer and is responsible for final decision for publication of the manuscripts in Bagcilar Medical Bulletin.

Please review the COPE publication ethics guidelines on <https://publicationethics.org/files/u7141/1999pdf13.pdf> Reviewers evaluate manuscripts based on content without regard to ethnic origin, gender, sexual orientation, citizenship, religious belief or political philosophy of the authors. They should have no conflict of interest with respect to the research, the authors and/or the research funders. Their judgments should be objective.

Reviewers should identify the relevant published work that has not been cited by the authors. They must ensure that all the information related to submitted manuscripts is kept as confidential and must report to the Editor-in-Chief if they are aware of copyright infringement and plagiarism on the author's side.

A reviewer who feels unqualified to review the topic of a manuscript or knows that its prompt review will be impossible should notify the Editor-in-Chief and excuse himself from the review process.

The editor informs the reviewers that the manuscripts are confidential information and that this is a privileged interaction. The reviewers and editorial board cannot discuss the manuscripts with other persons. The reviewers are not allowed to have copies of the manuscripts for personal use and they cannot share manuscripts with others. Unless the authors and editor permit, the reviews of referees cannot be published or disclosed. The anonymity of the referees is important. In particular situations, the editor may share the review of one reviewer with other reviewers to clarify a particular point.

Please review the COPE publication ethics guidelines on: <http://publicationethics.org/files/Peer%20review%20guidelines.pdf>

#### Open Access Statement

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.

Publication Ethics and Publication Malpractice Statement

#### Standards and Principles

Bagcilar Medical Bulletin is committed to upholding the highest standards of publication ethics and observes the following principles of Publication Ethics and Malpractice Statement which is based on the recommendations and guidelines for journal editors developed by the Committee on Publication Ethics (COPE), Council of Science Editors (CSE), World Association of Medical Editors (WAME) and the International Committee of Medical Journal Editors (ICMJE).

All submissions must be original, unpublished (including as full text in conference proceedings), and not under the review of any other publication synchronously. Each manuscript is reviewed by one of the editors and at least two referees under double-blind peer review process. We reserve the right to use plagiarism detecting software to screen submitted papers at all times. We check for plagiary and fraudulent data; falsification (fabrication or manipulation of research data, tables, or images) and improper use of humans or animals in research. All manuscripts not in accordance with these standards will be removed from the publication. This also contains any possible malpractice discovered after the publication. In accordance with the code of conduct we will report any cases of suspected plagiarism or duplicate publishing.

We follow the COPE Ethics Flowcharts for dealing with cases of possible scientific misconduct and breach of publication ethics (<http://publicationethics.org/resources/flowcharts>)

#### Human and Animal Rights, Informed Consent, Conflict of Interest

Bagcilar Medical Bulletin adopts highest ethical and scientific standards and ensures that it is free of influences regarding commercial interests. It is authors' responsibility that the articles are in accordance with ethical codes of conduct. Bagcilar Medical Bulletin takes as principle to comply with the ethical standards of 1975 Helsinki Declaration-Ethical Principles for Medical Research Involving Human Subjects- revised in 2004- <http://www.wma.net/en/30publications/10policies/b3/index.html> and WMA Statement on Animal Use in



### INSTRUCTIONS TO AUTHORS

Biomedical Research-revised in 2006 <http://www.wma.net/en/30publications/10policies/a18/>

For this reason, regarding the subjects of clinical experiments, it should be indicated in the submitted manuscripts definitely that the above mentioned codes of conduct were applied. Besides approvals, from national or local ethical committees should be sent together with the papers as well. Manuscripts that report the results of experimental investigation with human subjects must include a statement that informed consent was obtained after the procedure(s) had been fully explained. In the case of children and those under wardship or with confirmed insanity, authors are asked to include information about whether the legal custodian's assent was obtained. And a letter of affirmation signed by all authors, confirming the collection of informed consents has to be sent to the journal.

Identifying information such as names, initials, hospital numbers, dates, photographs, and family pedigree must be avoided, unless disclosure is allowed by written consent of patient or the legal custodian of the patient. Informed consent for this purpose requires that an identifiable patient be shown in the manuscript to be published. Patient consent should be written and archived either with the journal, the authors, or both, as dictated by local regulations or laws. It must be mentioned in the text that informed consent was obtained from the participants. Especially for case report, identifying information should be avoided as much as possible. Eye masking on photos is not sufficient to conceal the identity of the patient. Authors have to stipulate lack of impact on scientific significance in case of changing the identifying information. Written informed consent should be taken from the patients presented in case studies; and it should be indicated in the manuscript.

Authors have to confirm in the section "Materials and Methods" that study has been conducted in compliance to above mentioned principles, approvals have been obtained from related institutional ethical committees and informed consents were collected.

When reporting experiments on animals, authors should indicate whether the institutional and national guides for the care and use of laboratory animals were followed as in "Guide for the Care and Use of Laboratory Animals" ([www.nap.edu/catalog/5140.html](http://www.nap.edu/catalog/5140.html)) and approval from ethical committee should be taken. The editor and the publisher do not guarantee or accept responsibility for the published features or definitions of commercial products. If there is direct or indirect grant support, it should be acknowledged in the section titled "declaration of interest" and should include the full name of the sponsor and grant number. Existence or lack of sponsorship of

any kind as well as the type of sponsorship (consulting etc) has to be acknowledged, as well.

Adopts WAME's definition <http://www.wame.org/about/wame-editorial-on-coi> which states that conflict of interest exists when author, peer reviewer or editor has a competing interest that could unduly influence (or be reasonably seen to do so) his or her responsibilities in the publication process. The types of competing interests that should be declared include financial ties, academic commitments, personal relationships, political or religious beliefs, institutional affiliations. The conflict of interest is to be acknowledged in the manuscript.

#### Language

The language of the Bagcilar Medical Bulletin is American English. In addition, abstracts of the articles are published in both English and Turkish, and abstracts in both languages are requested from the author(s).

#### Manuscript Organization And Format

All correspondence will be sent to the first-named author unless otherwise specified. Papers should be accompanied by a cover letter indicating that the paper is intended for publication and specifying for which section of the Journal it is being submitted (i.e., original research article, brief research article, review article, case report or letter to the editor). In addition, a Copyright Transfer Form, Author Contribution Form and ICJME Form for Disclosure of Potential Conflicts of Interest must be submitted. Authors will be notified of the receipt of their paper and the number assigned to it. The number should be included in all further correspondence. All parts of the manuscript, including case reports, quotations, references, and tables, must be double-spaced throughout. All four margins must be at least 2.5 cm. The manuscript should be arranged in the following order, with each item beginning a new page: 1) title page, 2) abstract, 3) text, 4) acknowledgement 5) references, and 6) tables and/or figures. All pages must be numbered consecutively.

#### Title Page

On the title page, include full names of authors, academic or professional affiliations, and complete address with phone, fax number(s) and e-mail address (es) of the corresponding author. Acknowledgments for personal and technical assistance should be indicated on the title page.

#### Abstract and Key Words

Title of the manuscript in English should be written in English abstract, and a Turkish title must be for Turkish abstract.. All articles should include abstract and keywords. For abstracts are most distinct parts of an article and take place on the electronic



### INSTRUCTIONS TO AUTHORS

databases, author should be sure that abstract represents the content of the article accurately. Abstract should inform about the basis of the study and include the purpose, basic procedures (selection of cases and laboratory animals, observatory and analytical methods), key findings and conclusions. New and significant aspects of the study or observations should be stated. Up to 3-10 key words in English and in Turkish should be in accordance with National Library of Medicine's Medical Subjects Subheadings (MeSH).

#### Manuscript Types

##### Original Research

Original research articles report substantial and original scientific results within the journal scope. Original research articles comprised of Abstract, Key Words, Introduction, Material and Methods, Results, Discussion, Conclusion, References and Table/Figures. The abstract should be structured as the following.

##### Abstract

The abstract should be no longer than 500 words and structured as follows: objective, method, results, and conclusions. Objective -the primary purpose of the article; Material and Method(s) -data sources, design of the study, patients or participants, interventions, and main outcome measures; Results -key findings; Conclusions -including direct clinical applications.

##### Key Words

Up to 3-10 key words in English and in Turkish should be in accordance with National Library of Medicine's Medical Subjects Subheadings (MeSH).

##### Introduction

This section should contain a clear statement of the general and specific objectives as well as the hypotheses which the work is designed to test. It should also give a brief account of the reported literature. The last sentence should clearly state the primary and secondary purposes of the article. Only, the actual references related with the issues have to be indicated and data or findings related with the current study must not be included in this section.

##### Material and Methods

This section should contain explicit, concise descriptions of all procedures, materials and methods used in the investigation to enable the reader to judge their accuracy, reproducibility, etc. This section should include the known findings at the beginning of the study and the findings during the study must be reported in results section. Ethics Committee Approval of the research and written Informed Consent obtained from the participants should be indicated.

##### The selection and description of the participants

The election, source of population, inclusion and exclusion criteria of the people who participate to experimental or clinical study must be clearly defined in this section. The particular study sample must be explained by the authors (i.e., why the study is performed in a definite age, race or sex population, etc.)

##### Technical information

The methods, apparatus (the manufacturer's name and address in parentheses), and procedures in sufficient detail must be defined to allow others to reproduce the results. References to established methods, including statistical methods (see below) must be given and brief descriptions for methods that have been published but are not well-known must be provided; new or substantially modified methods must be described, the reasons for using them must be given, and their limitations of the methods must be evaluated. The all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration must be identified. Authors submitting review manuscripts should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract.

##### Statistics

The statistical methods must be described with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. If possible, findings should be quantified and presented with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Relying solely on statistical hypothesis testing, such as P values, which fail to convey important information about effect size must be avoided. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. The computer software used must be specified.

##### Results

The results should be presented in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. The all the data in the tables or illustrations should not be repeated in the text; only the most important observations must be emphasized or summarized. Extra or supplementary materials and technical detail can be placed in an appendix where they will be accessible but will not interrupt the flow of the text, or they can be published solely in the electronic version of the journal.

##### Discussion

The findings of the study, the findings and results which support or do not support the hypothesis of the study should



### INSTRUCTIONS TO AUTHORS

be discussed, results should be compared and contrasted with findings of other studies in the literature and the different findings from other studies should be explained. The new and important aspects of the study and the conclusions that follow from them should be emphasized. The data or other information given in the Introduction or the Results section should not be repeated in detail.

#### Conclusions

Conclusions derived from the study should be stated. For experimental studies, it is useful to begin the discussion by summarizing briefly the main findings, then explore possible mechanisms or explanations for these findings, compare and contrast the results with other relevant studies, state the limitations of the study, and explore the implications of the findings for future research and for clinical practice. The conclusions should be linked with the goals of the study but unqualified statements and conclusions not adequately supported by the data should be avoided. New hypotheses should be stated when warranted, but should be labeled clearly as such.

#### Tables, Graphics and Illustrations

Tables, graphics and illustrations should be numbered in Arabic numerals in the text. The places of the illustrations should be signed in the text. Detailed information is under the related heading in below.

#### Brief Research

Brief researches are similar to original research in that they follow the same format and guidelines, but they consider small-scale research or research that is in early stages of development. These may include preliminary studies that has a simple research design or a small sample size and that have produced limited pilot data and initial findings that indicate need for further investigation. Brief researches are much shorter than manuscripts associated with a more advanced, larger-scale research project. They are not meant to be used for a short version of an article about research that would otherwise qualify for a full original research manuscript or for publishing material on research that lacks significance, is not rigorous or, if expanded, would not qualify for a full article or for research.

#### Case Report

Case reports consider new, interesting and intriguing case studies in detail. They should be unique and present methods to overcome any health challenge by use of novel tools and techniques and provide a learning source for the readers. Case reports comprise of: Abstract (unstructured summary), Key-words, Introduction, Case Report, Discussion, Reference,

Tables and Figures. Written informed consent of the patient should be obtained and indicated in the manuscript.

#### Review

Review articles are written by individuals who have done substantial work on the subject or are considered experts in the field. The Journal invites authors to write articles describing, evaluating and discussing the current level of knowledge regarding a specific subject in the clinical practice.

The manuscript should have an unstructured abstract representing an accurate summary of the article, key words, introduction, conclusion. Authors submitting review article should include a section describing the methods used for locating, selecting, extracting, and synthesizing data. These methods should also be summarized in the abstract.

#### Letter to the Editor

Letter to the Editor is short and decisive manuscript. They should be preferably related to articles previously published in the Journal or views expressed in the Journal. The letter should not include preliminary observations that need a later study for validation.

#### Tables

Tables capture information concisely and display it efficiently; they also provide information at any desired level of detail and precision. Including data in tables rather than text frequently makes it possible to reduce the length of the text. Each table should be typed or printed with double spacing on a separate sheet of paper. The tables should be numbered consecutively in the order of their first citation in the text and a brief title for each table should be supplied. Any internal horizontal or vertical lines should not be used and a short or an abbreviated heading should be given to each column. Authors should place explanatory matter in footnotes, not in the heading. All nonstandard abbreviations should be explained in footnotes, and the following symbols should be used in sequence: \*, †, ‡, §, ||, ¶, \*\*, ††, ‡‡. The statistical measures of variations, such as standard deviation and standard error of the mean should be identified. Be sure that each table is cited in the text. If you use data from another published or unpublished source, obtain permission and acknowledge that source fully. Additional tables containing backup data too extensive to publish in print may be appropriate for publication in the electronic version of the journal, deposited with an archival service, or made available to readers directly by the authors. An appropriate statement should be added to the text. Such tables should be submitted for consideration with the paper so that they will be available to the peer reviewers.

## INSTRUCTIONS TO AUTHORS

### Illustrations (Figures)

Figures should be either professionally drawn and photographed, or submitted as digital prints in photographic-quality. In addition to requiring a version of the figures suitable for printing, authors are asked for electronic files of figures in a format (for example, JPEG or GIF) that will produce high-quality images in the Web version of the journal; authors should review the images of such files on a computer screen before submitting them to be sure they meet their own quality standards. For X-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, sharp, glossy, black-and-white or color photographic prints should be sent, usually 127x173 mm. Letters, numbers, and symbols on figures should therefore be clear and consistent throughout, and large enough to remain legible when the figure is reduced for publication. Figures should be made as self-explanatory as possible, since many will be used directly in slide presentations. Titles and detailed explanations belong in the legends-not on the illustrations themselves. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background. Photographs of potentially identifiable people must be accompanied by written permission to use the photograph. Figures should be numbered consecutively according to the order in which they have been cited in the text. If a figure has been published previously, the original source should be acknowledged and written permission from the copyright holder should be submitted to reproduce the figure. Permission is required irrespective of authorship or publisher except for documents in the public domain. Accompanying drawings marked to indicate the region to be reproduced might be useful to the editor. We publish illustrations in color only if the author pays the additional cost.

### Legends for Illustrations (Figures)

The legends for illustrations should be typed or printed out using one spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, each one clearly should be identified and explained in the legend. The internal scale should be explained and the method of staining in photomicrographs should be identified. Units of Measurement.

Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. Temperatures should be in degrees Celsius, blood pressures should be in millimeters of mercury. Authors must consult the Information for Authors of the particular journal and should report laboratory information in both local

and International System of Units (SI). Drug concentrations may be reported in either SI or mass units, but the alternative should be provided in parentheses where appropriate.

### Abbreviations and Symbols

Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement.

### Acknowledgement(s)

All forms of support, including individual technical support or material support must be acknowledged in the author's footnote before references.

### Case Reports and Word Limitation

Original papers and reviews have no specific word limitation. A case report must be strictly limited to 1000 words excluding abstract and have minimal figures, tables, and references. Letters to the Editor (maximum of 500 words, including references; no tables or figures) will be considered if they include the notation "for publication." A letter must be signed by all of its authors. Letters critical of an article published in the journal must be received within 12 weeks.

### Preparation of Manuscripts

The "Bagcilar Medical Bulletin" follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals" (International Committee of Medical Journal Editors - <http://www.icmje.org/>). Upon submission of the manuscript, authors are to indicate the type of trial/research and provide the checklist of the following guidelines when appropriate:

CONSORT statement for randomized controlled trials (Moher D, Schultz KE, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 1987-91) (<http://www.consort-statement.org/>),

PRISMA for preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7): e1000097.) (<http://www.prisma-statement.org/>),

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al, for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4.) (<http://www.stard-statement.org/>),



### INSTRUCTIONS TO AUTHORS

STROBE statement-checklist of items that should be included in reports of observational studies (<http://www.strobe-statement.org/>),

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12).

CARE guidelines are designed to increase the accuracy, transparency, and usefulness of case reports. (Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.) (<http://www.care-statement.org/>)

#### References

Although references to review articles can be an efficient way to guide readers to a body of literature, review articles do not always reflect original work accurately. Readers should therefore be provided with direct references to original research sources whenever possible. On the other hand, extensive lists of references to original work on a topic can use excessive space on the printed page. Small numbers of references to key original papers often serve as well as more exhaustive lists, particularly since references can now be added to the electronic version of published papers, and since electronic literature searching allows readers to retrieve published literature efficiently. Using abstracts as references should be avoided.

References to papers accepted but not yet published should be designated as “in press” or “forthcoming”; authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source. Citing a “personal communication” should be avoided unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, written permission and confirmation of accuracy from the source of a personal communication must be obtained.

#### Reference Style and Format

The Uniform Requirements style for references is based largely on an American National Standards Institute style adapted by the National Library of Medicine for its databases. Authors should consult NLM’s Citing Medicine ([http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)) for information on its recommended formats for a variety of reference types. References should be numbered

consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals in parentheses. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. The titles of journals should be abbreviated according to the style used in the list of Journals in National Library of Medicine sources. In addition the list should be obtained in the web address of <http://www.nlm.nih.gov>. Accuracy of citation is the author’s responsibility. All references should be cited in text. Type references in the style shown below. If there are more than 6 authors, list them followed by et al. Abbreviations of journal names should conform to the style used in National Library of Medicine. If a journal is not indexed in National Library of Medicine’s MEDLINE/PubMed, it should not be abbreviated.

#### Examples for References:

##### 1. For articles in journals:

For the published article from the journal which placed and abbreviated in MEDLINE:

Crow SJ, Peterson CB, Swanson SA, Raymond NC, Specker S, Eckert ED, et al. Increased mortality in bulimia nervosa and other eating disorders. Am J Psychiatry 2009;166(12):1342-1346.

For the published article from the journal which is not placed and is not abbreviated in MEDLINE:

Sevinçer GM, Konuk N. Emotional eating. Journal of Mood Disorders 2013;3(4):171-178.

##### 2. For the supplement:

For the published article from the journal which placed and abbreviated in MEDLINE:

Sharan P, Sundar AS. Eating disorders in women. Indian J Psychiatry 2015;57(Suppl 2):286-295.

For the published article from the journal which is not placed and is not abbreviated in MEDLINE:

Maner F. Yeme bozukluklarının tedavisi. Anadolu Psikiyatri Dergisi 2009;10(Ek 1):55-56.

##### 3. For articles in press:

Cossrow N, Pawaskar M, Witt EA, Ming EE, Victor TW, Herman BK, et al. Estimating the prevalence of binge eating disorder in a community sample from the United States: comparing DSM-IV-TR and DSM-5 criteria. J Clin Psychiatry, 2016. (in press).

##### 4. For the citations from books:

Books edited by one editor:

McKnight TL. Obesity Management in Family Practice. 1st ed., NewYork: Springer, 2005:47-51.

### INSTRUCTIONS TO AUTHORS

For the citation from a section of book edited by editor(s):

Jebb S, Wells J. Measuring body composition in adults and children. In *Clinical Obesity in Adults and Children*, Copelman P, Caterson I, Dietz W (editors). 1st ed., London: Blackwell Publishing, 2005:12-18.

If the authors of the cited section are the editors of the book:

Eckel RH (editor). Treatment of obesity with drugs in the new millennium. In *Obesity Mechanisms and Clinical Management*. First ed., Philadelphia: Lippincott Williams & Wilkins, 2003:449-476.

For the citation from a translated book:

McGuffin P, Owen MJ, Gottsman II. Psikiyatri Genetiği ve Genomiği. Abay E, Görgülü Y (Çevirenler) 1st ed., Istanbul: Nobel Tıp Kitabevleri, 2009:303-341.

#### 5. For the citation from thesis:

Keçeli F. Yeme bozukluğu hastalarında obsesif kompulsif bozukluk ve kişilik bozukluğu. Thesis, T.C. Sağlık Bakanlığı Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi, Istanbul:2006.

#### 6. For the citation from posters:

Akbaş Öncel D, Akdemir A. Üniversite öğrencilerinde diyet, beden algısı ve kendilik algısı arasındaki ilişkiler. 47. Ulusal Psikiyatri Kongresi Özet Kitabı, 26-30 Ekim 2011, Antalya, 2011:102.

#### 7. Online Article:

Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann Intern Med* [Internet]. 2006 Jul 4 [cited 2007 Jan 4];145(1):62-9. Available from:<http://www.annals.org/cgi/reprint/145/1/62.pdf>

### SUBMISSION TO JOURNAL

All new manuscripts must be submitted through the Bağcılar Medical Bulletin online manuscript submission and peer review system. Complete instructions are available at the website (). A cover letter should accompany with manuscripts, including the knowledge of:

•The findings of previous same studies should be informed and should be cited. The copies of previous same studies should be sent with manuscripts that might help to the editor in the decision process.

•The knowledge of “all authors have read and accepted the study in its form, all authors meet the criteria for being in authorship” should be stated.

•All helpful things for editorial ship should be stated: The comments of previous editor/reviewers and the response

of authors should be added if the manuscript has been sent to another journal for consideration, previously. The editor requested this information to accelerate the publication process.

### SUBMISSION CHECKLIST

It is hoped that this list will be useful during the final checking of an article prior to sending it to the journal’s editor for review. Please consult this Guide for Authors, for further details of any item.

Ensure that the following items are present:

- Cover letter to the editor
- The category of the manuscript
- Acknowledgement of “the paper is not under consideration for publication in another journal”
- Disclosure of any commercial or financial involvement
- Reviewing the statistical design of the research article
- Last control for fluent English
- Copyright Transfer Form
- Author Contribution Form
- ICJME Form for Disclosure of Potential Conflicts of Interest
- Permission of previous published material if used in the present manuscript
- Acknowledgement of the study “in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of in 2000.
- Statement that informed consent was obtained after the procedure(s) had been fully explained.
- Indicating whether the institutional and national guide for the care and use of laboratory animals was followed as in “Guide for the Care and Use of Laboratory Animals”.
- Title page
- The title of the manuscript both in Turkish and in English
- All authors and their affiliations
- All authors’ e-mail address, full postal address, GSM phone, business telephone and fax numbers
- Abstracts (400-500 words) Both in Turkish and in English
- Key words: 3 to 10 words (in Turkish and in English)
- Body text
- Acknowledgement
- Reference
- All tables (including title, description, footnotes)



## YAZARLARA BİLGİ

### Derginin Tanımı

Bağcılar Tıp Bülteni (Bağcılar Medical Bulletin), tıbbın her alanında araştırma makalelerini, güncel derleme yazılarını, olgu sunumlarını ve editöre mektupları İngilizce tam metin ve Türkçe özle yayınlayan hakemli bir dergidir. Dergi online olarak yılda 4 sayı yayınlanmaktadır. Tüm makaleler kabul edilir edilmez, online olarak pdf formatında bu web sitesinde, o dönemdeki sayının bir makalesi olarak yer alacaktır. Dergi Galenos Yaynevi tarafından yayımlanmaktadır.

### Editöryal Politikalar ve Hakem Süreci

#### Yayın Politikası

Bağcılar Tıp Bülteni, yayınlanmak üzere gönderilen yazıları aşağıda belirtilen şekillerde kabul eder:

- Orijinal araştırmalar,
- Kısa araştırmalar,
- Olgu sunumları,
- Derlemeler,
- Editöre mektup

Dergi, Türkiye’de yapılan araştırmaların uluslararası bilim arenasına duyurulması, uluslararası bilim çevrelerince paylaşılması ve bu bağlamda Türkiye’nin tanıtılmasına katkıda bulunmayı misyon edindiğinden özellikle orijinal araştırma niteliğindeki yazıları yayınlamaya öncelik vermektedir. Dergide yayınlanacak derleme türündeki yazılar editör tarafından konu ile ilgili çalışan yetkin kişilere hazırlanmaktadır.

#### Genel İlkeler

Daha önce yayınlanmamış ya da yayınlanmak üzere başka bir dergide halen değerlendirilmediği olmayan ve her bir yazar tarafından onaylanan makaleler dergide değerlendirilmeye kabul edilir. Yayın kurulu, yazarların iznini alarak yazıda değişiklikler yapabilir. Editör ve dil editörleri dil, imlâ ve kaynakların National Library of Medicine MEDLINE/PubMed Resources’da belirtildiği gibi yazılmasında ve ilgili konularda tam yetkilidir.

Eğer makalede daha önce yayınlanmış alıntı yazı, tablo, resim vs. mevcut ise makale yazarı, yayın hakkı sahibi ve yazarlarından yazılı izin almak ve bunu makalede belirtmek zorundadır. Gerekli izinlerin alınıp alınmadığından yazar(lar) sorumludur.

Bilimsel toplantılarda sunulan özet bildiriler, makalede belirtilmesi koşulu ile kaynak olarak kabul edilir. Editör, dergiye gönderilen makale biçimsel esaslara uygun ise, gelen yazıyı yurtiçinden ve/veya yurtdışından en az iki hakemin değerlendirmesinden geçirir, hakemler gerek gördüğü takdirde yazıda istenen değişiklikler yazarlar tarafından yapıldıktan sonra yayınlanmasına onay verir. Makale yayınlanmak üzere dergiye gönderildikten sonra yazarlardan hiçbirinin ismi, tüm

yazarların yazılı izni olmadan yazar listesinden silinemez ve yeni bir isim yazar olarak eklenemez ve yazar sırası değiştirilemez. Yayına kabul edilmeyen makale, resim ve fotoğraflar yazarlara geri gönderilmez.

### Yazarların Sorumluluğu

Makalelerin bilimsel ve etik kurallara uygunluğu yazarların sorumluluğundadır. Yazar makalenin orijinal olduğu, daha önce başka bir yerde yayınlanmadığı ve başka bir yerde, başka bir dilde yayınlanmak üzere değerlendirilmediği konusunda teminat sağlamalıdır. Uygulamadaki telif kanunları ve anlaşmaları gözetilmelidir. Telifte bağlı materyaller (örneğin tablolar, şekiller veya büyük alıntılar) gerekli izin ve teşekkülle kullanılmalıdır. Başka yazarların, katkıda bulunanların çalışmaları ya da yararlanılan kaynaklar uygun biçimde kullanılmalı ve referanslarda belirtilmelidir.

Gönderilen makalede tüm yazarların akademik ve bilimsel olarak doğrudan katkısı olmalıdır, bu bağlamda “yazar” yayınlanan bir araştırmanın kavramsallaştırılmasına ve desenine, verilerin elde edilmesine, analizine ya da yorumlanmasına belirgin katkı yapan; yazının yazılması ya da bunun içerik açısından eleştirel biçimde gözden geçirilmesinde görev yapan; yazının yayınlanmak üzere nihai halini onaylayan ve çalışmanın herhangi bir bölümünün doğruluğuna ya da bütünlüğüne ilişkin soruların uygun şekilde soruşturulduğunun ve çözümlendiğinin garantisini vermek amacıyla çalışmanın her yönünden sorumlu olmayı kabul eden kişi olarak görülür. Fon sağlanması, ya da araştırma grubunun genel süpervizyonu tek başına yazarlık hakkı kazandırmaz. Yazar olarak gösterilen tüm bireyler sayılan tüm ölçütleri karşılamalıdır ve yukarıdaki ölçütleri karşılayan her birey yazar olarak gösterilebilir. Çok merkezli çalışmalarda grubun tüm üyelerinin yukarıda belirtilen şartları karşılaması gereklidir. Yazarların isim sıralaması ortak verilen bir karar olmalıdır. Tüm yazarlar yazar sıralamasını Telif Hakkı Devir Formunda imzalı olarak belirtmek zorundadırlar. Yazarların tümünün ismi yazının başlığının altındaki bölümde yer almalıdır.

Yazarlık için yeterli ölçütleri karşılamayan ancak çalışmaya katkısı olan tüm bireyler teşekkür (acknowledgement) kısmında sıralanmalıdır. Bunlara örnek olarak ise sadece teknik destek sağlayan, yazıma yardımcı olan ya da sadece genel bir destek sağlayan kişiler verilebilir. Finansal ve materyal destekleri de belirtilmelidir.

Yazıya materyal olarak destek veren ancak yazarlık için gerekli ölçütleri karşılamayan kişiler “klinik araştırmacılar” ya da “yardımcı araştırmacılar” gibi başlıklar altında toplanmalı ve bunların işlevleri ya da katılımları “bilimsel danışmanlık yaptı”, “çalışma önerisini gözden geçirdi”, “veri topladı” ya da “çalışma hastalarının bakımını üstlendi” şeklinde belirtilmelidir.

### YAZARLARA BİLGİ

Teşekkür (acknowledgement) kısmında belirtilen bu ifadeler için bu bireylerden de yazılı izin alınması gerekmektedir.

Bütün yazarlar, araştırmanın sonuçlarını ya da bilimsel değerlendirmeyi etkileyebilme potansiyeli olan finansal ilişkiler, çıkar çatışması ve çıkar rekabetini beyan etmelidirler. Bir yazar kendi yayınlanmış yazısında belirgin bir hata ya da yanlışlık tespit ederse, bu yanlışlıklara ilişkin düzeltme ya da geri çekme için yayın yönetmeni ile hemen temasa geçme ve işbirliği yapma sorumluluğunu taşır. Yazarların katkısını belirten Yazar Katkı Formu ve çıkar çatışması olup olmadığını belirten ICMJE Potansiyel Çıkar Çatışması Beyan Formu makale ile birlikte gönderilmelidir. Yazarların görevleri ve sorumlulukları konusunda aşağıdaki kaynağa bakabilirsiniz; <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/>

#### Editör ve Hakem Sorumlulukları ve Değerlendirme Süreci

Editörler, makaleleri, yazarların etnik kökeninden, cinsiyetinden, cinsel yöneliminden, uyruğundan, dini inancından ve siyasi felsefesinden bağımsız olarak değerlendirirler. Yayına gönderilen makalelerin adil bir şekilde çift taraflı kör hakem değerlendirmesinden geçmelerini sağlarlar. Gönderilen makalelere ilişkin tüm bilginin, makale yayınlanana kadar gizli kalacağını garanti ederler. Editörler içerik ve yayının toplam kalitesinden sorumludurlar. Gereğinde hata sayfası yayınlamalı ya da düzeltme yapmalıdır.

Genel Yayın Yönetmeni; yazarlar, editörler ve hakemler arasında çıkar çatışmasına izin vermez. Hakem atama konusunda tam yetkiye sahiptir ve Bağcılar Tıp Bülteni'nde yayınlanacak makalelerle ilgili nihai kararı vermekle yükümlüdür. Yayın etiği konusunda COPE kaynağına bakabilirsiniz. <https://publicationethics.org/files/u7141/1999pdf13.pdf>

Hakemler makaleleri, yazarların etnik kökeninden, cinsiyetinden, cinsel yöneliminden, uyruğundan, dini inancından ve siyasi felsefesinden bağımsız olarak değerlendirirler. Araştırmayla ilgili, yazarlarla ve/veya araştırmanın finansal destekçileriyle çıkar çatışmaları olmamalıdır. Değerlendirmelerinin sonucunda tarafsız bir yargıya varmalıdırlar. Hakemler yazarların atıfta bulunmadığı konuyla ilgili yayınlanmış çalışmalarını tespit etmelidirler. Gönderilmiş yazılara ilişkin tüm bilginin gizli tutulmasını sağlamalı ve yazar tarafında herhangi bir telif hakkı ihlali ve intihal fark ederlerse Genel Yayın Yönetmeni'ne raporlamalıdırlar. Hakem, makale konusu hakkında kendini vasıflı hissetmiyorsa ya da zamanında geri dönüş sağlaması mümkün görünmüyorsa, Genel Yayın Yönetmeni'ne bu durumu bildirmeli ve hakem sürecine kendisini dahil etmemesini istemelidir.

Editör makalelerle ilgili bilgileri (makalenin alınması, içeriği, gözden geçirme sürecinin durumu, hakemlerin eleştirileri ya da varılan sonuç) yazarlar ya da hakemler dışında kimseye paylaşmaz.

Değerlendirme sürecinde editör hakemlere gözden geçirme için gönderilen makalelerin, yazarların özel mülkü olduğunu ve bunun imtiyazlı bir iletişim olduğunu açıkça belirtir. Hakemler ve yayın kurulu üyeleri topluma açık bir şekilde makaleleri tartışamazlar. Hakemlerin kendileri için makalelerin kopyalarını çıkarmalarına izin verilmez ve editörün izni olmadan makaleleri başkasına veremezler. Hakemler gözden geçirmelerini bitirdikten sonra makalenin kopyalarını yok etmeli ya da editöre göndermelidirler. Dergimiz editörü de reddedilen ya da geri verilen makalelerin kopyalarını imha etmelidir.

Yazarın ve editörün izni olmadan hakemlerin gözden geçirmeleri basılamaz ve açıklanamaz. Hakemlerin kimliğinin gizli kalmasına özen gösterilmelidir. Bazı durumlarda editörün kararıyla, ilgili hakemlerin makaleye ait yorumları aynı makaleyi yorumlayan diğer hakemlere gönderilerek hakemlerin bu süreçte aydınlatılması sağlanabilir. Değerlendirme süreciyle ilgili olarak COPE kaynağına bakabilirsiniz: [http://publicationethics.org/files/Peer review guidelines.pdf](http://publicationethics.org/files/Peer%20review%20guidelines.pdf)

#### Açık Erişim İlkesi

Açık erişimli bir yayın olan Bağcılar Tıp Bülteni dergisinin tüm içeriği okura ya da okurun dahil olduğu kuruma ücretsiz olarak sunulur. Okurlar, yayıncı ya da yazardan izin almadan dergi makalelerinin tam metnini okuyabilir, indirebilir, kopyalayabilir, dağıtabilir, basabilir, arayabilir ve link sağlayabilir.

#### Yayın Etiği

##### İlke ve Standartlar

Bağcılar Tıp Bülteni yayın etiğinde en yüksek standartlara bağlıdır ve Committee on Publication Ethics (COPE), Council of Science Editors (CSE), World Association of Medical Editors (WAME) ve International Committee of Medical Journals (ICJME) tarafından geliştirilen yayın etiği ilkelerini ve tavsiyelerini gözetir.

Gönderilen tüm makaleler orijinal, yayınlanmamış (konferans bildirilerindeki tam metinler de dahil) ve başka bir dergide değerlendirme sürecinde olmamalıdır. Her bir makale editörlerden biri ve en az iki hakem tarafından çift kör değerlendirmeden geçirilir. Gönderilen makaleleri intihal yazılımı ile denetleme hakkımız haklıdır. İntihal, veride hile ve tahrif (araştırma verisi, tabloları ya da imajlarının manipülasyonu ve asılsız üretimi), insan ve hayvanların araştırmada uygun olmayan kullanımı konuları denetimden



### YAZARLARA BİLGİ

geçmektedir. Bu standartlara uygun olmayan tüm makaleler yayından çıkarılır. Buna yayından sonra tespit edilen olası kuraldışı, uygunsuzluklar içeren makaleler de dahildir. Yayın etiği kurallarına bağlı olarak, intihal şüphesini ve duplikasyon durumlarını rapor edeceğimizi belirtiriz. Olası bilimsel hatalı davranışları ve yayın etiği ihlali vakalarını ele alırken COPE Ethics Flowcharts <http://publicationethics.org/resources/flowcharts> izlenir.

#### **İnsan ve Hayvan Hakları, Bilgilendirilmiş Olur, Çıkar Çatışması**

Bağcılar Tıp Bülteni, yayınladığı makalelerin ticarî kaygılardan uzak ve konu ile ilgili en iyi etik ve bilimsel standartlarda olması şartını gözetmektedir. Makalelerin etik kurallara uygunluğu yazarların sorumluluğundadır.

Bağcılar Tıp Bülteni, 1975 Helsinki Deklarasyonu'nun 2004 yılında revize edilen Ethical Principles for Medical Research Involving Human Subjects'e <http://www.wma.net/en/30publications/10policies/b3/index.html> ve 2006 yılında revize edilen WMA Statement on Animal Use in Biomedical Research'e <http://www.wma.net/en/30publications/10policies/a18/uyumayı> prensip edinmiştir. Bu yüzden dergide yayınlanmak üzere gönderilen yazılarda, klinik deneylere katılan denekler ile ilgili olarak yukarıda belirtilen etik standartlara uyulduğunun mutlaka belirtilmesi gerekmektedir. Ayrıca deneyin türüne göre gerekli olan yerel veya ulusal etik komitelerden alınan onay yazıları yazı ile birlikte gönderilmelidir. Bununla birlikte deneye katılan kişi/hastalardan, hastalar eğer temyiz kudretine sahip değilse vâsilerinden yazılı bilgilendirilmiş onam alındığını belirten bir yazı ile beraber tüm yazarlar tarafından imzalanmış bir belgenin editöre gönderilmesi gerekmektedir.

Hastalardan izin alınmadan mahremiyet bozulamaz. Hastaların ismi, isimlerinin baş harfleri ya da hastane numaraları gibi tanımlayıcı bilgiler, fotoğraflar ve soy ağacı bilgileri vb. bilimsel amaçlar açısından çok gerekli olmadıkça ve hasta (ya da anne-baba, ya da vâsisi) yazılı bilgilendirilmiş onam vermedikçe basılmazlar. Özellikle olgu bildirimlerinde, çok gerekli olmadıkça hasta ile ilgili tanımlayıcı ayrıntılar çıkarılmalıdır. Örneğin, fotoğraflarda göz bölgesinin maskelenmesi kimliğin gizlenmesi için yeterli değildir. Eğer veriler kimliğin gizlenmesi için değiştirildiyse yazarlar bu değişikliklerin bilimsel anlamı etkilemediği konusunda güvence vermelidirler. Olgu sunumlarında yer verilen hastalardan bilgilendirilmiş onam alınmalıdır. Bilgilendirilmiş onam alındığı da makalede belirtilmelidir.

Bu tip çalışmaların varlığında yazarlar, makalenin YÖNTEM(LER) bölümünde bu prensiplere uygun olarak çalışmayı yaptıklarını, kurumlarının etik kurullarından ve

çalışmaya katılmış insanlardan “bilgilendirilmiş onam” aldıklarını belirtmek zorundadırlar.

Çalışmada “hayvan” kullanılmış ise yazarlar, makalenin YÖNTEM(LER) bölümünde “Guide for the Care and Use of Laboratory Animals” ([www.nap.edu/catalog/5140.html](http://www.nap.edu/catalog/5140.html)) doğrultusunda çalışmalarında hayvan haklarını koruduklarını ve kurumlarının etik kurullarından onay aldıklarını belirtmek zorundadırlar. Hayvan deneyleri rapor edilirken yazarlar, laboratuvar hayvanlarının bakımı ve kullanımı ile ilgili kurumsal ve ulusal rehberlere uyup uymadıklarını yazılı olarak bildirmek zorundadırlar.

Editör ve yayıncı, reklâm amacı ile dergide yayınlanan ticarî ürünlerin özellikleri ve açıklamaları konusunda hiçbir garanti vermemekte ve sorumluluk kabul etmemektedir. Eğer makalede doğrudan veya dolaylı ticarî bağlantı veya çalışma için maddî destek veren kurum mevcut ise yazarlar; kaynak sayfasında, kullanılan ticarî ürün, ilaç, ilaç firması v.b. ile ticarî ilişkisinin olmadığını veya varsa nasıl bir ilişkisinin olduğunu (konsültan, diğer anlaşmalar) bildirmek zorundadır. Bağcılar Tıp Bülteni, WAME'nin çıkar çatışması tanımını benimser <http://www.wame.org/about/wame-editorial-on-coi>

Buna göre, yazar, hakem ya da editör sorumluluklarını aşırı düzeyde ve/veya haksızlığa yol açabilecek düzeyde etkileyebilecek ya da etkileyebileceği olası bir çıkar rekabeti içindeyse, çıkar çatışması söz konusudur ve bunun açıklanması gerekir. Açıklanması öngörülen çıkar çatışması tipleri, finansal bağlar, akademik taahhütler, kişisel ilişkiler, politik ya da dini inançlar, kurumsal bağlantılardır. Çıkar çatışması söz konusuysa bu makalede açıklanmalıdır.

#### **Dil**

Bağcılar Tıp Bülteni'nin yayın dili Amerikan İngilizcesi'dir, ayrıca makalelerin özleri hem İngilizce, hem Türkçe yayınlanır. Her iki dildeki özler yazarlardan istenir.

#### **Yazıların Hazırlanması**

Aksi belirtilmedikçe gönderilen yazılarla ilgili tüm yazışmalar ilk yazarla yapılacaktır. Gönderilen yazılar, yazının yayınlanmak üzere gönderildiğini ve Bağcılar Tıp Bülteni'nin hangi bölümü (Orijinal Araştırma, Kısa Araştırma, Olgu Sunumu, Derleme, Editöre Mektup) için başvurulduğunu belirten bir mektup, yazının elektronik formunu içeren Microsoft Word 2003 ve üzerindeki versiyonları ile yazılmış elektronik dosya ile tüm yazarların imzaladığı 'Telif Hakkı Devir Formu', Yazar Katkı Formu ve ICMJE Potansiyel Çıkar Çatışması Beyan Formu ile gönderilmelidir. Yazıların alınmasının ardından yazarlara makalenin alındığı, bir makale numarası ile bildirilecektir. Tüm yazışmalarda bu makale numarası kullanılacaktır. Makaleler sayfanın her bir kenarından 2,5



### YAZARLARA BİLGİ

cm kenar boşluğu bırakılarak ve çift satır aralıklı yazılmalıdır. Makalelerde aşağıdaki sıra takip edilmelidir ve her bölüm yeni bir sayfa ile başlamalıdır: 1) başlık sayfası, 2) öz, 3) metin, 4) teşekkür / 5) kaynaklar ve 6) tablo ve/veya şekiller. Tüm sayfalar sırayla numaralandırılmalıdır.

#### Başlık

Başlık sayfasında, yazarların adları, akademik ünvanları ve yazılacak yazarın tam adres, telefon ve faks numaraları ile e-mail adresi mutlaka bulunmalıdır. Yazıların Türkçe özetlerinde mutlaka Türkçe başlık da yer almalıdır.

#### Öz ve Anahtar Sözcükler

Makalenin İngilizce başlığı İngilizce özde, Türkçe başlığı da Türkçe özde yer almalıdır. Bütün makaleler öz ve anahtar kelime içermelidir. Özler bir makalenin birçok elektronik veri tabanında yer alan en belirgin kısmı olduğundan, yazarlar özün makalenin içeriğini doğru olarak yansıttığından emin olmalıdır. Öz çalışmanın temeliyle ilgili bilgi vermeli ve çalışmanın amacını, temel prosedürleri (olguların ya da laboratuvar hayvanlarının seçimi, gözlemsel ve analitik yöntemler), ana bulguları (mümkünse özgül etki büyüklüklerini ve istatistiksel anlamlılıklarını vererek) ve temel çıkarımları içermelidir. Çalışmanın ya da gözlemlerin yeni ve önemli yönleri belirtilmelidir. Anahtar sözcükler, her türlü yazıda Türkçe ve İngilizce özetlerin altındaki sayfada 3-10 adet verilmelidir. Anahtar sözcük olarak National Library of Medicine'in Tıbbi Konu Başlıkları'nda (Medical Subject Headings, MeSH) yer alan terimler kullanılmalıdır. MeSH'de yer alan terimlerin Türkçe karşılıklarına Türkiye Bilim Terimleri'nden <http://www.bilimterimleri.com> erişilebilir.

#### Makale Türleri

##### Orijinal Araştırma

Orijinal araştırma makaleleri derginin kapsamına uygun konularda önemli, özgün bilimsel sonuçlar sunan araştırmaları raporlayan yazılardır. Orijinal araştırma makaleleri, Öz, Anahtar Kelimeler, Giriş, Yöntem ve Gereçler, Bulgular, Tartışma, Sonuçlar, Kaynaklar bölümlerinden ve Tablo, Grafik ve Şekillerden oluşur. Öz bölümü araştırma yazılarında aşağıda belirtilen formatta yapılandırılmış olmalıdır.

#### Öz

Araştırma yazılarında Türkçe ve İngilizce özetler en fazla 500 kelime olmalı ve şu şekilde yapılandırılmalıdır: Amaç/Objective: Yazının birincil ve asıl amacı; Yöntem ve Gereçler/Material and Method(s): Veri kaynakları, çalışmanın iskeleti, hastalar ya da çalışmaya katılanlar, görüşme/değerlendirmeler ve temel ölçümler; Bulgular/Results: Ana bulgular; Sonuç(lar)/Conclusion(s): Doğrudan klinik uygulamalar, çıkartılacak sonuçlar belirtilmelidir.

#### Anahtar Kelimeler

National Library of Medicine'in Tıbbi Konu Başlıkları'nda (Medical Subject Headings, MeSH) yer alan terimler kullanılmalıdır, en az üç anahtar kelime belirtilmelidir.

#### Giriş

Giriş/Introduction bölümünde konunun önemi, tarihe ve bugüne kadar yapılmış çalışmalar, hipotez ve çalışmanın amacından söz edilmelidir. Hem ana hem de ikincil amaçlar açıkça belirtilmelidir. Sadece gerçekten ilişkili kaynaklar gösterilmeli ve çalışmaya ait veri ya da sonuçlardan söz edilmemelidir.

#### Yöntem ve Gereçler

Yöntem ve Gereçler/Material and Methods bölümünde, veri kaynakları, hastalar ya da çalışmaya katılanlar, ölçekler, görüşme/değerlendirmeler ve temel ölçümler, yapılan işlemler ve istatistiksel yöntemler yer almalıdır. Yöntem bölümü, sadece çalışmanın planı ya da protokolü yazılırken bilinen bilgileri içermelidir; çalışma sırasında elde edilen tüm bilgiler bulgular kısmında verilmelidir. Yöntem ve Gereçler bölümünde olguların seçimi ve tanımlanması hakkında bilgi, teknik bilgi ve istatistik hakkında bilgi yer almalıdır. Araştırmanın Etik Kurul Onayı ve katılımcılardan alınan yazılı Bilgilendirilmiş Onam belirtilmelidir.

#### Olguların Seçimi ve Tanımlanması

Gözlemsel ya da deneysel çalışmaya katılanların (hastalar, hayvanlar, kontroller) seçimi, kaynak popülasyon, çalışmaya alınma ve çalışmadan dışlanma ölçütleri açıkça tanımlanmalıdır. Yaş ve cinsiyet gibi değişkenlerin çalışmanın amacıyla olan ilişkisi her zaman açık olmadığından yazarlar çalışma raporundaki kullanımlarını açıklamalıdır; örneğin yazarlar niçin sadece belli bir yaş grubunun alındığını ya da neden kadınların çalışma dışında bırakıldığını açıklamalıdır. Çalışmanın niçin ve nasıl belli bir şekilde yapıldığı açık bir şekilde belirtilmelidir. Yazarlar etnisite ya da ırk gibi değişkenler kullandıklarında bu değişkenleri nasıl ölçtüklerini ve geçerliklerini açıklamalıdır.

#### Teknik Bilgi

Diğer çalışmacıların sonuçları yineleyebilmesi için yöntem ve kullanılan araçlar (üretici firma ve adres paragraf içinde belirtilerek) ayrıntılı bir şekilde belirtilmelidir. Önceden kullanılan bilinen yöntemler için (istatistiksel yöntemler dahildir) kaynak gösterilmeli, basılmış ama iyi bilinmeyen bir yöntem için kaynak verilmeli ve yöntem açıklanmalıdır. Aynı şekilde yeni ya da belirgin olarak modifiye edilmiş yöntemler tanımlanmalı ve kullanıma nedenleri belirtilip kısıtlılıkları değerlendirilmelidir. Kullanılan tüm ilaç ve kimyasallar doğru olarak tanımlanıp jenerik isimleri, dozları ve kullanım biçimleri



### YAZARLARA BİLGİ

belirtilmelidir. Gözden geçirme yazısı gönderen yazarlar veriyi bulma, seçme, ayırma ve sentezleme yöntemlerini belirtmelidir. Bu yöntemler aynı zamanda özde de yer almalıdır.

#### İstatistik

İstatistiksel yöntem, orijinal veriye erişebilecek bilgili bir okuyucunun rapor edilen sonuçları onaylayabileceği bir ayrıntıda belirtilmelidir. Mümkünse, bulgular niceliksel hale getirilmeli ve hata ölçümleri (güvenlik aralıkları gibi) sunulmalıdır. Etki büyüklüğünü vermeyen, p değerlerinin kullanımı gibi, salt istatistiksel hipotez sınamasına dayanılmamalıdır. Çalışma deseni ve istatistiksel yöntemlere dair kaynaklar sayfalar belirtilerek mümkün olduğu sürece standart kaynaklar olmalıdır. İstatistiksel terimler, kısaltmalar ve semboller tanımlanmalıdır. Kullanılan bilgisayar programı belirtilmelidir.

#### Bulgular

Ana bulgular istatistiksel verilerle desteklenmiş olarak eksiksiz verilmeli ve bu bulgular uygun tablo, grafik ve şekillerle görsel olarak da belirtilmelidir. Bulgular yazıda, tablolarda ve şekillerde mantıklı bir sırayla önce en önemli sonuçlar olacak şekilde verilmelidir. Tablo ve şekillerdeki tüm veriyi yazıda vermemeli, sadece önemli noktaları vurgulanmalıdır. Ekstra materyal ve teknik bilgi ek kısmında verilerek yazının akışının bozulmaması sağlanmalı, alternatif olarak bunlar sadece elektronik versiyonda yer almalıdır.

#### Tartışma

Tartışma/Discussion bölümünde o çalışmadan elde edilen veriler, kurulan hipotez doğrultusunda hipotezi destekleyen ve desteklemeyen bulgular ve sonuçlar irdelenmeli ve bu bulgu ve sonuçlar literatürde bulunan benzeri çalışmalarla kıyaslanmalı, farklılıklar varsa açıklanmalıdır. Çalışmanın yeni ve önemli yanları ve bunlardan çıkan sonuçları vurgulanmalıdır. Giriş ya da sonuçlar kısmında verilen bilgi ve veriler tekrarlanmamalıdır.

#### Sonuçlar

Sonuçlar/Conclusions bölümünde çalışmadan çıkarılan sonuçlar sıralanmalıdır. Deneysel çalışmalar için tartışmaya sonuçları kısaca özetleyerek başlamak, daha sonra olası mekanizmaları ya da açıklamaları incelemek ve bulguları önceki çalışmalarla karşılaştırmak, çalışmanın kısıtlılıklarını özetlemek, gelecekteki çalışmalar ve klinik pratik için uygulamalarını belirtmek faydalıdır. Varılan sonuçlar çalışmanın amacıyla karşılaştırılmalı, ancak elde edilen bulgular tarafından yeterince desteklenmeyen çıkarımlardan kaçınılmalıdır. Yazarlar, eğer elde ettikleri veriler ekonomik veri ve analizler içermiyorsa, ekonomik çıkar ya da faydalarla ilgili yorumlardan özellikle kaçınılmalıdır. Gerektiğinde yeni hipotezler ortaya konmalı, ancak bunların yeni hipotezler olduğu belirtilmelidir.

#### Tablo, Grafik ve Şekiller

Yazı içindeki grafik, şekil ve tablolar Arap sayıları ile numaralandırılmalıdır. Şekillerin metin içindeki yerleri belirtilmelidir. Ayrıntılı bilgi aşağıda ilgili başlık altında yer almaktadır.

#### Kısa Araştırma

Kısa Araştırma makaleleri tarz ve format açısından Orijinal Araştırma makaleleri gibidir; ancak daha küçük ölçekli araştırmaları ya da geliştirme çalışmasının erken aşamalarında olan araştırmaları ele alır. Basit araştırma tasarımı kullanan ön çalışmalar, sınırlı pilot veri sağlayan küçük örnek kitle ile yapılan çalışmalar, ileri araştırma gereksinimine işaret eden başlangıç bulguları bu tür araştırmalar kapsamında sayılabilir. Kısa Araştırma makaleleri, büyük ölçekli gelişkin araştırma projelerini konu alan Orijinal Araştırma makalelerinden daha kısadır. Ancak Kısa Araştırma, Orijinal Araştırma makalesi olabilecek kalitede bir araştırma makalesinin kısa versiyonu olarak anlaşılmalıdır; önem derecesi düşük, titizlikle yapılmamış bir araştırma hakkında bir yayın malzemesi hazırlamak için kullanılmamalıdır ya da genişletildiğinde Orijinal Araştırma makalesi ya da araştırma niteliği kazanmayacak bir içeriği değerlendirecek bir makale türü olarak anlaşılmalıdır.

#### Olgu Sunumu

Olgu sunumu makaleleri özgün vakaları rapor eden yazılardır. Derginin kapsamına giren konulara ilişkin bir problemin üstesinden gelen tedaviyle ilgili, yeni araçlar, teknikler ve metotlar göstererek okuyucular için bilgilendirme sağlamalıdır. Olgu sunumu yazıları Öz (özün araştırma makalesinde olduğu gibi belli bir formatta yapılandırılmış olması gerekmiyor), Anahtar Kelimeler, Giriş, Olgu Sunumu, Tartışma, Referanslar, gerekirse Tablo ve açıklayıcı bilgilerden oluşur. Olgu sunumunda yazılı bilgilendirilmiş onam alınmalı ve makalede belirtilmelidir.

#### Derleme

Derleme makaleleri alanında zengin birikime ve atıf alan çalışmalara sahip uzman kişilerce yazılan yazılardır. Klinik pratiğe ilişkin bir konuda mevcut bilgiyi tanımlayan, değerlendiren ve tartışan; geleceğe ilişkin çalışmalara yol gösteren derleme yazıları yazmaları için dergi belirlediği yazarlara davet gönderir. Derleme makaleleri, Öz (özün, araştırma makalesinde olduğu gibi belli bir formatta yapılandırılmış olması gerekmiyor), Anahtar Kelimeler, Giriş, Sonuç bölümlerinden oluşur. Derleme makale gönderen yazarların, makalede kullandıkları verinin seçimi, alınması, sentezi için kullandıkları yöntemleri tanımlayan bir bölüme de makalede yer vermeleri gerekir. Bu yöntemler Öz bölümünde de belirtilmelidir.

### YAZARLARA BİLGİ

#### Editöre Mektup

Editöre Mektup, kısa ve net görüş bildiren yazılardır. Dergide daha önce yayınlanmış olan makalelerle ilgili olarak ya da dergide ifade edilmiş görüşlerle ilgili olarak yazılmış olması tercih edilir. Editöre Mektup yazıları, daha sonra yeni bir yazı ile geçerlilik ispatı gerektirebilecek ön görüş bildiren yazılar olmamalıdır.

#### Tablolar

Tablolar bilgileri etkin bir şekilde gösterir ve ayrıca bilginin istenen tüm ayrıntı seviyelerinde verilmesini sağlar. Bilgileri metin yerine tablolarda vermek genelde metnin uzunluğunu kısaltır.

Her tablo ayrı bir sayfaya çift aralıklı olarak basılmalıdır. Tablolar metindeki sıralarına göre numaralanıp, her birine kısa bir başlık verilmelidir. MS Word 2003 ve üstü versiyonlarında otomatik tablo seçeneğinde “tablo klasik 1” ya da “tablo basit 1” seçeneklerine göre tablolar hazırlanmalıdır. Başlık satırı ve tablo alt üst satırları dışında tablonun içinde başka dikey ve yatay çizgiler kullanılmamalıdır. Her sütuna bir başlık verilmelidir. Yazarlar açıklamaları başlıkta değil, dipnotlarda yapmalıdır. Dipnotlarda standart olmayan tüm kısaltmalar açıklanmalıdır. Dipnotlar için sırasıyla şu semboller kullanılmalıdır: (\*, †, ‡, §, ||, ¶, \*\*, ††, ‡‡).

Varyasyonun standart sapma ya da standart hata gibi istatistiksel ölçümleri belirtilmelidir. Metin içinde her tabloya atıfta bulunulduğuna emin olunmalıdır. Eğer yayınlanmış ya da yayınlanmamış herhangi başka bir kaynaktan veri kullanılıyorsa izin alınmalı ve onlar tam olarak bilgilendirilmelidir. Çok fazla veri içeren tablolar, çok yer tutar ve sadece elektronik yayınlar için uygun olabilir ya da okuyuculara yazarlar tarafından doğrudan sağlanabilir. Böyle bir durumda uygun bir ifade metne eklenmelidir. Bu tip tablolar, hakem değerlendirmesinden geçmesi için makaleyle beraber gönderilmelidir.

#### Şekiller

Şekiller ya profesyonel olarak çizilmeli ve fotoğflanmalı ya da fotoğraf kalitesinde dijital olarak gönderilmelidir. Şekillerin basıma uygun versiyonlarının yanı sıra JPEG ya da GIF gibi elektronik versiyonlarda yüksek çözünürlükte görüntü oluşturacak biçimlerde elektronik dosyaları gönderilmeli ve yazarlar göndermeden önce bu dosyaların görüntü kalitelerini bilgisayar ekranında kontrol etmelidir.

Röntgen, CT, MRI filmleri ve diğer tanısal görüntülemeler yüksek kalitede basılmış olarak gönderilmelidir. Bu nedenle şekillerin üzerindeki harfler, sayılar ve semboller açık ve tüm makalede eşit ve yayın için küçültüldüklerinde bile okunabilecek boyutlarda olmalıdır. Şekiller mümkün olduğunca tek başlarına

anlaşılabilir olmalıdır. Fotomikrografik patoloji preparatları iç ölçekler içermelidir. Semboller, oklar ya da harfler fonla kontrast oluşturmamalıdır. Eğer insan fotoğrafı kullanılacaksa, ya bu kişiler fotoğraftan tanınmamalıdır ya da yazılı izin alınmalıdır (Etik bölümüne bakınız).

Şekiller metinde geçiş sıralarına göre numaralandırılmalıdır. Eğer önceden yayınlanmış bir şekil kullanılacaksa, yayın hakkını elinde bulunduran bireyden izin alınmalıdır. Toplum alanındaki belgeler hariç yazarlığa ve yayıncıya bakılmadan bu izin gereklidir. Basılacak bölgeyi gösteren ek çizimler editörün işini kolaylaştırır. Renkli şekiller editör gerekli gördüğünde ya da sadece yazar ek masrafı karşılırsa basılır.

#### Şekillerin Dipnotları

Ayrı bir sayfadan başlayarak şekiller için tablo başlıkları ve dipnotları tek aralıklı olarak ve Arap sayıları ile hangi şekle karşı geldikleri belirtilerek yazılmalıdır. Semboller, oklar, sayılar ya da harfler şeklin parçalarını belirtmek için kullanıldığında, dipnotlarda her biri açıkça tanımlanmalıdır. Fotomikrografik patoloji preparatlarında iç ölçek ve boyama tekniği açıklanmalıdır.

#### Ölçüm Birimleri

Uzunluk, ağırlık ve hacim birimleri metrik (metre, kilogram, litre) sistemde ve bunların onlu katları şeklinde rapor edilmelidir. Sıcaklıklar Celsius derecesi, kan basıncı milimetre civa cinsinden olmalıdır. Ölçü birimlerinde hem lokal hem de Uluslararası Birim Sistemleri (International System of Units, SI) kullanılmalıdır. İlaç konsantrasyonları ya SI ya da kütle birimi olarak verilir, alternatif olarak parantez içinde de verilebilir.

Kısaltmalar ve semboller sadece standart kısaltmaları kullanın, standart olmayan kısaltmalar okuyucu için çok kafa karıştırıcı olabilir. Başlıkta kısaltmadan kaçınılmalıdır. Standart bir ölçüm birimi olmadıkça kısaltmaların uzun hali ilk kullanılışlarında açık, kısaltılmı hali parantez içinde verilmelidir.

#### Teşekkür(ler)

Yazının sonunda kaynaklardan önce yer verilir. Bu bölümde kişisel, teknik ve materyal yardımı gibi nedenlerle yapılacak teşekkür ifadeleri yer alır.

#### Kelime Sayısı Sınırlandırması

Türkçe ve İngilizce özlere en fazla 500 kelime olmalıdır. Orijinal makaleler ve derleme yazılarında özel bir kelime sayısı sınırlandırması yoktur. Olgu Sunumları Öz hariç 1000 kelime ile sınırlandırılmalı ve en az sayıda şekil, tablo ve kaynak içermelidir. Editöre mektuplar (en fazla 1000 kelime, tablosuz ve şekilsiz) olmalı ve mektup, tüm yazarlar tarafından imzalanmış olmalıdır. Bağcılar Tıp Bülteni'nde yayınlanmış olan bir yazı ile ilgili eleştiri ya da değerlendirme niteliğindeki mektuplar



### YAZARLARA BİLGİ

sözü edilen yazının yayınlanmasından sonraki 12 hafta içinde alınmış olmalıdır.

#### Makale Hazırlığı:

“Bağcılar Tıp Bülteni”, Tıp Dergilerinde Bilimsel Çalışmaların Yürütülmesi, Raporlanması, Düzenlenmesi ve Yayınlanmasına İlişkin yönergeleri takip eder” (Uluslararası Tıp Dergisi Editörleri Komitesi - <http://www.icmje.org/>). Makalenin sunulması üzerine, yazarlar deneme/araştırma türünü belirtmeli ve uygun olduğunda aşağıdaki kuralların kontrol listesini sağlamalıdır:

Randomize çalışmalar için CONSORT açıklaması (CONSORT Grubu için Moher D, Schultz KF, Altman D. CONSORT beyanı paralel grup randomize çalışmaların raporlarının kalitesini iyileştirmek için önerileri gözden geçirdi. JAMA 2001; 285: 1987-91) (<http://www.consort-statement.org/>),

Sistemik gözden geçirmeler ve meta-analizler için tercih edilen raporlama maddeleri için PRISMA (Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Grubu. Sistemik İncelemeler ve Meta-Analizler için Tercih Edilen Raporlama Maddeleri: PRISMA Beyanı. PLoS Med 2009; 6 ( 7): e1000097.) (<http://www.prisma-statement.org/>),

Tanısal doğruluk çalışmalarının raporlanması için STARD kontrol listesi (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, vd, STARD Grubu için. Teşhis doğruluğu çalışmalarının eksiksiz ve doğru raporlanmasına yönelik: STARD girişimi, Ann Intern Med 2003; 138: 40-4.) (<http://www.stard-statement.org/>),

STROBE gözlemsel çalışma raporlarında yer alması gereken maddelerin kontrol listesi (<http://www.strobe-statement.org/>),

Gözlemsel çalışmaların meta-analizi ve sistemik incelemeleri için MOOSE yönergeleri (Stroup DF, Berlin JA, Morton SC, vd.) Epidemiyolojideki gözlemsel çalışmaların meta-analizi: Epidemiyoloji (MOOSE) grubundaki gözlemsel çalışmaların Meta-analizini bildirme önerisi JAMA 2000; 283: 2008-12).

CARE kuralları, vaka raporlarının doğruluğunu, şeffaflığını ve kullanılabilirliğini artırmak için tasarlanmıştır. (Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; CARE Grubu. CARE Yönergeleri: Konsensüs Tabanlı Klinik Vaka Raporlama Rehberinin Geliştirilmesi.) (<http://www.care-statement.org/>)

#### Kaynaklar

#### Kaynaklarla İlgili Genel Konular

Gözden geçirme yazıları okuyucular için bir konudaki kaynaklara ulaşmayı kolaylaştıran bir araç olsa da, her zaman orijinal çalışmayı doğru olarak yansıtmaz. Bu yüzden mümkün olduğunca yazarlar orijinal çalışmaları kaynak göstermelidir. Öte yandan, bir konuda çok fazla sayıda orijinal çalışmanın kaynak gösterilmesi yer israfına neden olabilir. Birkaç anahtar orijinal çalışmanın kaynak gösterilmesi genelde uzun listelerle

aynı işi görür. Ayrıca günümüzde kaynaklar elektronik versiyonlara eklenebilmekte ve okuyucular elektronik literatür taramalarıyla yayınlara kolaylıkla ulaşabilmektedir.

Özler kaynak olarak gösterilmemelidir. Kabul edilmiş ancak yayınlanmamış makalelere atıflar “basımda” ya da “çıkacak” şeklinde verilmelidir; yazarlar bu makaleleri kaynak gösterebilmek için yazılı izin almalı ve makalelerin basımda olduğunu ispat edebilmelidir. Gönderilmiş ancak yayına kabul edilmemiş makaleler, “yayınlanmamış gözlemler” olarak gösterilmeli ve kaynak yazılı izinle kullanılmalıdır. Genel bir kaynaktan elde edilemeyecek temel bir konu olmadıkça “kişisel iletişime” atıfta bulunulmamalıdır. Eğer atıfta bulunulursa parantez içinde iletişim kurulan kişinin adı ve iletişimin tarihi belirtilmelidir. Bilimsel makaleler için yazarlar bu kaynaktan yazılı izin ve iletişimin doğruluğunu gösterir belge almalıdır.

#### Referans Stili ve Formatı

Tek tip kurallar esas olarak National Library of Medicine, tarafından uyarlanmış olan bir ANSI standart stilini kabul etmiştir. Kaynak atıfta bulunma örnekleri için yazarlar [www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html) sitesine başvurabilirler. Dergi isimleri National Library of Medicine kaynağında yer alan şekilleriyle kısaltılmalıdır. Kaynaklar yazının sonunda (Kaynaklar/References) başlığı altında metindeki geçiş sırasına göre numaralandırılıp dizilmelidir. Metin içinde ise parantez içinde belirtilmelidir. Kaynakların listesiyle metin içinde yer alış sırası arasında bir uyumsuzluk bulunmamalıdır.

Kaynaklar yazının sonunda (Kaynaklar) başlığı altında metindeki geçiş sırasına göre numaralandırılıp dizilmelidir. Metin içinde ise () şeklinde parantez içinde referans numarası belirtilmelidir. Kaynakların listesiyle metin içinde yer alış sırası arasında bir uyumsuzluk bulunmamalıdır.

Kaynakların doğruluğundan yazar(lar) sorumludur. Tüm kaynaklar metinde belirtilmelidir. Kaynaklar aşağıdaki örneklerdeki gibi gösterilmelidir. Altı yazardan fazla yazarı olan çalışmalarda ilk altı yazar belirtilmeli, sonrasında “ve ark.” ya da “et al.” ibaresi kullanılmalıdır. Kaynak dergi adlarının kısaltılması National Library of Medicine’de belirtilen kısaltmalara (<https://www.ncbi.nlm.nih.gov/nlmcatalog/journals>) uygun olmalıdır. National Library of Medicine’da indekslenmeyen bir dergi kısaltılmadan yazılmalıdır.

#### Kaynaklar için örnekler aşağıda belirtilmiştir:

##### 1. Dergilerdeki makaleler için örnekler:

MEDLINE’da yer alan ve kısaltması MEDLINE’a göre yapılan dergi makalesi için: Crow SJ, Peterson CB, Swanson SA,

### YAZARLARA BİLGİ

Raymond NC, Specker S, Eckert ED, et al. Increased mortality in bulimia nervosa and other eating disorders. *Am J Psychiatry* 2009;166(12):1342-1346.

MEDLINE'da yer almayan ve kısaltması olmayan dergi makalesi için: Sevinçer GM, Konuk N. Emotional eating. *Journal of Mood Disorders* 2013;3(4):171-178.

#### 2. Ek sayı için:

MEDLINE'da yer alan ve kısaltması MEDLINE'a göre yapılan dergi makalesi için: Sharan P, Sundar AS. Eating disorders in women. *Indian J Psychiatry* 2015;57(Suppl 2):286-295.

MEDLINE'da yer almayan ve kısaltması olmayan dergi makalesi için: Maner F. Yeme bozukluklarının tedavisi. *Anadolu Psikiyatri Dergisi* 2009;10(Ek 1):55-56.

#### 3. Baskıdaki makale için:

Cossrow N, Pawaskar M, Witt EA, Ming EE, Victor TW, Herman BK, et al. Estimating the prevalence of binge eating disorder in a community sample from the United States: comparing DSM-IV-TR and DSM-5 criteria. *J Clin Psychiatry*, 2016. (in press).

#### 4. Kitaptan alıntılar:

Tek yazarlı kitaptan alıntı için:

McKnight TL. *Obesity Management in Family Practice*. 1st ed., New York:Springer, 2005:47-51.

Kitaptan bir bölüm için, editör(ler) varsa:

Jebb S, Wells J. Measuring body composition in adults and children. In *Clinical Obesity in Adults and Children*, Copelman P, Caterson I, Dietz W (editors). 1st ed., London: Blackwell Publishing, 2005:12-18.

Editörler aynı zamanda kitabın içindeki metin ya da metinlerin yazarı ise: Önce alınan metin ve takiben kitabın ismi yine kelimeler büyük harfle başlatılarak yazılır.

Eckel RH (editor). Treatment of obesity with drugs in the new millennium. In *Obesity Mechanisms and Clinical Management*. 1st ed., Philadelphia: Lippincott Williams & Wilkins, 2003:449-476.

Çeviri Kitaptan Alıntı için:

McGuffin P, Owen MJ, Gottesman II. *Psikiyatri Genetiği ve Genomiği*. Abay E, Görgülü Y (translation editors) 1st ed., İstanbul: Nobel Tıp Kitabevleri, 2009:303-341.

#### 5. Tezden alıntı için:

Keçeli F. Yeme bozukluğu hastalarında obsesif kompulsif bozukluk ve kişilik bozukluğu. Thesis, T.C. Sağlık Bakanlığı Bakırköy Prof. Dr. Mazhar Osman Ruh Sağlığı ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi, İstanbul:2006.

#### 6. Kongre bildirimleri için:

Akbaş Öncel D, Akdemir A. Üniversite öğrencilerinde diyet, beden algısı ve kendilik algısı arasındaki ilişkiler. 47. Ulusal

Psikiyatri Kongresi Özet Kitabı, 26-30 Ekim 2011, Antalya, 2011:102.

#### 7. Online Makale:

Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann Intern Med* [Internet]. 4 Temmuz 2006 [Atf tarihi:4 Ocak 2007];145(1):62-9. Erişim adresi:<http://www.annals.org/cgi/reprint/145/1/62.pdf>

#### Makalenin Dergiye Gönderilmesi

Çevrimiçi gönderim (online submission) ile birlikte Bağcılar Tıp Bülteni web sitesinin ([www.ijfed.org](http://www.ijfed.org)) ilgili kısımlarındaki talimatlara uyarak makale gönderilebilmekte, hakem süreçleri de bu yolla yapılabilmektedir.

Makalelere eşlik eden ve aşağıdaki bilgileri içeren bir kapak mektubu olmalıdır.

- Aynı ya da çok benzer çalışmadan elde edilen raporların daha önce yayına gönderilip gönderilmediği mutlaka belirtilmelidir. Böyle bir çalışmaya özgül olarak atıfta bulunulmalı ve ayrıca yeni makalede de eskisine atıfta bulunulmalıdır. Gönderilen makaleye bu tip materyalin kopyaları da eklenerek editöre karar vermesinde yardımcı olunmalıdır.

- Eğer makalenin kendisinde ya da yazar formunda belirtilmemişse çıkar çatışmasına neden olabilecek mâli ya da diğer ilişkileri belirten bir ifade olmalıdır.

- Makalenin tüm yazarlar tarafından okunup kabul edildiğini, önceden belirtilen şekilde yazarlık ölçütlerinin karşılandığını, her yazarın makalenin dürüst bir çalışmayı yansıttığına inandığını belirten bir ifade olmalıdır. Mektup editöre yardımcı olabilecek tüm diğer bilgileri içermelidir. Eğer makale önceden başka bir dergiye gönderilmişse önceki editörün ve hakemlerin yorumları ve yazarların bunlara verdiği cevapların gönderilmesi faydalıdır. Editör, önceki yazışmaların gönderilmesini hakem sürecini dolayısıyla yazının yayınlanma sürecini hızlandırabileceğinden istemektedir.

Yazarların makalelerini göndermeden önce bir eksiklik olmadığından emin olmalarını sağlamak için bir kontrol listesi bulunmaktadır. Yazarlar derginin kontrol listesini kullanıp gönderilerini kontrol etmeli ve makaleleri ile birlikte bu formu göndermelidirler.

#### SON KONTROL LİSTESİ

- Editöre sunum sayfası
- Makalenin kategorisi
- Başka bir dergiye gönderilmemiş olduğu bilgisi
- Sponsor veya ticari bir firma ile ilişkisi (varsa belirtiniz)



### YAZARLARA BİLGİ

- İstatistik kontrolünün yapıldığı (araştırma makaleleri için)
- İngilizce yönünden kontrolünün yapıldığı
- Telif Hakkı Devir Formu
- Yazar Katkı Formu
- ICMJE Potansiyel Çıkar Çatışması Beyan Formu
- Daha önce basılmış materyal (yazı-resim-tablo) kullanılmış ise izin belgesi
- İnsan ögesi bulunan çalışmalarda “gereç ve yöntemler” bölümünde Helsinki Deklarasyonu prensiplerine uygunluk, kendi kurumlarından alınan etik kurul onayının ve hastalardan “bilgilendirilmiş olur (rıza)” alındığının belirtilmesi
- Hayvan ögesi kullanılmış ise “gereç ve yöntemler” bölümünde “Guide for the Care and Use of Laboratory Animals” prensiplerine uygunluğunun belirtilmesi
- Kapak sayfası
- Makalenin Türkçe ve İngilizce başlığı (tercihen birer satır)
- Yazarlar ve kurumları
- Tüm yazarların yazışma adresi, iş telefonu, faks numarası, GSM, e-posta adresleri
- Özler (400-500 kelime) (Türkçe ve İngilizce)
- Anahtar Kelimeler: 3-10 arası (Türkçe ve İngilizce)
- Tam metin makale
- Teşekkür
- Kaynaklar
- Tablolar-Resimler, Şekiller

### CONTENTS / İÇİNDEKİLER

#### Original Articles / ARAŞTIRMA

- 1** Spinal Metastasis as Presenting Feature of Follicular Type Thyroid Carcinoma: A Case Report and Review of the Literature  
*Spinal Metastazla Belirti Veren Folliküler Tıp Tiroid Karsinomu: Olgu Sunumu ve Literatür Taraması*  
Azmi Tufan, Burak Eren, Abdurrahim Taş, Neslihan Berker, Özgür Yusuf Aktaş, İlker Güleç, Mustafa Safi Vatansever, Murat Karacan, Günay Vahabova, Feyza Karagöz Güzey; İstanbul, Turkey
- 10** Evaluation of Readmitted Patients After Intensive Care Unit Discharge (Retrospective Study)  
*Yoğun Bakım Ünitesinden Taburcu Sonrası Tekrar Yatışı Yapılan Hastaların Değerlendirilmesi (Retrospektif Çalışma)*  
Pınar Öngel Çayören, Kerem Erkalp, Mehmet Salih Sevdı, Serdar Demirkan, Hüseyin Çayören, Aysin Selcan; Iğdır, İstanbul, Turkey
- 16** Effect of Nasopharyngeal Irrigation on Early Eustachian Tube Functions in Patients Undergoing Adenoidectomy: A Clinical Prospective Study  
*Adenoidektomi Sırasındaki Nazofaringeal İrigasyon Yönteminin Erken Dönemde Östaki Tüp Fonksiyonlarına Etkisi: Prospektif Çalışma*  
Şahin Öğreden, Hasan Deniz Tansuker, Abdurrahman Buğra Cengiz, Alper Tabaru, Cemal Özyılmaz, Mehmet Faruk Oktay; İstanbul, Turkey
- 21** Different Therapeutic Approach to Idiopathic Normal Pressure Hydrocephalus: Lumboperitoneal Shunts Versus Ventriculoperitoneal Shunts  
*İdiyopatik Normal Basınçlı Hidrosefalide Farklı Tedavi Yaklaşımları: Lumboperitoneal Şantlar ya da Ventriküloperitoneal Şantlar?*  
Ayçiçek Çeçen, Merih İş, Erhan Çelikoğlu; İstanbul, Turkey
- 25** Retrospective Analysis of Six Primary Cutaneous T-cell Lymphoma Cases in the Light of Recent Advancements  
*Altı Primer Kütanöz T-Hücreli Lenfoma Olgusunun Yeni Gelişmeler Işığında Retrospektif Analizi*  
Betül Taş; İstanbul, Turkey



# Spinal Metastasis as Presenting Feature of Follicular Type Thyroid Carcinoma: A Case Report and Review of the Literature

## Spinal Metastazla Belirti Veren Folliküler Tip Tiroid Karsinomu: Olgu Sunumu ve Literatür Taraması

**İD** Azmi Tufan<sup>1</sup>, **İD** Burak Eren<sup>1</sup>, **İD** Abdurrahim Taş<sup>1</sup>, **İD** Neslihan Berker<sup>2</sup>, **İD** Özgür Yusuf Aktaş<sup>1</sup>, **İD** İlker Güleç<sup>1</sup>, **İD** Mustafa Safi Vatansever<sup>1</sup>, **İD** Murat Karacan<sup>1</sup>, **İD** Günay Vahabova<sup>1</sup>, **İD** Feyza Karagöz Güzey<sup>1</sup>

<sup>1</sup>University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Neurosurgery, İstanbul

<sup>2</sup>University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Pathology, İstanbul

### Abstract

**Objective:** Follicular type thyroid carcinoma (FTC) rarely presented with spinal metastasis. We aimed to report such a case and to review the literature.

**Method:** A 45 year old male with L2 metastasis of FTC was reported, and other 26 cases were found in literature. Characteristics of the patients and tumors were evaluated.

**Results:** Total 27 patients were 55.2±15 years of age, and male/female ratio was 12/15. Nineteen patients had paresis of extremities, 9 of them could not mobilize on admission. Total resection of the spinal tumor had been performed in 14 cases and subtotal resection in 5. Radioactive iodine treatment had been added in 20 cases with or without other adjuvant treatment. Twenty-three patients had been followed for 43.7±53.2 months. Only four of them died 214, 66, 36 and 7 months after their presentations. Out of other 19 cases, 13 had been neurologically normal. Type of surgery (total resection versus others) the only factor affecting outcome. In the patients treated with total resection, outcome had been statistically better.

**Conclusion:** Spinal metastasis as initial finding is very rare in the patients with FTC. However, prognosis is quite well with total tumor resection and adjuvant treatment. This cancer type must be kept in mind for differential diagnosis and must be screened in the patients with spinal tumors.

**Keywords:** Differentiated thyroid carcinoma, follicular type thyroid carcinoma, spinal metastasis, spinal tumor

### Öz

**Amaç:** Folliküler tip tiroid karsinomu (FTK) nadiren spinal metastazla belirti verir. Böyle bir olgu sunmayı ve bu konuda literatür taramayı amaçladık.

**Yöntem:** Lomber 2 spinal metastazla belirti veren 45 yaşında erkek FTK olgusu sunuldu ve literatürde benzer 26 olgu bulundu. Tüm olguların özellikleri değerlendirildi.

**Bulgular:** Toplam 27 olgu 55,2±15 yaşındaydı (35-88 arasında, ortalama ± SS) ve erkek/kadın oranı 12/15 idi. Başvuruda 19 olguda kol ve/veya bacaklarda güçsüzlük vardı ve 9'u mobilize olamıyordu. Spinal tümör 14 olguda total, 5 olguda subtotal çıkarıldı. Yirmi olguya radyoaktif iyot tedavisi eklendi. Olguların 23'ü 3-214 ay (43,7±53,2, ortalama ± SS) süreyle izlenmişti, sadece 4 olgu başvurudan 214, 66, 36 ve 7 ay sonra ölmüştü. Halen sağ olan 19 olgunun 13'ü nörolojik olarak normaldi. Uygulanan cerrahi tipi (total çıkarmaya karşılık diğer cerrahi tipleri) son durumu etkileyen tek faktör olarak saptandı. Tümörü total çıkarılan hastalarda son durum anlamlı olarak daha iyiydi.

**Sonuç:** Folliküler tip tiroid karsinomunun spinal metastazla belirti vermesi çok nadirdir. Ancak total tümör çıkarılması ve adjuvan tedaviyle prognoz iyidir. Spinal tümörlü hastalarda bu kanser tipi de ayrıca tanıda akılda tutulmalı ve tarama testleri yapılmalıdır.

**Anahtar kelimeler:** Diferansiye tiroid karsinomu, folliküler tip tiroid karsinomu, spinal metastaz, spinal tümör



**Address for Correspondence:** Günay Vahabova, University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Neurosurgery, İstanbul

**E-mail:** gunay\_baghirova@yahoo.com **ORCID ID:** orcid.org/0000-0002-4942-9380 **Received:** 18.01.2019 **Accepted:** 18.01.2019

**Cite this article as:** Tufan A, Eren B, Taş A, Berker N, Aktaş ÖY, Güleç İ, Vatansever MS, Karacan M, Vahabova G, Karagöz Güzey F. Spinal Metastasis as Presenting Feature of Follicular Type Thyroid Carcinoma: a Case Report and Review of the Literature. Bagcilar Med Bull 2019;4(1):1-9.

©Copyright 2019 by the Health Sciences University, Bağcılar Training and Research Hospital  
Bagcilar Medical Bulletin published by Galenos Publishing House.



## Introduction

Differentiated thyroid cancers (DTC) contain papillary, follicular and Hurthle cell types. Follicular type thyroid cancer (FTC) is the second most frequent type of DTCs, and it is more inclined to metastasize to the bone than papillary type (1). This characteristic is probably due to that FTC usually spreads via blood, however, papillary type prefers lymphatic route for dissemination (2). There is bone involvement in 7-12% of the cases with FTC (3), and the most frequently involved region is spinal column (4). However, most of the spinal metastases occur in the late stage of the disease, and presentation of the disease with spinal metastasis is extremely rare during initial diagnosis.

We presented such a rare case who was admitted with lumbar spinal metastasis, and thyroid cancer was diagnosed after pathological evaluation of the spinal tumor. Also we reviewed the literature for presentation with spinal metastasis of FTC, and we evaluated the characteristics of the cases that we found.

## Case Report


A 45 year-old male was admitted to our outpatient clinic with complaints of low back and severe left leg pain and numbness of left leg for 5 months. There was hypoesthesia on left L1 and L2 dermatomes on his physical examination. Muscle strength was full. Radiological examinations revealed an L2 vertebral body tumor. On lumbar computerized tomography (CT) examination, an osteolytic heterogeneous tumor involving left half of the L2 vertebral body extending into the left paravertebral muscles and into the left L1-2 and L2-3 neural foramina was seen (Figure 1). On lumbar magnetic resonance imaging (MRI), it was hypointense on T1-weighted images, and heterogeneous hypo- and hyperintense on T2-weighted images (Figure 2). The lesion was hypermetabolic on positron emission tomography (PET) CT, and there were also a hypermetabolic enhancement in the left thyroid lobe and mildly hypermetabolic bilateral multiple cervical lymph nodes.

A lumbar biopsy was performed and a carcinoma consistent with FTC was diagnosed (Figure 3a). It was decided to perform tumor resection and stabilization for lumbar tumor first because there was severe leg pain of the patient and instability of the lumbar spine, and also the tumor was the sole metastasis on the PET-CT. Total tumor resection and stabilization with interbody cage insertion and pedicle


screw fixation was performed via posterior approach (Figure 4). There was not residual tumor on postoperative MRI.

Immunohistochemical investigations revealed that the tumor cells were positive for thyroglobuline, thyroid transcription factor 1 (TTF-1), Hectort Battifora mesothelial cells 1 (HBME-1) and cytokeratin-19 (CK-19), and negative for calcitonin (Figure 3b-f). These findings verified the diagnosis of DTC.

Total thyroidectomy was performed by endocrine surgery team 10 days after our lumbar operation, and pathological



**Figure 1.** Sagittal and axial sections of the lumbar vertebral computerized tomography demonstrating lytic L2 vertebral tumor extending into the left paravertebral region and neural foramina



**Figure 2.** Sagittal and axial sections of the T2-weighted lumbar spinal magnetic resonance imaging demonstrating heterogeneous hypo- and hyperintense tumor in the L2 vertebral body compressing the nerve roots

examination revealed follicular type carcinoma. He was treated with iodine 131 ablation. His follow-up examinations were uneventful, and there was not recurrence or new metastasis 2 years later.

## Material and Methods

Review of the literature: we reviewed the literature for spinal metastasis as presenting feature of FTC from Medline and Google Scholar. We found 28 such cases. However 2 cases were not introduced into the study because there was not adequate data in the articles (5,6). The characteristics of total 27 cases including our one were evaluated (1,2,4,7-24) (Table 1). Demographic characteristics, levels and numbers of the spinal metastases, neurological conditions, other metastases, treatment modalities, follow-up time, and outcome of the cases were recorded.

Outcome was accepted as good if the patient was neurologically normal or could mobilize without external support, and it was accepted as poor if the patient could not mobilize without support or was dead.


## Statistical Analysis

For statistical analysis, chi-square test, Fisher exact test, and Student's t-tests were used, and  $p < 0.05$  was accepted as significant.


## Results

The patients were  $55.2 \pm 15$  years of age (mean  $\pm$  SD, between 35 and 88), and male/female ratio was 12/15. The most involved levels were thoracic and thoracolumbar segments. The involved vertebral levels in the patients were shown in the Table 2.

The lesion was intradural extramedullary (IDEM) in one case (20), and vertebral and/or epidural in the others. The IDEM tumor extended beyond 2 lumbar levels. In the others, only one vertebra was involved in 11 patients, 2 adjacent vertebrae in 5, and 3 adjacent vertebrae in 7 were involved. Most of the patients had solitary vertebral metastases or multiple adjacent levels involvement. In



**Figure 4.** Lateral lumbar radiograph and sagittal and axial lumbar computerized tomography demonstrating total tumor resection and spinal stabilization with interbody cage and pedicle screws



**Figure 3.** a) Spinal metastasis of the thyroid carcinoma, hematoxylin-eosin (HE) x10. The arrow indicated the tumor cells with colloidal appearance. b) Thyroglobuline (anti-Tg antibody, x10), c) TTF-1 (anti-TTF-1 antibody, x20), d) HBME-1 (anti-HBME-1 antibody, x40), and e) CK-19 (anti-CK-19 antibody, x20) positivity, and f) calcitonin negativity

**Table 1: Characteristics of the patients and tumors**

No	Literature	Age/gender	Level	Neurologic Finding	Other metastases	Surgery	Thyroid surgery	Other treatment	FU (mos)	Outcome
1	Akhtar (7)	52/M	L4-5	Paraparesis 4/5	Rib	TR/St	TT	RAI	12	Good (ASIA E)
2	Baiao (8)	84/F	T7-8-9	Paraparesis 0/5	No	B	TT	RAI	6	Poor (ASIA B)
3	Carhill (1)	49/F	S1	Pain	Ilium, multiple lung and liver	B	TT	RAI	43	Good (ASIA E)
4	Chafiki (9)	81/F	L4-5-S1	Paraparesis 0/5	No	B	TT	RAI	NM	NM
5	Chander (4)	57/F	L3	Right leg weakness	NM	TR/St	NM	RAI	61	Good (KPS 80)
6	Dong (10)	48/F	C2-3	Paresis of both arms	C5, L1, S1,	D	TT	RAI	52	Good (ASIA E)
7	Khan (11)	35/F	T11-12-L1	Paraparesis 1/5	NM	D	NTT	RAI	6	Good (ASIA E)
8	Kim (12)	72/M	L4	Right big toe DF weakness	No	TR	TT	RAI	15	Good (ASIA E)
9	McNeely (2)	88/F	T8-9-10	Paraparesis 3/5	Multiple lung nodules	B	No	RT/TSH	NM	Poor (could not walking)
10	Ogbodo (13)	79/F	L1-2 IDEM	Right leg weakness 3/5	Multiple lung nodules	TR	No	RT	6	Good (ASIA E)
11	Okutan (14)	33/F	L3	Paraparesis 4/5	No	TR/St	TT	RAI	NM	NM
12	Sandu (15)	50/F	T11	Pain	Multiple lung nodules, L3, ilium, femur	D/St	TT	RAI	45	Good (ASIA E)
13	Sharma (16)	39/M	S1-2-3	Urinary incontinence	No	B	TT	RT/RAI	12	Good
14	Sharma (16)	35/F	T2-3	Paraparesis NM	No	D	TT	RT/RAI	6	NM
15	Shibuya (17)	67/F	L4	Pain	No	B, D/St (2yrs), D/St (5 yrs)	TT	RT/RAI	66	Died/lung metastases
16	Toshkezi (18)	55/M	T4-5-6	Paraparesis 4/5	No	TR	NTT	RAI	36	Good (ASIA E)
17	Upreti (19)	55/F	C1-2	Tetraparesis 0-2/5	NM	D/St	TT	RAI	3	Poor (could not walking)
18	Hakeem (20)	58/M	L2	Paraparesis 4/5	No	TR/St	TT	RT/RAI	36	Good (ASIA E)
19	Hakeem (20)	50/M	T1-T2	Pain	No	TR/St	TT	RT/RAI	36	Died/systemic metastases
20	Matsumoto (21)	48/M	T8	Paraparesis 4/5	No	TR/St	NM	NM	156	Good (ASIA E)
21	Matsumoto (21)	42/M	T8-9-10	Paraparesis 3/5	No	TR/St	NM	NM	125	Good (ASIA D)
22	Scarrow (22)	50/M	C6	Pain	No	TR	TT	RAI	NM	NM
23	Goldberg (23)	65/F	C2	Paresthesia on one hand	No	TR	NTT	RAI	28	Good (ASIA E)
24	Goldberg (23)	43/F	T1	Paraparesis	No	Biopsy	STT	RT	7	Ex
25	Brodner (24)	57/M	T5-6	Paraparesis	No	TR	TT	RAI	12	Good (ASIA D)
26	Brodner (24)	56/M	L2, C6	Paraparesis	No	No	TT	RAI	214	Ex due to leukemia
27	Our patient	45/M	L2	Pain	No	TR/St	TT	RAI	24	Good (ASIA E)

ASIA: American spinal cord injury association, D: Decompression, IDEM: Intradural extramedullary, NM: Not mentioned, KPS: Karnofsky performance score, NTT: Near total thyroidectomy, RAI: Radioactive iodine, St: Stabilization, STT: Subtotal thyroidectomy, TR: Total resection, TT: Total thyroidectomy

**Table 2: The involved vertebral levels of the patients. The presenting levels were shown as red boxes, and the associated involved levels were shown as green boxes**

Patient Level	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
C1																											
C2																											
C3																											
C4																											
C5																											
C6																											
C7																											
T1																											
T2																											
T3																											
T4																											
T5																											
T6																											
T7																											
T8																											
T9																											
T10																											
T11																											
T12																											
L1																											
L2																											
L3																											
L4																											
L5																											
S1																											
S2																											
S3																											

only 3 patients, there was multiple non-adjacent vertebral levels involvement. There were 5 patients with other bony metastases and/or systemic metastases such as lung or liver.

Nineteen patients were presented with paresis of arms and/or legs (9 of them could not mobilize without support), one with urinary incontinence and other 7 with back, neck, arm, or leg pain.

Various surgical modalities were performed in the patients. They could be classified as biopsy (in 7 cases), decompression with subtotal resection of the tumor (with or without stabilization, in 5 cases), and total resection of the tumor (with or without stabilization, in 14 cases). Any surgical procedure was not performed in one patient. Spinal stabilization was performed in total 10 patients during first surgery. In one patient in whom biopsy was performed first, subtotal resection and stabilization was performed in 2 times, 2 and 5 years after first biopsy.

Total or near total thyroidectomy was performed in 21 patients and subtotal thyroidectomy in one patient after spinal operation. Thyroid resection was not performed in 1 case and it was not mentioned in the article in 4. In 2 cases, adjuvant treatment modalities were not mentioned in the articles, only radioactive iodine treatment (RAI) was performed in 17 cases, only radiotherapy (RT) for spinal lesions in 3 cases, and RAI and RT in combination in 5 cases.

The follow-up time was not mentioned in the articles in 4 cases. Other 23 cases were followed during 3 to 214 months ( $43.7 \pm 53.2$ , mean  $\pm$  SD). Outcome was not mentioned for 3 patients. Three cases died due to systemic metastases of the disease 66, 36 and 7 months after their spinal surgeries, and one case died due to leukemia 214 months after diagnosis of the thyroid cancer. This last case was neurologically normal without systemic disease until development of his second neoplastic disease. Out of other 19 cases, 15 had good outcome with good neurological condition and without systemic disease (12 of them were neurologically normal), 3 cases had severe neurological deficits, and one case alive with systemic disease, but neurologically normal. Some patients who were severe neurological deficits before operation were neurologically normal on last follow-up (11,13,21).

Presence of other distant metastases did not affect the last outcome ( $p=0.51$ ). However, the type of the spinal surgery was found as an important factor on last outcome of the patient. The rate of good outcome was statistically higher in the patients performed total resection of the

spinal metastasis than to be in the patients with only decompression or biopsy or without any surgical modality ( $p=0.027$ ).

## Discussion

Follicular type thyroid cancers constitute 15% of the DTCs (1). They are well-differentiated tumors and have good outcome when they are compared with other cancers. However, bony metastasis is not rare in the cases with FTC (2). Rate of bony metastasis of FTC was reported as 7 to 20% and the rate of spinal metastasis as 1 to 7% (7,25). This characteristic is probably due to spreading ability via blood of FTC in contrary to the lymphatic spreading tendency of the papillary thyroid cancer (1,2). FTC may synthesize some substrates providing attachment to bone matrix and promoting to bone reabsorption (1).

The FTC usually presents as thyroid nodules. Presentation with distant metastases is quite rare, and it was reported in 1.9% to 11% of the cases with FTC (6,26). Presentation with spinal cord compression due to spinal metastases is extremely rare. Pomorski and Bartos (6) reported only one case out of 309 FTC cases. We could only find 26 cases in literature and we added our case. In the series reported by Marcocci et al. (25), there were 18 patients whose presenting symptoms were related to bony metastases, however, it was not mentioned that how much of them were spinal metastases.

Survival of the DTCs is very long. It was reported that 10 year survival rate was about 80-95%. However presence of bony distant metastases caused to decrease of this rate (12). Shaha et al. (26) reported that long-term survival in the cases with distant metastasis during initial presentation was quite high as 44%. On the other hand, in spite of this long survival trend, presence of spinal metastases causes to reduce quality of life due to severe pain and/or neurological deficits (27). Coleman (28) reported in a retrospective study that spinal metastases of the DTCs more frequently cause spinal cord compression than other spinal metastases. Most of the cases reviewed in our study had neurological deficits and 10 of them could not mobilize on their admissions, and the patients without deficits had severe pain due to spinal metastases.

Reeve et al. (29) reported in a series consisting 258 cases with DTCs that age and gender were the most important factors affecting long-term outcome, and older patients (<60 years) and males had significantly shorter survival. In our review, we could not perform survival analysis because most of the cases were still alive on their last follow-up.

However, both age and gender of the cases did not affect the rate of good outcome.

Total resection of the spinal metastases of the DTCs is usually recommended because of their resistance to radiotherapy. Furthermore, spinal metastases of the DTCs are usually isolated metastases (27). In our review, also, there were associated other bony or systemic metastases in only 5 cases. Demura et al. (5) reported in a study evaluating the results of total en bloc spondylectomy for spinal metastases of thyroid carcinoma that there was no significant difference between the rate of long survival after total spondylectomy and debulking surgery, however, the rate of local recurrence was significantly higher in the cases treated with debulking surgery than the cases treated with total spondylectomy. In our review, the rate of good outcome was significantly higher in the patients whose spinal metastases were totally resected. However, in our study, the term of “total resection” was not similar to “total en bloc spondylectomy” in the study by Demura et al. (5) We classified total tumor resection only without total spondylectomy also as total resection. Response to RAI of DTC is very well, and the guidelines recommended adding this treatment modality to high risk group patients such as the ones with distant metastases (30). To add RAI into the treatment protocol may provide to take away the mandatory of total en bloc resection of the vertebrae with metastases.

Embolization of the spinal metastasis of DTCs before operation may be a smart choice because of tendency of these tumors to profuse bleeding (4). Sellin et al. (31) reported in a study evaluating the factors affecting survival of the patients with spinal metastases of thyroid carcinoma that preoperative emboliation was significantly associated with fewer complications. However, in the patients whose spinal metastases are the initial presentation, this choice can usually not be performed because the primary tumor is not known yet. In the patients presented with only pain without paresis, spinal biopsy may be performed and histological diagnosis can be provided before operation. However, emergency decompression may be required in some patients because of spinal cord or cauda compression, and there may not be adequate time for biopsy or embolization.

The Guideline of American Thyroid Association (ATA) reported in 2016 recommended resection of the lesion, stereotactic radiation treatment (RT) and RAI for treatment of central nervous system metastases of the DTCs (32). In our review, only 8 patients had received RT, therefore, we

could not evaluate its efficacy on last outcome. Bernier et al. (33) recommended to perform total resection of bony metastases and RAI treatment instead of RT in the young patients (<45 years) with bony metastases of the FTC.

Biochemical thyroid functional tests are usually in normal levels in the patients with thyroid cancers (13), therefore, routine tests usually do not provide diagnosis of thyroid cancer in the cases with spinal tumors, and some imaging tests such as thyroid ultrasonography are required during primary site screening. In the cases with cervical spinal tumors, cervical MRI can provide diagnosis of the primary thyroid tumors however most of the spinal metastases of the DTCs are located in the thoracic and lumbar levels. Therefore, if the more possible sites such as breast, lung or prostate are negative in the screening tests, thyroid screening with imaging modalities must certainly be added to the screening protocol of the spinal tumors. PET is also a very valuable method to show both primary site of the cancer and metastases (34).

Survival of the patients with spinal metastases due to DTCs is quite long. Sellin et al. (31) reported median 15.4 months in 43 cases, and Bernier et al. (33) reported 4.1 years. We could not evaluate the survival time of the patients in our review because most of them was still alive on their reported last follow up time. However, their follow up times were quite long (43.7±53.2).

## Conclusion

In conclusion, spinal metastasis as initial finding is very rare in the patients with FTC. However, this diagnosis must be kept in mind especially in the cases whose primary tumor site could not be found with routine cancer screening, and imaging modalities for thyroid must be added. Although survival of the patients with spinal metastases of FTC is significantly shorter than without spinal metastases, it is very longer than the patients with spinal metastases of other cancer types. Surgical resection of the spinal metastases especially in the patients with spinal cord or cauda equine compression, total/near total thyroidectomy and RAI treatment may provide a long term disease free survival to the patients.

## Ethics

**Ethics Committee Approval:** N/A.

**Informed Consent:** N/A.

**Peer-review:** Externally peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: A.T., B.E., A.T., N.B., Concept: A.T., B.E., A.T., N.B., Ö.Y.A., İ.G., M.S.V., M.K., G.V., F.K.G., Design: A.T., B.E., A.T., N.B., Ö.Y.A., İ.G., M.S.V., M.K., F.K.G., Data Collection or Processing: A.T., B.E., A.T., Ö.Y.A., İ.G., M.S.V., M.K., G.V., F.K.G., Analysis or Interpretation: A.T., B.E., A.T., N.B., Ö.Y.A., İ.G., M.S.V., M.K., G.V., F.K.G., Literature Search: A.T., B.E., A.T., G.V., F.K.G., Writing: A.T., B.E., A.T., N.B., Ö.Y.A., İ.G., M.S.V., M.K., G.V., F.K.G.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Carhill AA, Vassilopoulou-Sellin R. Durable effect of radioactive iodine in a patient with metastatic follicular thyroid carcinoma. *Case Rep Endocrinol* 2012;2012:231912.
2. McNeely MF, Sabath A, Linnau KF. Follicular thyroid carcinoma presenting as acute cord compression due to thoracic vertebral metastasis. *Radiol Case Rep* 2012;7:1-4.
3. Pacini F, Schlumberger M, Dralle H, Ilisea R, Smith Y, Viersinga V. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 2006;154:787-803.
4. Chander A, Jayabalan V, Ganesan GR, Shanmugasundaram G, Kannan KK. Surgical management of follicular carcinoma of thyroid with spinal metastasis. *International Surgery Journal* 2015;2:599-603.
5. Demura S, Kawahara N, Murakami H, Abdel-Wanis ME, Kato S, Yohshioka K, Tomita K, Tsuchiya H. Total en-bloc spondylectomy for spinal metastases in thyroid carcinoma. *J Neurosurg Spine* 2011;14:172-176.
6. Pomorski L, Bartos M. Metastasis as the first sign of thyroid cancer. *Neoplasma* 1999;46:309-312.
7. Akhtar S, Adeel M. An unusual case of cauda equina secondary to spinal metastasis of thyroid cancer. *Iranian J Otorhinolaryngol* 2016;28:67-71.
8. Baiao JM, Guimaraes A, Moreira N, Correia JG, Rosevinge CU, Gonçalves D, Calvo MA. Acute paraparesis as presentation of an occult follicular thyroid carcinoma: A case report. *Int J Surg Case Reports* 2017;41:498-501.
9. Chafiki Z, Merzouki B, Hasnaoui J, Rouadi S, Abada R, Roubal M, Mahtar M. An occult follicular thyroid carcinoma revealed by an isolated cauda equina syndrome: a rare presentation. *Glob J Otolaryngol* 2017;3:1-4.
10. Dong P, Chen N, Li L, Huang R. An upper cervical cord compression secondary to occult follicular thyroid carcinoma metastases successfully treated with multiple radioiodine therapies. A clinical case report. *Medicine* 2017;96:e8215.
11. Khan MN, Sharfuzzaman A, Mostafa MG. Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma. *J Neurosci Rural Pract* 2014;5:155-159.
12. Kim DH, Yoo SD, Kim SM, Im SJ, Kang JK, Cho EH. Thyroid cancer initially presenting compression fracture without common thyroid symptoms. *Ann Rehabil Med* 2012;36:735-738.
13. Ogbodo E, Kaliaperumal C, Keohane C, Bermingham N, Kaar G. Sciatica as a presenting feature of thyroid follicular adenocarcinoma in a 79-year-old woman. *BMJ Case Rep* 2011;2011.pii: bcr1020115014.
14. Okutan O, Kaptanoglu E, Gocmen E, Solaroglu I, Beskonakli E, Koc M. Metastasis of follicular carcinoma of the thyroid to the lumbar vertebrae: A case report. *Turkish Neurosurg* 2005;15:32-35.
15. Sandu N, Pöpperl G, Toubert ME, Arasho B, Spiriev T, Orabi M, Schaller BJ. Molecular imaging of potential bone metastasis from differentiated thyroid cancer: a case report. *J Med Case Rep* 2011;5:522.
16. Sharma N, Purkayastha A. Follicular thyroid carcinoma presenting as large solitary vertebral metastasis: Report of two unusual cases treated with radiotherapy. *Asia Pac J Oncol Nurs* 2017;4:269-272.
17. Shibuya I, Sairyo K, Kanamori Y, Dezawa A. Four-Rod Stabilization of severely destabilized lumbar spine caused by metastatic tumor. *Case Rep Orthop* 2013;2013:254684.
18. Thoskezi G, Galgano MA, Libohova S, Marawar S. Isolated spinal metastasis with spinal cord compression leads to a diagnosis of a follicular thyroid carcinoma. *Cureus* 2015;7:e346.
19. Upreti V, Sridhar MS, Dhull P, Seri A. An unusual cause of progressive quadripareis. *Indian J Endocrinol Metab* 2013;17(Suppl 1): S155-S156.
20. Hakeem AH. Spinal cord compression as initial presentation of follicular thyroid carcinoma. *Thyroid. Thyroid Disorders Ther* 2014;3:3.
21. Matsumoto M, Tsuji T, Iwanami A, Watanabe K, Hosgane N, Ishii K, Nakamura M, Morioka H, Toyama Y. Total en bloc spondylectomy for spinal metastasis of differentiated thyroid cancers. A long-term follow-up. *J Spinal Disord Tech* 2013;26:E137-142.
22. Scarrow AM, Colina JL, Levy EI, Welch WC. Thyroid carcinoma with isolated spinal metastasis: case history and review of the literature. *Clin Neurol Neurosurg* 1999;101:245-248.
23. Goldberg H, Stein ME, Ben-Ithzak O, Duek D, Ravkin A, Gaitini D. Metastatic spinal cord compression as initial presentation of follicular thyroid carcinoma. *J Surg Oncol* 1998;67:186-189.
24. Brodner RA, Berman AJ, Wisniewski M, Nakagawa HK. Thyroid carcinoma presenting as epidural metastasis with spinal cord compression. *Mt Sinai J Med (NY)* 1975;42:207-215.
25. Marcocci C, Pacini F, Elisei R, Schipani E, Ceccarelli C, Miccoli P, Arganini M, Pinchera A. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. *Surgery* 1989;106:960-966.
26. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. *Am J Surg* 1997;174:474-476.
27. Kushchayeva YS, Kushchayev SV, Wexler JA, Carroll NM, Preul MC, Teytelboym OM, Sonntag VK, Van Nostrand D, Burman KD, Boyle LM. Current treatment modalities for spinal metastases secondary to thyroid carcinoma. *Thyroid* 2014;24:1443-1455.
28. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 2006;12:6243-6249.
29. Reeve TS, Delbridge L, Crummer P. Total thyroidectomy in the management of differentiated thyroid cancer: a review of 258 cases. *Aust N Z J Surg* 1986;56:829-833.

30. Uslu Besli L, Uslu I. Evaluation of response to therapy in thyroid carcinoma patients after radioactive iodine therapy. *Bagcilar Medical Bulletin* 2016;1:30-32.
31. Sellin JN, Suki D, Harsh V, Elder BD, Fahim DK, McCutcheon IE, Rao G, Rhines LD, Tatsui CE. Factors affecting survival in 43 consecutive patients after surgery for spinal metastases from thyroid carcinoma. *J Neurosurg Spine* 2015;23:419-428.
32. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016;26:1-133.
33. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. *J Clin Endocrinol Metab* 2001;86:1568-1573.
34. Ramadan S, Ugas MA, Berwick RJ, Notay M, Cho H, Jerjes W, Giannoudis PV. Spinal metastasis in thyroid cancer. *Head Neck Oncol* 2012;4:39.



# Evaluation of Readmitted Patients After Intensive Care Unit Discharge (Retrospective Study)

## Yoğun Bakım Ünitesinden Taburcu Sonrası Tekrar Yatışı Yapılan Hastaların Değerlendirilmesi (Retrospektif Çalışma)

 Pınar Öngel Çayören<sup>1</sup>,  Kerem Erkalp<sup>2</sup>,  Mehmet Salih Sevdı<sup>2</sup>,  Serdar Demirgan<sup>2</sup>,  
 Hüseyin Çayören<sup>3</sup>,  Ayşin Selcan<sup>2</sup>

<sup>1</sup>Iğdır State Hospital, Clinic of Anesthesia and Reanimation, Iğdır, Turkey

<sup>2</sup>University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Anesthesia and Reanimation, İstanbul, Turkey

<sup>3</sup>Iğdır State Hospital, Clinic of General Surgery, Iğdır, Turkey

### Abstract

**Objective:** Nearly %10 of the discharged patients are readmitted to intensive care unit (ICU) at the same hospital stay. Reduction of readmission rates could be used as a hospital performance indicator. Our aim is to analyse the reasons and results of readmissions of patients who were discharged to a general ward from ICU in a two-year period.

**Method:** Readmissions of the patients who had been treated in our ICU between the dates of 01.01.2015-31.12.2016 were analysed retrospectively. Demographic characteristics of patients, readmission rates, initial admission indications and comorbidities, distribution of readmission indications, timing of readmission after discharge, distribution of patients in terms of mechanical ventilation need, discharge time of readmitted patients at initial admission to ICU after weaning, readmission mortality rates, Glasgow Coma Scale (GCS), APACHE-II and SOFA scores of patients at initial admission and readmission were analysed and compared.

**Results:** 59 patients (3.55%) are readmitted to ICU after discharge at the same hospital stay. When examining the departments where the readmitted patients came from, it is seen that 19 patients (32.2%) were readmitted to ICU from department of general surgery. 22 of readmissions (37.29%) occurred within first 48 hours after discharge. The most common reasons of readmissions are for postoperative monitoring after revisional surgery (44.07%) and acute respiratory failure (40.68%).

**Conclusion:** The patients who are discharged from ICU are at a high risk of being readmitted to ICU (35). Readmission to ICU is associated with higher mortality risk than the initial admission. The first step of reducing

### Öz

**Amaç:** Taburcu edilen hastaların yaklaşık %10' u yatış süresi içerisinde yeniden yoğun bakım ünitesine (YBÜ) gitmektedir. YBÜ'ye yeniden yatış oranlarındaki azalma, hastane performansında bir kalite göstergesidir. Bu çalışmadaki amacımız, YBÜ'den hastane içine, iki yıllık süre içerisinde taburcu edilen hastaların yeniden yatışlarının nedenlerini ve sonuçlarını analiz etmektir.

**Yöntem:** 01.01.2015-31.12.2016 tarihleri arasında hastanemiz YBÜ'de tedavi edilen hastaların tekrar yatışları geriye dönük olarak incelendi. Hastaların demografik özellikleri, tekrar yatış oranları, hastaların ilk yatış endikasyonları ve yandaş hastalıkları, tekrar yatışların endikasyonlarına göre dağılımı, tekrar yatışın taburculuk sonrası ne zaman gerçekleştiği, mekanik ventilasyon ihtiyacına göre hastaların dağılımı, tekrar yatışı olan hastaların birinci kabullerinde weaning sonrası taburcu olma zamanı, tekrar yatışlardaki mortalite oranları, hastaların YBÜ'ye ilk ve tekrar yatışındaki Glasgow Koma Skalası (GCS), APACHE-II ve SOFA skorları incelenerek kıyaslandı.

**Bulgular:** YBÜ'den taburcu edilen ve hastaneden taburcu olmadan tekrar yatışı yapılan hasta sayısı 59 olarak bulundu (%3,55). Hastaların tekrar geldikleri bölümler incelendiğinde en fazla 19 (%32,2) hasta Genel Cerrahi Kliniği'ndendi. Tekrar kabul edilen hastaların 22'si (%37,29) taburcu edildikten sonraki ilk 48 saat içinde gerçekleşti. Tekrar kabul edilen hastaların en sık nedenleri; revizyon cerrahisi sonrasında postoperatif monitorizasyon (%44,07) ve akut solunum yetersizliği (%40,68) olarak belirlendi.

**Sonuç:** YBÜ'den taburcu edilen hastalar, tekrar YBÜ'ye kabul için yüksek risk altındadırlar. Yoğun bakım ünitesine geri kabul, ilk kabulden çok



**Address for Correspondence:** Kerem Erkalp, University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Anesthesia and Reanimation, İstanbul, Turkey

**E-mail:** keremerkalp@hotmail.com **ORCID ID:** orcid.org/0000-0002-4025-7092 **Received:** 24.12.2018 **Accepted:** 23.01.2019

**Cite this article as:** Öngel Çayören P, Erkalp K, Sevdı SM, Demirgan S, Çayören H, Selcan A. Evaluation of Readmitted Patients After Intensive Care Unit Discharge (Retrospective Study). Bağcılar Med Bull 2019;4(1):10-15.

©Copyright 2019 by the Health Sciences University, Bağcılar Training and Research Hospital  
Bağcılar Medical Bulletin published by Galenos Publishing House.

## Abstract

the rates of readmission to ICU process is to anticipate the patients who would be readmitted to ICU priorly and improve service wards healthcare quality.

**Keywords:** Readmission, intensive care unit, critical patient

## Öz

daha yüksek mortalite oranları ile ilişkilidir. YBÜ'ye geri kabul oranlarını azaltmadaki önemli adım, önceden hastaları tanımak, tanımlamak ve servis bakım düzeylerini yükseltmektir.

**Anahtar kelimeler:** Tekrar yatış, yoğun bakım ünitesi, kritik hasta

## Introduction

Readmission to intensive care unit (ICU) is frequently seen in critically ill patients (1,2). Nearly %10 of patients who has been discharged from ICU to a ward are being readmitted to ICU at the same hospital stay (3). Readmission is a risky condition; it is associated with increased mortality and longer length of hospital stay (4, 5). Also the financial effects of treatment are remarkable, costs gets higher (6). Decrease in readmission rates to ICU is seen as a quality indicator of a hospital performance (7). First step of lowering readmission rates to ICU is to anticipate which patients could be readmitted.

In this study, our aim is to analyze the reasons and results of readmission to ICU of our hospital at a two year period.

## Material and Methods

Readmissions of the patients who had been treated in our ICU between the dates of 01.01.2015-31.12.2016 were retrospectively analyzed by the approval University of Health Sciences İstanbul Bağcılar Training and Research Hospital Ethics Committee dated 27.12.2016 and numbered 2016/526.

Data of patients who were discharged to a general ward from 20 bed ICU and readmitted back in the same hospital stay were obtained from patient files and electronic patient record system.

Demographic characteristics of patients, readmission rates, initial admission indications and comorbidities, distribution of readmission indications, timing of readmission after discharge (within 48 hours it is considered as early readmission), distribution of patients in terms of mechanical ventilation need, discharge time of readmitted patients at initial admission to ICU after weaning, readmission mortality rates, Glasgow Coma Scale (GCS), APACHE-II ve SOFA scores of patients at initial admission and readmission were analyzed and compared.

Comparative statistical analysis was performed with NCSS (Number Cruncher Statistical System) 2007 Statistical

Software (Utah, USA). At analysis, descriptive statistical methods (mean value, standard deviation and percentile rank) were used as well as independent samples t-test for the comparison of two-sample groups, paired samples t-test for the comparison of repeated measures and chi-square test for the comparison of qualitative data. We considered  $p < 0.05$  as statistically significant.

## Results

One thousand-nine hundred ninety seven patients received treatment in our ICU during two years period. One thousand-six hundred sixty four patients were discharged (83.32%) and 353 patients died (17.68%) fifty-nine patients (3.55%) were readmitted to ICU after discharge at the same hospital stay (%3.55). Demographic characteristics of patients are shown in Table 1. When examining the departments where the readmitted patients came from, it is seen that 19 patients (32.2%) were readmitted to ICU from department of general surgery. Sixteen patients (27.12%) were readmitted to ICU from department of neurosurgery and 11 patients were readmitted to ICU from department of orthopedics and traumatology (Table 2). Twenty-two

**Table 1: Demographic data of the patient: readmitted after intensive care unit discharged**

	<b>n=59</b>
Age (year)	61.22±18.80
Gender (M/F)	39/20
Height (cm)	162.75±9.26
Weight (kg)	73.22±7.86
Indication for ICU admission	43 (72.88%) Postoperative monitoring 5 (8.47%) Polytrauma 5 (8.47%) Cerebrovascular diseases 4 (6.78%) Acute respiratory failure 1 (%) Arrhythmia 1 (%) Sepsis
Indication for ICU readmission	26 (44.07%) Postoperative monitoring 24 (40.68%) Acute respiratory failure 6 (10.16%) Sepsis 3 (5.08%) Shock

M: Male, F: Female, ICU: Intensive care unit

patients' readmission (37.29%) occurred within first 48 hours and 37 patients' readmission (62.71%) occurred after the first 48 hours. Twenty-one (35.59%) of 59 readmitted patients died, 38 (64.41%) of them were discharged.

Mean length of stay was  $6.58 \pm 7.44$  days for the living patients and  $17.29 \pm 15.12$  days for dead patients. Second length of ICU stay of dead patients was longer than living patients ( $p=0.002$ ). When readmitted patients were evaluated, mean initial length of stay was  $5.89 \pm 10.59$  days for living patients and  $6.19 \pm 10.56$  days for dead patients ( $p=0.878$ ).

Mean length of ICU stay was  $6 \pm 10.49$  days at initial admission and  $10.39 \pm 11.87$  days at readmission. Mean length of ICU stay was longer at readmission than the initial admission ( $p=0.001$ ).

Glasgow coma scale (GCS), APACHE-II ve SOFA scores of patients at initial admission and readmission were analyzed. Mean GCS score was  $13.32 \pm 2.58$  at initial admission and  $11.88 \pm 3.29$  at readmission. Mean GCS score was lower at readmission than the initial admission ( $p=0.005$ ). Mean APACHE-II score was  $11.46 \pm 4.60$  at initial admission and  $15.47 \pm 6.15$  at readmission. Mean APACHE-II score was higher at readmission than the initial admission ( $p=0.0001$ ). Mean SOFA score was  $1.59 \pm 1.48$  at initial admission and  $2.66 \pm 2.05$  at readmission. Mean SOFA score was higher at readmission than the initial admission ( $p=0.001$ ) (Table 3).

## Discussion

Readmission to ICU within 48 hours after discharge is used as an important quality indicator by Society of Critical Care Medicine (8).

In our study, 59 patients have been readmitted to ICU during the same hospitalization (3.55%). There is a wide

**Table 2: Distribution of patients with readmission by their clinic**

Readmission to ICU from which clinic	Patients (n=59)	%
General surgery clinic	19	32.20
Neurosurgery clinic	16	27.12
Orthopaedics and traumatology clinic	11	18.64
Urology clinic	7	11.86
Internal medicine clinic	3	5.08
Obstetrics and gynaecology clinic	1	1.69
Plastic, reconstructive and aesthetic surgery clinic	1	1.69
Ear, nose and throat clinic	1	1.69

ICU: Intensive care unit

**Table 3: Comparison of invasive mechanical ventilation support, GCS, APACHE II Score, SOFA score and length of ICU stay between first admission and readmission**

	First admission	Readmission	p
Invasive mechanical ventilation support (%)	35.60%	62.71%	<0.05
GCS	$13.32 \pm 2.58$	$11.88 \pm 3.29$	<0.05
APACHE II Score	$11.46 \pm 4.60$	$15.47 \pm 6.15$	<0.05
SOFA Score	$1.59 \pm 1.48$	$2.66 \pm 2.05$	<0.05
Length of ICU stay (day)	$6.00 \pm 10.49$	$10.39 \pm 11.87$	<0.05

GCS: Glasgow coma scale/score, APACHE: Acute physiology and chronic health evaluation, SOFA: Sequential organ failure assessment, ICU: Intensive care unit

range of readmission rates (5-17.5%) in various studies (1,2). Readmission rate was 9.6% in a study by Jo et al. (9). Rate of readmission to ICU within 48 hours after discharge and within 120 hours after discharge were 2% and 3.7% respectively in a study by Brown et al. (10). Our readmission rate is slightly less than that reported in the literature.

According to Amin et al. (1), reasons of readmission to ICU are deterioration or relapse of the disease, newly emerged complications irrelevant to initial admission and purpose of follow up with the patients who needs repeating surgery. In a study by Rosenberg et al. (4), it is reported that intensification of symptoms due to improper or delayed treatment may lead to readmission. Prolonged hospital stay and being older than 70 are amongst the risk factors associated with readmission to ICU. Cardiovascular and respiratory system problems are prominent causes of readmission (11). Gajic et al. (12) highlight the importance of prolonged ICU stay and lower GCS at the day of discharge. Risk factors for readmission to pediatric ICU are being younger, emergency indications and the critical condition at initial admission (13). Male sex, history of DM, application of continuous renal replacement therapy (CRRT) during ICU stay, white blood cell count on the day of extubation and heart rate just before ICU discharge are also associated with increased risk of ICU (9). When examining the departments where the readmitted patients came from, it is seen that largest number of patients (32.2%) were readmitted to ICU from general surgery clinic because of respiratory failure which is a result of repetitive surgeries for the medical condition.

37.29% of patients' readmissions occurred within the first 48 hours after discharge from ICU. In the literature, cases of readmissions within 48 hours after discharge from ICU are considered as early discharges. Nearly 22-30% of the patients are early discharged (14,15). Our early discharge

rate is higher than that reported in the literature and the most probably reason for this is the bed scarcity that can't meet the high demand. However, there is no mortality rate difference between the patients who are readmitted to ICU within 48 hours or after 48 hours. Brown et al. (10), reported that there is no association between length of ICU stay and readmission to ICU within 48 hours after discharge. Risk factors for readmission within 48 hours are severity of disease, functional condition, length of mechanical ventilation, chronic respiratory or renal disease, chronic immunosuppression and presence of a solid organ tumour (10).

Readmission to ICU is directly proportional to the severity of disease scores (15,16). GCS scores of our patients at readmission are lower than the initial admission. Mean APACHE-II scores at readmission are higher than the initial scores. Chan et al. (7) reported that APACHE-II scores of the patients who were readmitted to ICU and eventually died are the highest and higher APACHE-II score is associated with increased mortality risk. In our study, also average SOFA scores of patients at readmission are higher than the initial admission scores. Higher SOFA score measured at any time during ICU stay is associated with older age, emergency surgery and readmission to ICU (17).

Length of stay is longer and mortality rates are higher at readmission in our study. In a study by Wong et al. (18) the patients who were readmitted to ICU had longer length of stay and their mortality rates significantly increased. It is showed that nearly 22-44% of the patients had been early discharged from ICU (19). Rate of readmission to ICU is considered as a quality indicator, because it can be easily measured. Especially, rate of readmission within the first 48-72 hours after discharge is advised as a clinical performance criteria (20). Even though readmission to ICU is associated with early discharge from ICU and poor clinical outcomes, there are considerable amount of studies in which there is not a convincing connection between readmission and objective quality criterias of an ICU (21,22). It is seen that 10 of 21 patients (47.62%) who needed mechanical ventilation at readmission to ICU have been discharged within first 48 hours after weaning. It is possible to say that if the patients' length of stay at ICU after weaning is shorter than 48 hours, they will be more likely to readmitted to ICU. We believe that the reason of this is the scarcity of bed capacity which is not enough for high demand and the new patients who require ICU care. Early discharge from ICU is one of the most important risk factors for the increased mortality

(23). In a study from USA in which more than two hundred thousand discharges from ICU to general wards have been examined retrospectively from hundred and fifty five ICUs, it is understood that length of ICU stay of the patients' gets shorter at the times when the demand for ICU beds arises (24). The patients are more likely to be readmitted to ICU after discharge at these times and it shows us that variations of ICU bed availability is so important that it could effect clinicians' triage decisions. In this high-volume study, despite the pressure of increased demand on triage decisions, in-hospital mortality rate and the probability of home discharge were not negatively effected. Strain spurs providers to reduce their provision of what seems to be low-value care by critically re-examining needs for ICU-level care and transferring patients who could be equally well-managed outside the ICU setting (25,26). Consequently, readmission rates are lower in hospitals which have more ICU beds (27).

Respiratory failure is the most common reason of readmission to ICU in our study. For this reason, after discharging to general wards from ICU we may advice respiratory physiotherapy practices including aspiration, percussion and postural drainage by healthcare providers and a respiratory therapist which might be very beneficial and even could lower the readmission rate.

Choosing the right time to discharge a patient from ICU still remains a challenge (28). Discharging from ICU is protective against iatrogenic and nasocomial complications during ICU stay and it makes ICU available for efficient use and decreases costs (29). When considering the rewards, the decision of discharge from ICU may have some level of risk (30). Unfortunately, after being discharged from ICU to health facilities, the patients are at the risk of reduced monitoring which could lead to delayed recognition of probable complications and clinical deterioration (31,32,33).

## Conclusion

In conclusion, the patients who are discharged from ICU are at a high risk of being readmitted to ICU (34). Readmission to ICU is associated with higher mortality risk than the initial admission (35). Considering the funding for ICU services which consumes substantial amount of health resources, a decrease in the readmission to ICU rates can be used as a hospital performance indicator (36-38). The first step of reducing the rates of readmission to ICU process is to anticipate the patients who would be readmitted to ICU priorly and improve general wards healthcare quality (39-41).

## Ethics

**Ethics Committee Approval:** The study was approved by the University of Health Sciences İstanbul Bağcilar Training and Research Hospital Ethics Committee dated 27.12.2016 and numbered 2016/526.

**Informed Consent:** Retrospective study.

**Peer-review:** Externally peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: P.Ö.Ç., K.E., M.S.S., S.D., H.Ç., Concept: P.Ö.Ç., K.E., A.S., Design: P.Ö.Ç., K.E., A.S., Data Collection or Processing: P.Ö.Ç., M.S.S., S.D., H.Ç., Analysis or Interpretation: P.Ö.Ç., K.E., A.S., Literature Search: P.Ö.Ç., K.E., M.S.S. Writing: P.Ö.Ç., K.E., H.Ö.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Amin N, Divatia JV, Agarwal V, Kulkarni AP. Readmissions in a surgical intensive care unit: patient characteristics and outcome. *Indian J Crit Care Med* 2003;7:14-17.
2. van Sluisveld N, Bakhshi-Raiez F, de Keizer N, Holman R, Wester G, Wollersheim H, van der Hoeven JG, Zegers M. Variation in rates of ICU readmissions and post-ICU in-hospital mortality and their association with ICU discharge practices. *BMC Health Serv Res* 2017;17:281.
3. Alex J, Shah R, Griffin SC, Cale AR, Cowen ME, Guvendik L. Intensive care unit readmission after elective coronary artery bypass grafting. *Asian Cardiovasc Thorac Ann* 2005;13:325-329.
4. Rosenberg AL, Watts C. Patients readmitted to ICUs: a systematic review of risk factors and outcomes. *Chest* 2000;118:492-502.
5. Kramer AA, Higgins TL, Zimmerman JE. Intensive care unit readmissions in U.S. hospitals: patient characteristics, risk factors, and outcomes. *Crit Care Med* 2012;40:3-10.
6. Campbell AJ, Cook JA, Adey G, Cuthbertson BH. Predicting death and readmission after intensive care discharge. *Br J Anaesth* 2008;100:656-662.
7. Chan K, Tan CK, Fang CS, Tsai CL, Hou CC, Cheng KC, Lee MC. Readmission to the intensive care unit: An indicator that reflects the potential risks of morbidity and mortality of surgical patients in the intensive care unit. *Surgery Today* 2009;39:295-299.
8. Nates LJ, Nunnally M, Kleinpell R, Blosser S, Goldner J, Birriel B, Fowler CS, Byrum D, Miles WS, Bailey H, Sprung CL. ICU admission, discharge, and triage guidelines: A framework to enhance clinical operations, development of institutional policies, and further research. *Crit Care Med* 2016;44:1553-1602.
9. Jo YS, Lee YJ, Park JS, Yoon HI, Lee JH, Lee CT, Cho YJ. Readmission to medical intensive care units: risk factors and prediction. *Yonsei Med J* 2015;56:543-549.
10. Brown SES, Ratcliffe SJ, Halpern SD. Assessing the utility of ICU readmissions as a quality metric: an analysis of changes mediated by residency work-hour reforms. *Chest* 2015;147:626-636.
11. Klimasauskas A, Kekstas G. Simple prediction of mortality in case of readmission to the intensive care unit. *Crit Care* 2007;11(Suppl 2):P469.
12. Gajic O, Malinchoc M, Comfere TB, Harris MR, Achouiti A, Yilmaz M, Schultz MJ, Hubmayr RD, Afessa B, Farmer JC. The stability and workload index for transfer score predicts unplanned intensive care unit patient readmission: initial development and validation. *Crit Care Med* 2008;36:676-682.
13. Odetola FO, Clark SJ, Dechert RE, Shanley TP. Going back for more: an evaluation of clinical outcomes and characteristics of readmissions to a pediatric intensive care unit. *Pediatr Crit Care Med* 2007;8:343-347.
14. Rosenberg AL, Hofer TP, Hayward RA, Strachan C, Watts CM. Who bounces back? Physiologic and other predictors of intensive care unit readmission. *Crit Care Med* 2001;29:511-518.
15. Ozbay HY, Bombaci, E, Ercan GC, Colakoglu S. Retrospective analysis of the re-admitted cases in intensive care unit; reasons, outcomes and evaluation of the factors that affect mortality. *J Turk Soc Intens Care* 2012;10:91-96.
16. Li Y, Chen D, Meike L, Ge XH, Xia ZJ. A study on causes of re-admission to surgical intensive care unit and risk factors analysis of their prognosis. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2013;25:403-407.
17. Woldhek AL, Rijkenberg S, Bosman RJ, van der Voort PH. Readmission of ICU patients: A quality indicator? *J Crit Care* 2017;38:328-334.
18. Wong EG, Parker AM, Leung DG, Brigham EP, Arbaje AI. Association of severity of illness and intensive care unit readmission: A systematic review. *Heart Lung* 2016;45:3-9.
19. Kramer AA, Higgins TL, Zimmerman JE. The association between ICU readmission rate and patient outcomes. *Crit Care Med* 2013;41:24-33.
20. Herbst LA, Desai S, Benscoter D, Jerardi K, Meier KA, Statile AM, White CM. Going back to the ward-transitioning care back to the ward team. *Transl Pediatr* 2018;7:314-325.
21. Son YG, Lee H, Oh SY, Jung CW, Ryu HG. Risk factors for intensive care unit readmission after liver transplantation: A retrospective cohort study. *Ann Transplant* 2018;23:767-774.
22. Bice T. ICU Readmissions: Good for reflection on performance but not a reflection of quality. *Crit Care Med* 2016;44:1790-1791.
23. Maharaj R. ICU readmission is a more complex metric than we first imagined. *Crit Care Med* 2018;46:2064-2067.
24. Kareliusson F, De Geer L, Tibblin AO. Risk prediction of ICU readmission in a mixed surgical and medical population. *J Intensive Care* 2015;3:30.
25. Rodríguez-Carvajal M, Mora D, Doblas A, García M, Domínguez P, Tristáncho A, Herrera M. Impact of the premature discharge on hospital mortality after a stay in an intensive care unit. *Med Intensiva* 2011;35:143-149.
26. Amin A, Deitelzweig S, Christian R, Friend K, Lin J, Belk K, Baumer D, Lowe TJ. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. *J Hosp Med* 2012;7:634-639.

27. Wagner J, Gabler NB, Ratcliffe SJ, Brown SE, Strom BL, Halpern SD. Outcomes among patients discharged from busy intensive care units. *Ann Intern Med* 2013;159:447-455.
28. Gumus F, Polat A, Yektas A, Erentug V, Alagol A. Readmission to intensive care unit after coronary bypass operations in the short term. *Turk J Anaesthesiol Reanim* 2014;42:162-169.
29. Seferian EG, Afessa B, Gajic O, Keegan MT, Hubmayr RD. Comparison of community and referral intensive care unit patients in a tertiary medical center: evidence for referral bias in the critically ill. *Crit Care Med* 2008;36:2779-2786.
30. Badawi O, Breslow MJ. Readmissions and death after ICU discharge: development and validation of two predictive models. *PLoS One* 2012;7:e48758.
31. Vollam SA, Dutton SJ, Young D, Watkinson PJ. Out-of-hours discharge from intensive care, in-hospital mortality and intensive care readmission rates: a systematic review protocol. *Syst Rev* 2015;4:93.
32. Wong GE, Parker AM, Leung DG, Brigham EP, Arbaje AI. Association of severity of illness and intensive care unit readmission: A systematic review. *Heart Lung* 2016;45:3-9.
33. Pakbin A, Rafi P, Hurley N, Schulz W, Harlan Krumholz M, Bobak Mortazavi J. Prediction of ICU readmissions using data at patient discharge. *Eng Med Biol Soc* 2018;2018:4932-4935.
34. Christiansen CF, Flaatten H. Out-of-hours discharge from intensive care: certain about uncertainty. *Intensive Care Med* 2018;44:1545-1547.
35. Lin WT, Chen WL, Chao CM, Lai CC. The outcomes and prognostic factors of the patients with unplanned intensive care unit readmissions. *Medicine (Baltimore)* 2018;97:e11124.
36. Vollam S, Dutton S, Lamb S, Petrinic T, Young JD, Watkinson P. Out-of-hours discharge from intensive care, in-hospital mortality and intensive care readmission rates: a systematic review and meta-analysis. *Intensive Care Med* 2018;44:1115-1129.
37. Wang HJ, Gao Y, Qu SN, et al. Preventable readmission to intensive care unit in critically ill cancer patients. *World J Emerg Med* 2018;9:211-215.
38. Lee H, Lim CW, Hong HP, Ju JW1, Jeon YT, Hwang JW, Park HP. Efficacy of the APACHE II score at ICU discharge in predicting post-ICU mortality and ICU readmission in critically ill surgical patients. *Anaesth Intensive Care* 2015;43:175-186.
39. Ofoma UR, Dong Y, Gajic O, Pickering BW. A qualitative exploration of the discharge process and factors predisposing to readmissions to the intensive care unit. *BMC Health Serv Res* 2018;18:6.
40. Rosa RG, Roehrig C, Oliveira RP, Maccari JG, Antônio AC, Castro Pde S, Neto FL, Balzano Pde C, Teixeira C. Comparison of unplanned intensive care unit readmission scores: A prospective cohort study. *PLoS One* 2015;10:e0143127.
41. Desautels T, Das R, Calvert J, Trivedi M, Summers C, Wales DJ, Ercole A. Prediction of early unplanned intensive care unit readmission in a UK tertiary care hospital: a cross-sectional machine learning approach. *BMJ Open* 2017;7:e017199.



# Effect of Nasopharyngeal Irrigation on Early Eustachian Tube Functions in Patients Undergoing Adenoidectomy: A Clinical Prospective Study

## Adenoidektomi Sırasındaki Nazofaringeal İrigasyon Yönteminin Erken Dönemde Östaki Tüp Fonksiyonlarına Etkisi: Prospektif Çalışma

Şahin Öğreden, Hasan Deniz Tansuker, Abdurrahman Buğra Cengiz, Alper Tabaru, Cemal Özyılmaz, Mehmet Faruk Oktay

University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Otolaryngology, İstanbul, Turkey

### Abstract

**Objective:** The hypertrophic adenoid tissue can cause to eustachian tube dysfunction by mechanical or inflammatory effect both of which block the nasopharyngeal ostium of the eustachian tube. Adenoidectomy, with or without tonsillectomy, is the most common surgical procedure in children. In this study, we aimed to investigate whether nasopharyngeal irrigation for hemorrhage control in adenoidectomy patients has an effect on eustachian tube functions.

**Method:** Patients who underwent adenoidectomy for adenoid hypertrophy evaluated on both the preoperatively and on the postoperative first day by otomicroscopic examination and with tympanometry for eustachian tube functions. Patients were divided into two groups according to nasopharyngeal irrigation type after surgery. Group 1 was the transnasal pressure irrigation group; group 2 was transoral passive irrigation group. Tympanometry was used to measure pressure, volumetric, and compliance values to compare pre- and postoperative values.

**Results:** 40 patients were included in the study. There was no significant difference between the age and sex distributions of the patients. Volume and compliance values between the groups were similar before and after the surgery. The mean pressure values of the tympanometry parameters were highly significantly different for the right ear and moderately different for the left ear in group 1; were significantly different for the right ear and highly significantly different for the left ear in group 2. Postoperative

### Öz

**Amaç:** Adenoid dokunun hipertrofisi, mekanik veya enflamatuvar süreçlerden dolayı östaki tüpünün nazofaringeal ağzını obstrükte ederek östaki disfonksiyonuna yol açmaktadır. Adenoidektomi, tonsillektomi ile birlikte çocuklarda yapılan en sık cerrahi prosedürdür. Bu çalışmada adenoidektomi yapılan hastalarda kanama kontrolü için yapılan nazofarenks irrigasyonunun östaki tüp fonksiyonlarına etkisinin olup olmadığını araştırmayı amaçladık.

**Yöntem:** Adenoid hipertrofisi nedeniyle opere edilen hastaların ameliyat öncesi ve ameliyat sonrası birinci gün otomikroskopik muayene ve timpanometri ile östaki tüp fonksiyonları değerlendirildi. Hastalar ameliyat sonrası nazofarenks irrigasyonuna göre iki gruba ayrıldı. Grup 1 hastalara transnazal basınçlı irrigasyon, grup 2 hastalara transoral pasif irrigasyon yapıldı. Timpanometri ile basınç, volüm, kompliyans değerleri ölçülerek ameliyat öncesi ve sonrası değerler karşılaştırıldı.

**Bulgular:** Çalışmaya 40 hasta dahil edildi. Hastaların yaş ve cinsiyet dağılımları arasında anlamlı bir fark bulunmadı. Gruplar arasında volüm ve kompliyans değerleri ameliyat öncesi ve sonrasında benzer bulundu. Timpanometri parametrelerinden basınç ortalama değerleri ameliyat öncesi-sonrası için grup 1'de sağ kulak için çok ileri düzeyde anlamlı olarak farklı ve sol kulak için sınırdan anlamlı farklı iken, grup 2'de sağ kulak için ileri düzeyde anlamlı olarak farklı ve sol kulak için çok ileri düzeyde anlamlı olarak farklı idi. Ameliyat sonrası timpanometri tipleri grup 1'de



**Address for Correspondence:** Abdurrahman Buğra Cengiz, University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Otolaryngology, İstanbul, Turkey

**E-mail:** drcengiz@gmail.com **ORCID ID:** orcid.org/0000-0003-3942-6765 **Received:** 23.01.2019 **Accepted:** 3.02.2019

**Cite this article as:** Öğreden Ş, Tansuker HD, Cengiz AB, Tabaru A, Özyılmaz C, Oktay MF. Effect of nasopharyngeal irrigation on early eustachian tube functions in patients undergoing adenoidectomy: a clinical prospective study. Bagcilar Med Bull 2019;4(1):16-20.

©Copyright 2019 by the Health Sciences University, Bağcılar Training and Research Hospital  
Bagcilar Medical Bulletin published by Galenos Publishing House.

## Abstract

typanometry types were seen as bilateral type C in 7 patients, as right side type C in 4 patients, as bilateral type B in 2 patients, as left side type C in 4 patients in group 1. However, in group 2, right side type B, left side type B and bilateral type C tympanogram were observed in 1 patient, 2 patients and 12 patients, respectively.

**Conclusion:** In this study, we observed that the nasopharyngeal irrigation to control bleeding after adenoidectomy had adverse effect on the eustachian tube functions but larger series of studies are needed to confirm this.

**Keywords:** Nasopharyngeal irrigation, adenoidectomy, tympanometry

## Öz

7 hastada bilateral tip C, 4 hastada sağ tip C, 2 hastada bilateral tip B, 4 hastada sol tip C görüldü. Grup 2'de ameliyat sonrası 1 hastada sağ tip B, 2 hastada sol tip B, 12 hastada bilateral tip C timpanogram izlendi.

**Sonuç:** Bu çalışmada adenoidektomi sonrası kanama kontrolü için yapılan nazofarenks irrigasyonunun östaki tüp fonksiyonlarına etkisinin olumsuz yönde olduğunu gördük ancak bunun doğrulanması için daha geniş serili çalışmalara ihtiyaç vardır.

**Anahtar kelimeler:** Adenoidektomi, nazofarenks irrigasyonu, timpanometri

## Introduction

Eustachian tube dysfunction results in all acute and chronic otologic pathologies to begin. Blustone ve Doyle defined the functions of the eustachian tube as ventilation, drainage and protection of the middle ear. Any disruption of these functions initiates middle ear pathologies (1). Clinical audiometry and tympanometry can be used for screening and diagnosis. However, tympanometry is the gold standard for assessing middle ear pressure, volume and tympanic membrane compliance. Treatment may vary depending on the duration and severity of the disease. Adenoid tissue was first described by Meyer in 1868 as a lymphoid tissue that is part of the Waldayer ring. Adenoid hypertrophy obstructs the upper respiratory tracts and causes complaints such as chronic nasal obstruction, mouth open sleep, snoring and recurrent sinusitis (2).

Traditional adenoidectomy using curette was first described in 1885 (3). Traditional adenoidectomy is usually performed using curette. Adenoidectomy usually is not associated with significant bleeding. In this technique hemostasis is achieved by pressure using postnasal packing and/or irrigation with saline solutions (4). Mathiasen et al. (5) demonstrated the safety and efficacy of a novel hemostatic sealant in children undergoing adenoidectomy. The nasopharynx is generally irrigated with saline after adenoidectomy for removal of blood and clots (4). This can be performed by two ways; by transnasal pressure irrigation, and by transoral passive irrigation. However it has been speculated that the eustachian tube function could be affected by the irrigation process.

In this study, we aimed to investigate the effect of nasopharyngeal irrigation methods for hemostasis on eustachian tube function in patients undergoing

adenoidectomy and to eliminate this defect in the literature since there has been no studies on this subject so far.

## Material and Methods

The study is performed in İstanbul Bağcılar Training and Research Hospital and the study protocol was carried out in accordance with the principles of the European Ethical Committee, and an approval from ethical committee in the same centre was obtained before initiation of the study (No: 2019.01.1.01.121.r1.001). Preoperative otomicroscopic examination and tympanometry were performed to evaluate the eustachian tube functions indirectly. Patients with tympanic membrane adhesions, retraction or perforations; with congenital deformities such as cleft palate lips, with history of previous ear surgery, and tympanometry findings different from type A were excluded from the study. Under general anesthesia and supine position, adenoidectomy was performed by traditional curettage method in all patients. All of the operations were performed by the same experienced surgeon. Postoperative bleeding control was achieved with pressure and electro-cautery. The patients were divided into two groups randomly. In the first group, nasopharynx irrigation was performed transnasally by closing one of the nostrils with approximately 500 cc physiological saline at the end of the operation. The patients in the second group were filled with saline orally and then nasopharynx irrigation was performed by aspiration. Patients in both groups were assessed by otomicroscopic examination and tympanometry on postoperative day 1. Tympanometry was performed again on the 7<sup>th</sup> day of those who were not Type A.

## Statistical Analysis

The minimum number of subjects required in each group was found to be 13 in order to make a significant difference



of 97.00 between the two groups. Type I Error=0.05, power of test (POWER) 0.80 Statistical analyzes were performed with the program MedCalc (MedCalc Software, Broekstraat, Mariakerke, Belgium). Normal distribution of continuous variables was investigated by Kolmogorov-Smirnov test. Gaussian distributions were shown as mean ± SD. The Student's t-test was used to compare the average values between the groups. The paired samples t-test was used in the comparison of the groups' average before and after surgery. Statistical significance was evaluated at the level of p<0.05 (two-tailed).

## Results

40 patients were included in the study. Fifteen patients (37.5%) were female and 25 patients (62.5%) were male. Age of the patients ranged from 1 to 15 years and the mean age was 6.87 years. Mean age of the patients was 6.8 in transnasal irrigation group (group 1) with 13 males and 7 females; and that was 6.9 in transoral irrigation group (group 2) with 12 males and 8 females (Table 1).

**Table 1: Demographic features of the patients**

	Transnasal pressure irrigation, group 1 (n=20)	Transoral passive irrigation, group 2 (n=20)	P
Age (year)	6.8±2.9	6.9±3.0	=0.915
Male/Female (N/N)	13/7	12/8	=0.744

There was no significant difference between the age and sex distributions of the patients. Volume and compliance values between the groups were similar before and after the surgery.

The mean pressure values of the tympanometry parameters were highly significantly different for the right ear and moderately different for the left ear in group 1; were significantly different from the pressure parameters comparing group 2 (Table 2) The pressure levels in group. Postoperative tympanometry types were seen as bilateral type C in 7 patients, as right side type C in 4 patients, as bilateral type B in 2 patients, as left side type C in 4 patients in Group 1. However, in group 2, right side type B, left side type B and bilateral type C tympanogram were observed in 1 patient, 2 patients and 12 patients, respectively.

## Discussion

The eustachian tube extends between the middle ear and the nasopharyngeal cavity and provides ventilation, drainage and protection of the middle ear. The most important function of the eustachian tube is the balance between the middle ear and atmospheric pressure (6). Adenoid tissue is localized in the lymphoepithelial tissue of the nasopharynx. The enlarged adenoid tissue results in nasopharyngeal obstruction. Adenoid hypertrophy is diagnosed by endoscopic nasopharyngoscopy and cephalometric radiography (7). Adenoidectomy is a

**Table 2: Volume and compliance values between the groups before and after the surgery**

		Preoperative	Postoperative	Sig after op.	
Transnasal pressure irrigation, group 1	Right ear	Volume	0.56±0.11	0.61±0.19	=0.142
		Comp	0.46±0.22	0.47±0.23	=0.895
		Pressure	-67.1±90.0	-170.8±97.6	<b>&lt;0.0001</b>
	Left ear	Gradient	0.39±0.25	0.32±0.16	=0.284
		Volume	0.57±0.10	0.54±0.15	=0.270
		Comp	0.52±0.20	0.47±0.21	=0.140
		Pressure	-74.7±72.6	-133.2±84.8	<b>=0.012</b>
Transoral passive irrigation, group 2	Right ear	Gradient	0.34±0.17	0.29±0.13	=0.146
		Volume	0.62±0.10	0.62±0.12	=0.963
		Comp	0.43±0.23	0.39±0.22	=0.256
	Left ear	Pressure	-80.0±67.8	-132.8±88.0	=0.067
		Gradient	0.26±0.21	0.25±0.20	=0.766
		Volume	0.59±0.17	0.58±0.15	=0.727
		Comp	0.43±0.23	0.40±0.23	=0.627
Significance between the groups	Right ear	Pressure	p=0.689	<b>p=0.001</b>	
	Left ear	Pressure	0.782	<b>p=0.03</b>	

frequently performed surgical procedure. In 1885, Wilhem Mayer first described adenoidectomy technique by curettage method that is still current today (3).

Ünlü et al. (8) reported 64 patients to have bilateral traumatic tube dysfunction, and 10 patients to have unilateral eustachian tube dysfunction preoperatively in a study of adenoidectomy and tonsillectomy performed 64 patients. In the tympanometric examination they performed on the seventh day postoperatively, they found that 2 patients had bilateral traumatic tube dysfunction. In our study, we found that all of the tympanometric examinations we performed on the seventh postoperative day were normal. Thompson and Crowther reported at least one ear to have type C tympanogram in 34 of 63 patients with septoplasty (9). In our study we observed that 27 of 40 patients with adenoidectomy had type C tympanograms. Montaña-Velázquez et al. (10) reported significant tympanometric abnormalities and decreased middle ear pressure in 20 patients aged between 4 to 9 years who underwent adenotonsillectomy. They thought that this abnormality was due to the deterioration of the coordination of the eustachian tube and nasopharyngeal muscles. In our study we observed that the middle ear pressure was falling and that resulted in type C tympanogram. Şerefican et al. (11) reported that edema induced eustachian tube dysfunction developed in 30 patients performed anterior nasal packing comparing to and improvement of eustachian tube function after took packing off postoperatively. Yılmaz et al. (12) reported that middle ear pressures continued to decrease in the nasal packing group rather than silicone nasal septal splint group after one week. In a study of 25 patients with adenotonsillectomy, type c tympanogram was reported in 74% on the first postoperative day (13). Hone et al. (14) reported that 39% of the patients had eustachian tube disfunction by tympanometric examination on first day after adenotonsillectomy. In our study, similar to these two studies, we found mean pressure values of the tympanometry parameters (type C tympanogram) were highly significantly different for the right ear and moderately different for the left ear in the transnasal pressure irrigation group; those were significantly different for the right ear and highly significantly different for the left ear in the transoral passive irrigation group.

## Conclusion

In this study, we observed that the nasopharyngeal irrigation to control bleeding after adenoidectomy had adverse effect on the eustachian tube functions but wider series of studies are needed to confirm this effect.

## Ethics

**Ethics Committee Approval:** The study is performed in İstanbul Bağcılar Training and Research Hospital and the study protocol was carried out in accordance with the principles of the European Ethical Committee, and an approval from ethical committee in the same centre was obtained before initiation of the study (no: 2019.01.1.01.121.r1.001).

**Informed Consent:** It was obtained from all the patients parents.

**Peer-review:** Externally peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: Ş.Ö., A.T., C.Ö., Concept: Ş.Ö., H.D.T., A.B.C., M.F.O., Design: Ş.Ö., H.D.T., A.B.C., Data Collection or Processing: A.T., C.Ö., A.B.C., Analysis or Interpretation: Ş.Ö., H.D.T., A.B.C., M.F.O., Literature Search: Ş.Ö., H.D.T., A.B.C., Writing: Ş.Ö., A.B.C.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Tysome JR, Sudhoff H. The Role of the Eustachian Tube in Middle Ear Disease. *Adv Otorhinolaryngol* 2018;81:146-152.
2. Mikals SJ, Brigger MT. Adenoidectomy as an adjuvant to primary tympanostomy tube placement: a systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg* 2014;140:95-101.
3. Thornval A. Wilhelm Meyer and the adenoids. *Arch Otolaryngol Head Neck Surg* 1969;90:383-386.
4. Ozmen S, Ozmen OA. Hot saline irrigation for control of intraoperative bleeding in adenoidectomy: a randomized controlled trial. *Otolaryngol Head Neck Surg* 2010;142:893-897.
5. Mathiasen RA, Cruz RM. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. *Otolaryngol Head Neck Surg* 2004;131:601.
6. Hong J, Chen K, Lyu H, Yin D, Yang L, Zhang T, Dai P. Age-related changes in the morphological relationship between the supratubal recess and the Eustachian tube. *Auris Nasus Larynx* 2018;45:88-95.
7. Paradise JL, Bernard BS, Colborn DK, Janosky JE. Assessment of adenoidal obstruction in children: clinical signs versus roentgenographic findings. *Pediatrics* 1998;101:979-986.
8. Unlu I, Unlu EN, Kesici GG, Guclu E, Yaman H, Ilhan E, Ulucanli S, Karadeniz D, Memis M. Evaluation of middle ear pressure in the early period after adenoidectomy in children with adenoid hypertrophy without otitis media with effusion. *Am J Otolaryngol* 2015;36:377-381.
9. Thompson AC, Crowther JA. Effect of nasal packing on eustachian tube function. *J Laryngol Otol* 1991;105:539-540.

10. Montaño-Velázquez BB, Villanueva-Padrón LA, Conde-Vázquez E, Alvarez-Romero E, Romero-Asato JG, Jáuregui-Renaud K. The middle ear pressure does not change after adenotonsillectomy in children younger than 10 years old. *Rev Invest Clin* 2014;66:152-156.
11. Şerefican M, Yurttaş V, Oral M, Yılmaz B, Dağlı M. Is Middle Ear Pressure Effected by Nasal Packings after Septoplasty? *J Int Adv Otol* 2015;11:63-65.
12. Yılmaz MS, Guven M, Buyukarslan DG, Kaymaz R, Erkorkmaz U. Do silicone nasal septal splints with integral airway reduce postoperative eustachian tube dysfunction? *Otolaryngol Head Neck Surg.* 2012;146:141-145.
13. Choi JH, Yoon HC, Kim TM, Choi J, Park IH, Kim TH, Lee HM, Lee SH, Lee SH. The immediate effect of adenotonsillectomy on Eustachian tube function in children. *Int J Pediatr Otorhinolaryngol* 2015;79:1444-1447.
14. Hone SW, Moodley S, Donnelly MJ, Fenton JE, Gormley PK, Walsh M. The effect of tonsillectomy on eustachian tube function. *Clin Otolaryngol Allied Sci* 1997;22:511-514.

# Different Therapeutic Approach to Idiopathic Normal Pressure Hydrocephalus: Lumboperitoneal Shunts Versus Ventriculoperitoneal Shunts

## İdiyopatik Normal Basıncılı Hidrosefalide Farklı Tedavi Yaklaşımları: Lumboperitoneal Şantlar ya da Ventriküloperitoneal Şantlar?

✉ Ayçiçek Çeçen, ✉ Merih İş, ✉ Erhan Çelikoğlu

University of Health Sciences, İstanbul Fatih Sultan Mehmet Training and Research Hospital, Clinic of Brain and Nerve Surgery, İstanbul, Turkey

### Abstract

**Objective:** Idiopathic normal pressure hydrocephalus (iNPH) or Adam-Hakims syndrome is an uncommon but important cause of dementia, gait disturbance and bladder incontinence. Our aim was to compare the efficacy and complication rates of ventriculoperitoneal and lumboperitoneal shunts in the treatment of iNPH.

**Method:** This is a retrospective study conducted in 25 patients who were treated with either ventriculoperitoneal or lumboperitoneal shunts for iNPH between 2003 and 2012. Age, gender, clinical presentation, methods of treatment, and complication rates were recorded.

**Results:** Two of the twelve patients in lumboperitoneal shunt (LPS) group were revised; 1 distal catheter infection was replaced by a ventriculoperitoneal shunt (VPS). In addition, there was one revision for wound detachment (due to scratching by the patient). In VPS group (13 patients), one of the patients was complicated with subdural haemorrhage 3 months after the operation and extraction of shunt was carried out immediately. Moreover one dysfunctioning VPS was revised with a LPS after 3 years.

**Conclusion:** Our results indicate that when the patients are properly selected for shunt insertion, both LPSs and VPSs, are effective in controlling all the clinical manifestations of iNPH with positive results.

**Keywords:** Amnesia, imbalance, lumboperitoneal shunt, normal pressure hydrocephalus, urinary incontinence, ventriculoperitoneal shunts

### Öz

**Amaç:** İdiyopatik normal basıncılı hidrosefali (iNPH) ya da Adam-Hakims sendromu demans, yürüme bozukluğu ve idrar inkontinansın önemli ve az bilinen bir nedenidir. Çalışmamızda iNPH tedavisinde kullanılan ventriküloperitoneal ve lumboperitoneal şantların etkinliğini ve komplikasyon oranlarını karşılaştırdık.

**Yöntem:** Kliniğimizde 2003-2012 yılları arasında iNPH tanısıyla ventriküloperitoneal veya lumboperitoneal şantla tedavi edilen 25 hasta geriye dönük olarak incelendi. Yaş, cinsiyet, klinik prezentasyon, tedavi yöntemi ve komplikasyon oranları kaydedildi.

**Bulgular:** Lumboperitoneal şant (LPS) grubunda iki revizyon yapıldı; 1 distal kateter enfeksiyonu ventriküloperitoneal şantla (VPS) değiştirildi. Bir hasta yara yeri kaşıntısı sonucu yara yeri açıldı ve peritoneal uç revize edildi. VPS (13 hasta) grubunda, 1 hasta subdural hematom nedeniyle 3 ay sonra kanama boşaltıldıktan sonra revize edildi. Çalışmayan bir VPS de 3 yıl sonra LPS ile değiştirildi.

**Sonuç:** Şant, yerleştirilmesi için uygun hastalar seçilecek olursa, tipi ister VPS olsun ister LPS olsun iNPH nedeniyle oluşan klinik bulguları kontrol etmede etkin bir yöntemdir.

**Anahtar kelimeler:** Amnezi, dengesizlik, lumboperitoneal şant, normal basıncılı hidrosefali, üriner inkontinans, ventriküloperitoneal şant



**Address for Correspondence:** Ayçiçek Çeçen, University of Health Sciences, İstanbul Fatih Sultan Mehmet Training and Research Hospital, Clinic of Brain and Nerve Surgery, İstanbul, Turkey

**E-mail:** ayceckecen@yahoo.com **ORCID ID:** orcid.org/0000-0003-2541-7200 **Received:** 01.03.2018 **Accepted:** 04.02.2019

**Cite this article as:** Çeçen A, İş M, Çilekoğlu E. Different Therapeutic Approach to Idiopathic Normal Pressure Hydrocephalus: Lumboperitoneal Shunts Versus Ventriculoperitoneal Shunts. Bagcilar Med Bull 2019;4(1):21-24.

©Copyright 2019 by the Health Sciences University, Bagcilar Training and Research Hospital  
Bagcilar Medical Bulletin published by Galenos Publishing House.

## Introduction

Normal pressure hydrocephalus (NPH) which has three main symptoms as gait disturbance, dementia and urinary incontinence, is a disorder of cerebrospinal fluid (CSF) absorption first described by Hakim and Adams in 1965 (1,2). The classical triad of NPH which can be primary, is named as idiopathic or it can be secondary caused by subarachnoid hemorrhage, trauma, meningitis, posterior fossa surgery, tumors causing meningitis carcinomatosa, Alzheimer patients, stenosis of aqueductus, insufficiency in arachnoid granulations (3). The incidence of idiopathic NPH (iNPH) is 5.5 per 100.000 and prevalence is 21.9 per 100.000 (4). Improved diagnostic and therapeutic methods have raised clinical success rates to a range of 70-90% and risk-benefit analysis have shown that surgery is superior to conservative treatment and natural course (5). Magnetic resonance imaging (MRI) provides important information for NPH by demonstrating a pulsatile flow void across the aqueduct and a hyperdynamic CSF flow on T2-weighted images (6). CSF drainage by lumbar puncture or extended lumbar drainage, CSF pressure dynamic measurements are confirmatory tests (7-9). The standard treatment of NPH is ventriculoperitoneal shunting (VPS) that has significant morbidity (30%) and re-operation rates due to subdural hematoma or hygroma, infection, obstruction, etc. (10,11). Lumboperitoneal shunt (LPS) is an alternative method to VPS for CSF diversion in these patients.

We have retrospectively analyzed our patients with iNPH for effectiveness and outcome of LPS versus VPS.

## Material and Methods

We retrospectively analyzed the medical records of patients undergoing LPS and VPS placement for idiopathic NPH by the same author (E.Ç) from 2003 to 2012. Secondary NPH cases were excluded. Ethical committee approval and written consent from the patients were obtained.

The diagnosis were confirmed by clinical findings (Table 1), CSF dynamic flow MRI demonstrating increased flow at the aqueduct, and positive CSF tap test. Positive CSF tap test was meant that gait, balance, incontinence and cognitive symptoms get better after daily lumbar puncture (30-45 mL CSF drainage in every puncture) for three days.

In our clinic the standard surgical technique was placement of VPS (Medtronic-CSF Flow-Control Valve, Integra Orbis Sigma Valve, Medtronic Delta valve) from Kocher point or Keen points until 2011, and LPS (Miethke LPS) after 2011 due to availability of the shunt system in our hospital.

There were 34 patients with NPH, but 9 of them were excluded because they were secondary NPH (sNPH) due to subarachnoid hemorrhage, trauma, tumor, or infection. The rest of the 25 patients were diagnosed as iNPH. The 25 patients were divided into two groups according to the type of CSF shunt used for their treatment (VPS group and LPS group).

## Statistical Analysis

IBM SPSS statistics 22.0 software was used for statistical evaluation of the data collected in the study. While comparing data with normal range between groups, Student's t-test was used, and comparing data without normal range, Mann-Whitney U test was used. Qualitative data was compared by Fisher's exact test or chi-square test according to the subject number. P values <0.05 were accepted as significant.

## Results

Of the 25 iNPH patients, 10 were female and 15 were male. The mean age was 71.52±8.48 years (range 56-83 years). There were 13 patients in VPS group, and 12 patients in LPS group.

The age, gender, symptom duration, rate of presence of concomitant systemic diseases and complication rates were not significantly different between two groups (p>0.05).

In 13 patients treated with VPS, 2 patients had complications. In one patient, there was with subdural hematoma three months after surgery. The VPS was removed and the hematoma was evacuated surgically. On follow-up of this patient, hydrocephalus progressed again and a new VPS was inserted. In another patient, a LPS was placed due to VPS dysfunction 2 years later. On long-term follow-up (mean 3.2 years with range 1-5 years) in VPS group, 2 patients died because of unrelated causes. The rest of the patients had improvement in gait disturbance

**Table 1: The demographic data and outcome of the two groups**

	VPS	LPS	p
Age	69.6±8.3	75.5±8.5	0.271
Gender (M/F)	9/4	6/6	0.428
Symptom duration (year)	1.2±0.7	2.1±2.9	0.852
Concomitant disease (n of patients)	10	9	1
Ex	2	2	1
Revision	2	2	1
Complication	2	2	1

M: Male, F: Female, VPS: Ventriculoperitoneal shunt, LPS: Lumboperitoneal shunt

and memory deficits, and there was a complaint about urinary incontinence only in one patient.

Two of twelve patients treated with LP shunts has complications (16.6%). In one patient, the LPS was replaced with a VPS for wound infection 7 days after first shunt operation. This patient died because of aspiration pneumonia 7 months later. In another patient with LPS, shunt revision was performed because of opening of the abdominal wound, and the peritoneal catheter was placed with another abdominal incision. In this group, 2 patients died owing to unrelated causes. In 10 patients, only two patients had residual symptoms at long-term follow-up (2.8 years, range 1 to 5 years). In one patient, she still had difficulty while steady gait possibly due to lumbar degenerative spondylosis, and in another patient, there was still complaint on memory function (Table 1).

## Discussion

The diagnosis of iNPH is made according to clinical triad of gait disturbance, cognitive impairment and urinary incontinence with ventricular enlargement in the absence of apparent cortical atrophy. The treatment of iNPH is preferably surgical. Natural history of iNPH is unclear, still there is a consensus that outcome is worse without surgery (12,13). The main shunt procedures are VPS and LPS for iNPH. VPS are usually chosen according to the surgeon's experience. However, as an advantage, LPS does not need to access to ventricular cavity within the brain tissue, which has risk of brain and cortical venous injury, and hemorrhage. Besides, LPS is associated with lower infection rates than VPS (14,15).

In the early surgical series of shunt insertion, the clinical improvement and efficacy of the procedure were reported to be low because of high complication rates (11,12). Current studies have stated that VPS insertion in iNPH have good outcome in 71% and has low mortality (1%), and low revision and complication rates (16% and 10.4% respectively) (16). Moreover, with the improvement of surgical technique and shunt technology, the stated subdural hemorrhage (SDH), intracerebral hemorrhage, and seizure rates have also declined (16).

Pujari et al. (17) have studied the long term results of shunt patients with a mean follow up of 5.9+2.5 years. Gait improved 83% at 3 years and 87% in 7 years, cognition improved %84 and 86% and urinary incontinence improved 84% and 80% respectively. However 53% required shunt revisions and 74% of them improved after revision surgery.

In our series, which included 25 patients, 13 patients had VPS and 12 patients had LPS. In VPS group, gait, cognition and urinary incontinence improvement rate was 100%, 100% and 92% respectively on last follow-up. In LPS group, gait, cognition and urinary incontinence improvement rate was 90%, 90% and 100% respectively. In a meta-analysis of 44 articles by Hebb et al. (11) it was reported that the pooled mean rate of shunt complication (including death, infection, seizures, shunt malfunction, SDH or effusion) was 38%. In our series, there was no mortality, and complication rate was 16% (2 patients from VPS group and 2 patients from LPS group), and revision rate was 16% (2 patients from VPS group and 2 patients from LPS group). We did not find a difference between groups for mortality, complication or revision rates.

McGirt et al. (18) demonstrated that gait disturbance as the primary symptom and short duration of symptoms are indicators for good outcome. In our series, there were residual complaints in three patients (urinary incontinence in one, memory function in one, and gait disturbance in one). Other patients had a very good improvement for all three symptoms.

## Conclusion

In conclusion, we state that the two CSF diversion methods, both VP and LP shunts, are safe and effective for treatment of iNPH. Our study is limited due to the small number of patients and variability in shunt devices. Controlled randomized prospective trials in larger groups are required to maintain high rank evidence of shunt effectiveness in iNPH management.

## Ethics

**Ethics Committee Approval:** Retrospective study.

**Informed Consent:** Retrospective study.

**Peer-review:** External and internal peer-reviewed.

## Authorship Contributions

Surgical and Medical Practices: E.C., A.Ç., Concept: A.Ç., Design: A.Ç., Data Collection or Processing: M.İ., A.Ç., Analysis or Interpretation: A.Ç., Literature Search: A.Ç., Writing: M.İ., A.Ç.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH. Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure. A treatable syndrome. *N Engl J Med* 1965;273:117-126.
2. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. *J Neurol Sci* 1965;2:307-327.
3. Gleason PL, Black PM, Matsumae M. The neurobiology of normal pressure hydrocephalus *Neurosurg Clin N Am* 1993;4:667-675.
4. Shprecher D, Schwab J, Kurlan R. Normal pressure hydrocephalus: diagnosis and treatment *Curr Neurol Neurosci Rep* 2008 ; 8:371-376.
5. Kiefer M, Unterberg A. The differential diagnosis and treatment of normal-pressure hydrocephalus. *Dtsch Arztebl Int.* 2012;109:15-25.
6. Tarnaris A, Kitchen ND, Watkins LD. Noninvasive biomarkers in normal pressure hydrocephalus: evidence for the role of neuroimaging. *J Neurosurg* 2009;110:837-851.
7. Eide PK, Sorteberg W. Diagnostic intracranial pressure monitoring and surgical management in idiopathic normal pressure hydrocephalus: a 6-year review of 214 patients. *Neurosurgery* 2010;66:80-91.
8. Woodworth GE, McGirt MJ, Williams MA, Rigamonti D. Cerebrospinal fluid drainage and dynamics in the diagnosis of normal pressure hydrocephalus. *Neurosurgery* 2009;64:919-926.
9. Governale LS, Fein N, Logsdon J, Black PM. Techniques and complications of external lumbar drainage for normal pressure hydrocephalus. *Neurosurgery* 2008;63(4 Suppl 2):379-384.
10. Bloch O, McDermott MW. Lumboperitoneal shunts for the treatment of normal pressure hydrocephalus. *J Clin Neurosci* 2012;19:1107-1111.
11. Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. *Neurosurgery* 2001;49:1166-1186.
12. Bergsneider M, Black PM, Klinge P, Marmarou A, Relkin N. Surgical management of idiopathic normal-pressure hydrocephalus. *Neurosurgery* 2005;57(3 Suppl):29-39.
13. Stein SC, Burnett MG, Sonnad SS. Shunts in normal-pressure hydrocephalus: do we place too many or too few? *J Neurosurg* 2006;105:815-822.
14. Aoki N. Lumboperitoneal shunt: clinical applications, complications, and comparison with ventriculoperitoneal shunt. *Neurosurgery* 1990;26:998-1004.
15. Choux M, Genitori L, Lang D, Lena G. Shunt implantation: reducing the incidence of shunt infection. *J Neurosurg* 1992;77:875-880.
16. Toma AK, Papadopoulos MC, Stapleton S, Kitchen ND, Watkins LD. Systematic review of the outcome of shunt surgery in idiopathic normal-pressure hydrocephalus. *Acta Neurochir (Wien)* 2013;155:1977-1980.
17. Pujari S, Kharkar S, Metellus P, Shuck J, Williams MA, Rigamonti D. Normal pressure hydrocephalus: long-term outcome after shunt surgery. *J Neurol Neurosurg Psychiatry* 2008;79:1282-1286.
18. McGirt MJ, Woodworth G, Coon AL, Thomas G, Williams MA, Rigamonti D. Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal pressure hydrocephalus. *Neurosurgery* 2008;62(Suppl 2):670-677.

# Retrospective Analysis of Six Primary Cutaneous T-cell Lymphoma Cases in the Light of Recent Advancements

## Altı Primer Kütanöz T-Hücreli Lenfoma Olgusunun Yeni Gelişmeler Işığında Retrospektif Analizi

 Betül Taş

University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Dermatology, İstanbul, Turkey

### Abstract

**Objective:** Primary cutaneous lymphomas (PCLs) are lymphoproliferative malignancies of skin. Although they have been confine to mycosis fungoides (MF) and Sezary syndrome over the years, the concept of PCL quite changed with the describing of new types in recent years. In our study, re-evaluation of diagnostic properties of our previously diagnosed six PCL cases was aimed, in the light of these advancements.

**Method:** The diagnostic features and progression of six PCL cases, which had been previously diagnosed and followed in the Dermatology clinic of İstanbul Şişli Etfal Training and Research Hospital, were retrospectively re-evaluated in the light of new advancements. For this purpose, besides their medical histories, clinical, laboratory and histopathologic findings were reviewed. In this manner, their diagnoses and clinical progressions were re-interpreted.

**Results:** Case 1 had been diagnosed with "Sezary syndrome" and re-evaluation confirmed the diagnosis. Case 2 and 3 had been diagnosed with "lymphomatoid papulosis" and "high-grade medium/large-T-cell lymphoma", respectively. After re-evaluation, 2<sup>nd</sup> case was thought to be more likely a high-grade CD30 (+) pleomorphic large-cell lymphoma, and 3. case a "CD30 (-) high-grade medium/large cell pleomorphic T-cell PCL". Case 4 had been diagnosed with "diffuse high grade pleomorphic mixed T and B-cell PCL". In the re-evaluation, lesions were thought to be an advanced "CD30 (+) high-grade pleomorphic large T-cell PCL that co-infiltrated with reactive B-cells". Case 5 and case 6 had been diagnosed with "MF", and "MF + follicular mucinosis (FM)", respectively. When re-evaluated, 5<sup>th</sup> case was thought to be more likely an "MF emerged from an ulceronecrotic pityriasis lichenoides et varioliformis acuta", whereas the previous diagnosis of 6<sup>th</sup> case was confirmed again.

### Öz

**Amaç:** Primer kütanöz lenfomalar (PKL) derinin lenfoproliferatif maligniteleridir. Yıllarca mikozis fungoides (MF) ve Sezary sendromu ile sınırlı kalmış olan PKL kavramı, son yıllarda yeni tiplerin tanımlanması ile oldukça değişmiştir. Çalışmamızda, daha önce kliniğimizde tanı almış altı PKL olgusunun tanınal özelliklerinin, bu gelişmeler ışığında yeniden değerlendirmesi amaçlandı.

**Yöntem:** İstanbul Şişli Etfal Eğitim ve Araştırma Hastanesi Dermatoloji Kliniği'nde önceki yıllarda PKL tanısı konularak takip edilmiş, altı PKL olgusunun tanınal özellikleri ve progresyonları yeni gelişmeler ışığında geriye dönük olarak değerlendirildi. Bu amaçla, olguların anamnezleri, klinik, laboratuvar ve histopatolojik bulguları tekrar gözden geçirildi. Böylelikle, hastaların önceden almış oldukları tanıları ve klinik progresyonları yeniden irdelendi.

**Bulgular:** Olgu 1 tipik bir "Sezary sendromu" olarak tanı almıştı ve bu tanı tekrar değerlendirmede teyit edildi. İkinci ve 3. olgular sırasıyla "lenfomatoid papülozis" ve "ileri-evre orta/büyük hücreli T-hücreli PKL" olarak tanı almışlardı. Yeniden değerlendirildiklerinde, 2'nin daha çok ileri-evre bir "CD (+) pleomorfik büyük hücreli PCL", 3'nün ise ileri-evre bir "orta/büyük hücreli CD (-) pleomorfik T-hücreli PKL" olabileceği düşünüldü. Dördüncü olgu "diffüz ileri evre pleomorfik mikst T ve B-hücreli PKL" olarak tanı almıştı. Tekrar değerlendirildiğinde ise lezyonların daha çok ileri-evre "reaktif B hücreleriyle ko-infiltrate edilmiş, CD30 (+) pleomorfik büyük-hücreli T-hücreli PKL" ile uyumlu olduğu düşünüldü. Beşinci ve 6. olgular, sırasıyla "MF" ve "MF (+) folliküler musinosis (FM)" olarak tanı almışlardı. Tekrar değerlendirildiklerinde, 5. olgu "ülseronekrotik pitriyazis likenoides et varioliformis akuta" üzerinden gelişmiş bir MF" olarak düşünülürken, 6. olgunun önceki tanısı teyit edildi.



**Address for Correspondence:** Betül Taş, University of Health Sciences, İstanbul Bağcılar Training and Research Hospital, Clinic of Dermatology, İstanbul, Turkey

**E-mail:** betulavc@yahoo.com **ORCID ID:** orcid.org/0000-0001-5378-1478 **Received:** 18.02.2019 **Accepted:** 20.02.2019

**Cite this article as:** Taş B. Retrospective Analysis of Six Primary Cutaneous T-cell Lymphoma Cases in the Light of Recent Advancements. Bagcilar Med Bull 2019;4(1):25-30.

©Copyright 2019 by the Health Sciences University, Bagcilar Training and Research Hospital  
Bagcilar Medical Bulletin published by Galenos Publishing House.



## Abstract

**Conclusion:** Diagnosis of a PCL with only clinical features or cellular morphology may lead a misdiagnosis. Patients should be evaluated with a multidisciplinary approach and methods, including immunophenotypic examination, DNA gene-rearrangement and, even electron microscope. It is very important to establish a close correlation between clinical findings and these examination findings to make correct diagnosis.

**Keywords:** Skin, lymphoma, malignant, non-Hodgkin, diagnosis, prognosis, analysis

## Öz

**Sonuç:** PKL'lerde, tanının sadece klinik özellikler ya da hücre morfolojisine göre konulması yanıltıcı sonuçlar doğurabilir. Olgular, immünofenotipik inceleme, DNA gen yeniden düzenlenmesi ve hatta elektronmikroskopik yöntemlerin birlikte kullanımıyla, multidisipliner bir yaklaşımla değerlendirilmelidir. Klinik bulgular ve bu inceleme sonuçları arasında korelasyonun sağlanması doğru tanı için çok önemlidir.

**Anahtar kelimeler:** Deri, lenfoma, malignite, Hodgkin dışı, tanı, prognoz, analiz

## Introduction

Lymphomas are main malignancies of lymphoreticular tissue. They are classically divided as Hodgkin and non-Hodgkin lymphomas (NHL). They can be originated from nodal, or extranodal tissues (skin/mucosa) (1). Skin is the second most frequent involvement of NHLs after gastrointestinal tissue, with an incidence of 1/100.000 (2). PCLs are majority of extranodal NHL which are stemmed from skin-resident lymphocytes. They are divided by the main tumor cell population into various sub-groups, and may exhibit different clinical, histological, immunophenotypical and prognostic properties (1,3). The main groups are T-cell primary cutaneous lymphomas (PCLs), B-cell PCLs, and non-classified or provisional types, with a dominance of the first. PCLs have been confined to mycosis fungoides (MF) and Sezary syndrome (SS) over the years. However, many new types were described owing to the recent diagnostic methods such as immunohistochemistry, T or B-cell DNA gene-rearrangement or monoclonal antibodies, and the concept of PCL has gained a new dimension with these advancements (1,4). The main characteristic features of a PCL are; having only/or predominantly skin involvement, presence of a compatibility between the epidermotropism and cellular maturity, progression from local to disseminated, and progression of lymphocyte proliferation from slow (cerebriform) to rapid growth phase consistent with the loss of epidermotropism (5). On the other hand, some lymphoproliferative conditions which have previously been described as benign lymphoproliferative conditions such as "large plaque parapsoriasis", "lymphomatoid papulosis (LP)", and "follicular mucinosis (FM)" were recently described as premalignant conditions or as "a real PCL" (6-8). Contrarily, there are some misdiagnosed "pseudolymphoma" cases in literature, who were previously diagnosed as real PCLs (9). The mentioned changes in the concept of PCL, and

presence of previously misdiagnosed cases in literature, encouraged us to perform this study to understand how accurately our patients were diagnosed previously.

## Material and Methods

The study was conducted as a retrospective study, and was performed on previously recorded data of six PCL cases, who had been diagnosed and followed in İstanbul Şişli Etfal Training and Research Hospital, Clinic of Dermatology. After an ethical approval was obtained from local ethics committee, an informed consent was obtained from each patient, or his/her legal guardian for dead patients, to use and report their medical records for academic purposes. Study population consisted of 2 females and 4 males, between the ages of 35 and 65 years. Their recorded individual histories, systemic and clinical examination findings, routine hemogram biochemical/microbiological analyses including treponema pallidum haemagglutination, venereal disease research laboratory, anti-HIV values, chest radiography, abdominopelvic ultrasonography and thoracoabdominal tomography findings in all patients, and available photographs of their lesions were checked and interpreted again. Histopathological slides of skin and lymph node biopsies and immunohistochemically-stained slides of skin biopsies were obtained from the archive of our pathology department. Histopathologic re-examinations of skin biopsies were made for all patients. Immunohistochemical re-examination of skin biopsies were made in case 4 and case 6, and histopathologic re-examinations of lymph node biopsies were made in case 1, 3 and case 6, because these examinations had been performed in only these patients. Besides their previous diagnoses were reviewed, the patients' responses to administered chemotherapies, and clinical courses of them were re-evaluated. In their medical courses, some of them had been hospitalized and followed in some different centers in certain time intervals.

Regarding data was requested from these clinics, and was included in this study to be able to fully interpret all the courses of patients. After the entire records of the patients were collected, they were re-evaluated with the available data. Non-pathological, and non-related findings with PCL were excluded from the interpretation to avoid data crowds.

## Results

A total of 6 PCL cases who consisted of 2 women and 4 men, between the ages of 35 and 65 years were evaluated. Mean age was 49. Clinical, laboratory and histological features of patients and their courses are below;

### Case 1

A 49-year-old-man was admitted to us with a complaint of extensive itchy erythema covering the entire skin, which first started 1.5 years ago. In his earlier admissions he had been diagnosed with “idiopathic erythroderma”, and “generalized eczema”. In the dermatological/systemic examinations, diffuse brownish-erythema, desquamation, edematous infiltration, alopecia, facies leonine, subungual hyperkeratosis, palmoplantar rhagadiform fissures, and axillar/inguinal lymphadenomegaly (LAMs), were detected. In the laboratory examinations, a high leukocytosis (13.4000), high blood sedimentation rate (40 mm/h), high lactate dehydrogenase (LDH) (698 Ü/L), and peripheral large lymphocytes with cerebriform nuclei in the rate of 40% were detected. Skin biopsy showed epidermal spongiosis and mononuclear focal lymphocytic infiltration, and linear infiltration of lymphocytes in upper reticular dermis. Nodal biopsy was consistent with dermatopathic lymphadenopathy (DPL). With the findings he was diagnosed with “SS”. All the clinical and laboratory findings disappeared within 6.5 months with prednisolone + chlorambucil (P + CHB) chemotherapy. He was still in cure in the 15<sup>th</sup> month.

### Case 2

A 59-year-old-man was admitted to us with papulo-nodules on the itchy desquamative erythematous patches on the face and extremities, which were diagnosed with “LP” 2 years ago. In the dermatological/systemic examinations, 1-2 cm in diameters, erythematous multiple papule, plaque and nodules, high blood sedimentation rate (40 mm/h), high LDH (620U/L) were detected. Multiple skin biopsies showed similar features, which were epidermal hiperkeratosis/acanthosis, dermal patchy infiltration consisting of eosinophilic, histiocyte-like, big pleomorphic

atypical cells, eosinophils, histiocytes, neutrophils and extravazed erythrocytes. Lesions were diagnosed as “LP” again, and he was began to be treated with cetirizine and topical corticosteroid. However, the lesions increased in number and size. Second skin biopsy was consistent with a “tumoral stage of MF”, which showed diffuse dermal atypical lymphocytic infiltration. He was began to be treated with CHOP therapy for 5 session, however was lost due to cardiovascular insufficiency.

### Case 3

A 59-year-old-man was admitted to us with itchy desquamation in his scalp, face and trunk, for 25 years. Two years ago he had been diagnosed with “early-stage-psoriasis (Ps)”. In the dermatological/systemic examinations, erythemato-squamous diffuse eruption and crusted plaques in whole skin, candle grease and Auspitz signs, unguual ridging, onycholysis, subungual hyperkeratosis, high blood sedimentation rate (55 mm/hg), and slight anemia were detected. Skin biopsy showed prominent epidermal parakeratosis, elongation of rete ridges, mononuclear epidermal microabcesses, spongiosis and perivascular mixed inflamatory infiltration in upper dermis, which were consistent with “eythrodermic Ps”. He was began to be treated with topical corticosteroids and oral antihistamine. However, multiple nodular lesions on the face and trunk, and a severe plantar pustulosis developed within one month. Skin biopsy showed epidermal polymorphic microabcesses, and meadium/large in size, high-mitotic atypical lymphocytes in whole dermis, which were consistent with “high-grade medium/large-T-cell PCL”. Detected right inguinal lymphadenomegaly also showed high-grade lymphoma features. Although he was treated with P + CHB combination for 3 session, and lesions were significantly regressed, the patient was lost from cardiac insufficiency.

### Case 4

A 65-year-old-woman was admitted to us with itchy skin lesions arising from a diffuse erythema, which firstly started 4 years ago. In the dermatological/systemic examinations, 0.5-7 cm in diameters, violaceous and desquamative multiple lenticular papules/nodules and on the face, hands, and lower extremities, and bilaterally axillar LAMs were detected. Blood sedimentation rate was 92 mm/h. Skin biopsy showed atypical immature/pleomorphic lymphocyte infiltration showing intense mitosis in the epidermis of papules, whereas throughout the whole skin in the nodules. All types of lesions were equally stained

with CD45RO and CD20 immunohistochemistries. With the findings the patient was diagnosed with “diffuse high-grade pleomorphic mixed T and B-cell PCL”. Because a slight regression was obtained in the lesions with P + CHB chemotherapy, the patient was recommended for CHOP therapy in the third month, but she did not accept it. Ten months later the lesions increased further.

### Case 5

A 58-year-old woman was admitted to us with a complaint of wounds in her scalp and whole skin, which had begun since 2 years, as recurrent lenticular small squamous papules. They had previously been diagnosed as “chronic superficial dermatitis” and “MF plaque stage”. In the dermatological, histologic and systemic examinations, 0.5-6 cm in diameters, multiple, violaceous-brownish, painful, hemorrhagic and exudative plaques and ulcers covered by white and brown/black necrotic crusts, epidermal necrosis, lymphocytic exocytosis, epidermal atypical cells showing big and hyperchromatic nuclei, spinal dyskeratosis, basal hydrophic degeneration, extensive dermal perivascular lymphoplasmocytic infiltration, keratoconjunctivitis sicca, hematuria and axillar LAPs were detected. Blood sedimentation rate was 115 mm/h. There was a slight hypoalbuminemia (3.1 gr/dL) and high fever (38 °C). She was diagnosed with “MF” and began to be treated with P + CHB chemotherapy. Because lesions continued to progress, therapy was changed to CHOP therapy. During this period she was lost due to respiratory insufficiency and hypotensive shock associated with high-fever, abdominal pain, myalgia, and hematuria.

### Case 6

A 35-year-old man was admitted to us with a complaint of itchy wounds. They had been begun as only one 5-6 cm plaque, and then increased in number within 5 years. In the dermatological/systemic examinations; multiple (higher than 10% of body surface area), 2-10 cm in diameters, red-violaceous, scaling patch/plaques, and disseminated follicular papules in whole skin, multiple cervical and inguinal LAMs, and 2% atypical cerebriform lymphocytes in the peripheral blood were detected. Skin biopsy showed acanthosis, hyperkeratosis, parakeratosis, light spongiosis, focal infiltration of atypical lymphocytes in epidermis, whereas a perivascular patchy atypical lymphocyte infiltration in the papillar/upper reticular dermis, and perifollicular mucinous degeneration in the lower reticular dermis. Lesions were positive for CD45RO, and negative for CD20 and CD 30 immunohistochemistries, and were

diagnosed with “MF + FM” Nodal biopsy was considered in consistent with MF. Clinical stage was considered as IIA (T2N2M0B0). He was administered two sessions of CHOP chemotherapy, but did not respond. The lesions began to be more pruritic.

## Discussion

SS is erythrodermic and leukemic variant of MF. There is three stage of it such as presezary, sezary and T-cell leukemia. In the first stage, an erythrodermia showing chronic dermatitis histopathology is seen. The number of peripheral atypical lymphocytes is under 1000/mm<sup>3</sup>. It can be difficult to diagnose during this period (1,3,4) The findings of our first case in his first admission, were complied with presezary-stage. In the SS stage, skin thickness increases and diffuse melanoerythrodermia, desquamation, edematous infiltration, alopecia, facies leonine, subungual hyperkeratosis, palmoplantar fissures and severe pruritus occur. Histopathology is variable. Epidermotropism may change, and usually perivascular band-like mononuclear lymphocytic infiltration occur. Nodal biopsy is usually complied with DPL, leucocytosis is between 10.000 and 30.000, and the percent of atypical peripheral lymphocytes is 15-30% (it is usually higher than 50% in leukemic-stage). LDH shows degree of leukemic activation and prognosis (3,4,10). Low-dose P + CH therapy is usually leads long-term remissions in this stage (11). All findings and course of our 1. case were consistent with typical SS-stage. On the other hand, LP is rithmic, paradoxal papular/small-nodular or papulonecrotic eruption, which shows benign clinical course but malignant histopathology, and may develop before or after MF, or accompany it (4,12). Lesions' histology may be various. Patchy and wedge-style perivascular lymphocytes, bigger-pleomorphic cells occur in type-A, whereas they are smaller and similar to MF cells in type-B (4,13). However, similar views may be seen in a high-grade CD30 (+) large-cell PCL, or CD30 (-) pleomorphic PCL (4,12,14). For these reasons, although the clinicopathological findings of our 2th case had thought to be consecutively developed patchy-MF, LP-plaque (type-A) and finally tumoral LP or MF, the exact diagnosis has remained in suspense because an immunostaining had not been performed. In the re-evaluation, we thought that 2th case was more likely to be a high-grade CD30 (+) pleomorphic large-cell PCL, due to its histologic similarities and aggressive course. Lesions of our 3th case had begun as Ps-like eruption. Early stages of both Ps and T-cell-PCLs may share common clinicopathological findings such as erythemato-squamous eruption, parakeratosis, acanthosis,

slight spongiosis, perivascular mononuclear infiltration and slight exocytosis (15,16). On the other hand, CD30 (-) high-grade medium/large cell pleomorphic T-cell PCLs are recently described lymphomas with a poor prognosis. Moreover, a palmoplantar-MF may show similar features to Ps, such as hyperkeratosis, verrucous or pustular-Ps like hyperplasia. Wakelin et al. (17) reported a CD30 (-) high-grade medium/large cell pleomorphic T-cell PCL arising from pre-existing palmoplantar Ps. These lymphomas need radiotherapy or polychemotherapy (4,18). Furthermore, few reports regarding a PCL development on pre-existing chronic dermatoses have been reported. However, no scientific evidence has been reported that whether such cases reflect a malignant transformation, or de-nova formation (19). After re-evaluation, he was thought to be more likely a “high-grade CD30 (-) medium/large cell pleomorphic T-cell PCL”. Although the available findings of our case strongly supported aforementioned literature, we could not be sure of our exact diagnosis due to the lack of immunostaining. Our 4<sup>th</sup> case had been diagnosed with a “diffuse high grade mixed T and B-cell PCL”. Although T and B-cell PCLs cannot exactly be distinguished without immunostaining, some indicators can help to diagnosis. T-cell PCLs are more symmetric, isolated or unified papule/plaque/nodules which are usually covered by squames/crusts, and show stage-compatible histopathology, whereas B-cell PCLs are usually smooth-surfaced, figured nodules/plaques which show follicular or full-thickness histopathologic features, early bone marrow involvement, and faster progress (20). Our different lesions equally stained for T and B-cells. These conditions can be explained with the concepts of “composite lymphoma (togetherness of two lymphomas originating from two different lymphocyte types)” (20,21), or “co-infiltration [togetherness of a single-type lymphocyte originated lymphoma (T or B), and accompanying benign reactive infiltration with other type lymphocytes]” (21). Moreover, no staining for CD30 had been performed for the lesions of case 4, because there was no PCL-classification including pleomorphic ones when she had been first diagnosed. When the case was re-evaluated together with all the findings and lesions’ moderate response to P + CHB chemotherapy, the lesions were thought to be more likely an advanced “CD30 (+) high-grade pleomorphic large T-cell PCL, that co-infiltrated with reactive benign B-cells”. Lesions of 5<sup>th</sup> case had begun as non pruritic, chronic, recurrent, pink to red, lenticular, squamous papules, which had not been proved histologically. Later, they were quickly transformed into ulceronecrotic plaques. Histopathology showed epidermal/

dermal atypical pleomorphic lymphocytes, accompanying severe ulceronecrotic/vasculitic changes, and basal vacuolar degeneration, which latter ones were not compatible with a classical MF, but closely compatible with an ulceronecrotic pityriasis lichenoides et varioliformis acuta (PLEVA). PLEVA is a small-papulonecrotic and hemorrhagic, chronic skin eruption, which can rarely progress to large plaques. Sometimes high-fever, myalgia, asthenia, weakness and hemorrhagic crusted ulcers may accompany it (22). Progression of a PLEVA to PCL is not usual condition. However, Forstner et al. (23) have reported that their two patients and other some PCL cases, which their lesions developed from pre-existing PLEVA lesions. Moreover, T-cell infiltration or clonality rarely can occur in PLEVA, so it was hypothesized that a PCL may develop from PLEVA lesions, when elimination capacity of immune system is exceeded (23,24). Thus, it was thought that development of these lesions was not consistent with just a conventional-MF, but was with an “MF emerged from an ulceronecrotic PLEVA”, both clinically and histopathologically. Also, the reason of patient’s death was thought more likely caused by intraabdominal hemorrhages due to progressive vasculitic changes. Our 6<sup>th</sup> case had been diagnosed with “MF + FM”. FM is characterized by pruritic, follicular, prominent papules, which is caused by perifollicular mucinous degeneration. It is considered as a poor prognostic factor when it accompanies Hodgkin lymphomas (25). Clinically, the lesions were compatible with patch/plaque stages of MF + disseminated FM. Skin involvement was higher than 10%, and peripheral atypical lymphocytes were lower than 5%. Lesions were positively stained for CD45RO, but not for CD20 and 30. Although nodal biopsy was complied with DPL, they were considered as involved in lymphoma, because the presence of multiple palpable nodes and prominent germinal center enlargements. Although the lesions were considered in low-stage of MF [IIA (T2N2M0B0)] according to “TNMB classification” for MF and SS (26), their unresponsiveness to administered CHOP sessions was thought to be related with accompanied FM. When the lesions were re-evaluated, previous diagnoses of them were confirmed. Additionally, it was thought that an accompanying FM may lead to worse prognosis in MF cases.

## Conclusions

PCLs are cutaneous malignancies composed of various subtypes, and there is no homogenization in these tumors. Each PCL case may have a distinctive attitude. Diagnosis of a PCL with only clinical or histopathologic findings may lead to a misdiagnosis. Therefore, PCL cases should

be evaluated with a multidisciplinary approach, and, immunophenotyping, DNA gene-rearrangement, and even electronmicroscopy. Establishing close correlation between the clinical and other examination findings is very important to make correct diagnosis.

### Acknowledgement

I thank Professor Dr. İlknur Kıvanç Altunay for her valuable contributions

### Ethics

**Ethics Committee Approval:** The study was approved by the İstanbul Şişli Etfal Training and Research Hospital Local Ethics Committee (approval no: ŞEH/96-49/017).

**Informed Consent:** A written informed consent was obtained from each patient or their legal guardian.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Burg G, Dommann S, Dummer R. Malignant lymphomas of the skin. *Ther Umsch* 1993;50:828-834.
2. Akay BN. Classification in cutaneous lymphomas. *Türkiye Klinikleri J Dermatol-Special Topics* 2014;7:1-5.
3. Pimpinelli N, Santucci M, Giannotti B. Cutaneous lymphoma: a clinically relevant classification. *Int J Dermatol* 1993;32:695-700.
4. Williemze R, Beljeaards RC, Meijer CJ. Classification of primer cutaneous T-cell lymphomas. *Histopathology* 1994;24:405-415.
5. Edelson RL. Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome and other variants. *J Am Acad Dermatol* 1980;2:89-106.
6. Zelickson BD, Peters MS, Muller SA, Thibodeau SN, Lust JA, Quam LM, Pittelkow MR. T-cell receptor gene rearrangement analysis: cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. *J Am Acad Dermatol* 1991;25:787-796.
7. Black MM, Jones EW."Lymphomatoid" pityriasis lichenoides; a variant with histological features simulating a lymphoma: A clinical and histopathological study of 15 cases with details of long term follow up. *Br J Dermatol* 1972;86:329-347.
8. Samman PD. The natural history of parapsoriasis en plaques (chronic superficial dermatitis) and prereticulotic poikiloderma. *Br J Dermatol* 1972;87:405-411.
9. Tian Z, Shiyu Z, Tao W, Li L, Yuehua L, Hongzhong J. Lymphoma or pseudolymphoma: A report of six cases and review of the literature. *Dermatol Ther* 2018:e12807.
10. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/sezary syndrome (cutaneous T cell lymphoma) A review of 222 biopsies including newly described patterns and the earliest pathologic changes. *Am J Surg Pathol* 1994;18:645-667.
11. Holloway KB, Flowers FP, Ramos-Caro FA. Therapeutic alternatives in Cutaneous T cell lymphoma. *J Am Acad Dermatol* 1992;27:367-378.
12. Kadin ME. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides and some types of Hodgkin's disease. *Lancet* 1985;19;2:864-865.
13. Black MM."Classical"lymphomatoid papulosis. A variant of pityriasis lichenoides. *Am J Dermatopathol* 1981;3:175-176.
14. Karp DL, Horn DT. Lymphomatoid papulosis. *J Am Acad Dermatol* 1994;30:379-395.
15. Nicolis GD, Stratigos JD, Tosca AD, Capetanakis JA. Mycosis fungoides with verrucous lesions. *Acta Dermatovenereol* 1979;59:80-82.
16. Verga M, Braverman IM. The use of immunohistologic analysis in differentiating cutaneous T-cell lymphoma from psoriasis and dermatitis. *Arch Dermatol* 1991;127:1503-1510.
17. Fink-Puches R, Soyer HP, Kerl H. Febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta. *J Am Acad Dermatol* 1994;30:261-263.
18. Forston JS, Schroeter AL, Esterly NB. Cutaneous T-cell lymphoma (parapsoriasis en plaque). An association with pityriasis lichenoides et varioliformis acuta. *Arch Dermatol* 1990;126:1449-1453.
19. Kikuchi A, Naka W, Harada T, Sakuraoka K, Harada R, Nishikawa T. Parapsoriasis en plaques: its potential for progression to malignant lymphoma. *J Am Acad Dermatol* 1993;29:419-422.
20. Wakelin SH, Salisbury j, Smith NE Primary cutaneous pleomorphic T cell lymphoma arising pustular psoriasis. *Br J Dermatol* 1994;131(Suppl.44):57-62.
21. Williemze R. New concepts in the classification of cutaneous lymphomas. *Arch Dermatol* 1995;131:1077-1080.
22. Lambert WC. Premycotic eruptions. *Dermatol Clin* 1985;3:629-645.
23. Arai E, Sakurai M, Nakayama H, Morinaga S, Katayama I. Primary cutaneous T-cell-rich B-cell lymphoma. *Br J Dermatol* 1993;129:196-200.
24. Yagi H, Ogai M, Izumi T, Ebihara T, Sugiura M, Tokura Y, Takigawa M. Cutaneous T-cell lymphoma with massive co-infiltration of polyclonal B cells. *Br J Dermatol* 1994;130:26-230.
25. Goldenhersh MA, Zlotogorski A, Rosenmann E. Follicular mycosis fungoides. *Am J Dermatopathol* 1994;16:52-55.
26. Onsun N. Erdemoglu Y. Updated classification and staging cutaneous lymphoma. *Turkderm* 2010;44:178-179.

# Bagcilar Medical Bulletin Alıntılanma

## **1- Comparing the rate of radiological and clinical adjacent segment degeneration after simple anterior cervical discectomy versus discectomy plus fusion.**

### **Atf:**

a) Jacobson RE, Granville M, Berti A. Minimally Invasive Anterior Cervical Discectomy Without Fusion to Treat Cervical Disc Herniations in Patients with Previous Cervical Fusions. *Cureus* 2017 Apr 3;9:e1131. doi: 10.7759/cureus.1131.

---

## **2- Cutaneous metastasis of pancreatic carcinoma seen in the left gluteal region and axilla**

### **Atf:**

a) Lai JH, Aznan MS, Reynu R, Taher NM, Firdaus H, Kosai NR. Non-Umbilical Metastases of a Pancreatic Adenocarcinoma: Case Report and Review of Literature. *Surg Chron* 2017;22:212-215.

---

## **3- In vivo analgesic potential in swiss albino mice and in vitro thrombolytic and membrane stabilizing activity of methanolic extract from suaeda maritima whole plant.**

### **Atf:**

a) Kar A, Bulbul L, Hussain S. Comparative In-Vivo Investigation Of Antipyretic Activity Of The Methnaolic Extract Of Two Plants Of Family Fabacaeae. *Global Journal for Research Analysis*. 2017;7:289-2892.

b) Akter S, Anjum R, Hossasin M, Hussain S, Rashid MO. Thrombolytic, Membrane Stabilizing, Analgesic activities along with Phytochemical Screening of the Methanolic Extract of *Xanthium indicum* Koenig Fruits. *Bagcilar Medical Bulletin* 2018;3:1-6 DOI: 10.5350/BMB20171220090230

---

## **4- Endoscopic management of dysphagia in plummer-vinson syndrome.**

### **Atf:**

a) Prasada ST, Prasad VB, Srividya L. Plummer Vinson Syndrome (PVS) with parotid gland squamous cell carcinoma in a young female. *World News of Natural Sciences* 2018;18:171-17.